
<html lang="en"     class="pb-page"  data-request-id="795557d1-e116-4cf7-a7c4-574a422f333c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00007;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma" /></meta><meta name="dc.Creator" content="Takeru  Ehara" /></meta><meta name="dc.Creator" content="Christopher M.  Adams" /></meta><meta name="dc.Creator" content="Doug  Bevan" /></meta><meta name="dc.Creator" content="Nan  Ji" /></meta><meta name="dc.Creator" content="Erik L.  Meredith" /></meta><meta name="dc.Creator" content="David B.  Belanger" /></meta><meta name="dc.Creator" content="James  Powers" /></meta><meta name="dc.Creator" content="Mitsunori  Kato" /></meta><meta name="dc.Creator" content="Catherine  Solovay" /></meta><meta name="dc.Creator" content="Donglei  Liu" /></meta><meta name="dc.Creator" content="Michael  Capparelli" /></meta><meta name="dc.Creator" content="Philippe  Bolduc" /></meta><meta name="dc.Creator" content="Jonathan E.  Grob" /></meta><meta name="dc.Creator" content="Matthew H.  Daniels" /></meta><meta name="dc.Creator" content="Luciana  Ferrara" /></meta><meta name="dc.Creator" content="Louis  Yang" /></meta><meta name="dc.Creator" content="Byron  Li" /></meta><meta name="dc.Creator" content="Christopher S.  Towler" /></meta><meta name="dc.Creator" content="Rebecca C.  Stacy" /></meta><meta name="dc.Creator" content="Ganesh  Prasanna" /></meta><meta name="dc.Creator" content="Muneto  Mogi" /></meta><meta name="dc.Description" content="Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, th..." /></meta><meta name="Description" content="Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, th..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 2, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00007" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00007" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00007" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00007" /></link>
        
    
    

<title>The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00007" /></meta><meta property="og:title" content="The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0012.jpeg" /></meta><meta property="og:description" content="Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound (+)-23, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00007"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00007">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00007&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00007&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00007&amp;href=/doi/10.1021/acs.jmedchem.8b00007" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2552-2570</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01884" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00128" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Discovery of (<i>S</i>)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Takeru Ehara</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takeru Ehara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>T.E.; e-mail, <a href="/cdn-cgi/l/email-protection#94e0f5fff1e6e1baf1fcf5e6f5d4fafbe2f5e6e0fde7baf7fbf9"><span class="__cf_email__" data-cfemail="6511040e0017104b000d041704250b0a130417110c164b060a08">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takeru++Ehara">Takeru Ehara</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4889-204X" title="Orcid link">http://orcid.org/0000-0002-4889-204X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher M. Adams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher M. Adams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+M.++Adams">Christopher M. Adams</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doug Bevan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doug Bevan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doug++Bevan">Doug Bevan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nan Ji</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nan Ji</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nan++Ji">Nan Ji</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erik L. Meredith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik L. Meredith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik+L.++Meredith">Erik L. Meredith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David B. Belanger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David B. Belanger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+B.++Belanger">David B. Belanger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Powers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Powers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Powers">James Powers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mitsunori Kato</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mitsunori Kato</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mitsunori++Kato">Mitsunori Kato</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine Solovay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine Solovay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Solovay">Catherine Solovay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donglei Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donglei Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donglei++Liu">Donglei Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Capparelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Capparelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Capparelli">Michael Capparelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philippe Bolduc</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philippe Bolduc</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Bolduc">Philippe Bolduc</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan E. Grob</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan E. Grob</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+E.++Grob">Jonathan E. Grob</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew H. Daniels</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew H. Daniels</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+H.++Daniels">Matthew H. Daniels</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luciana Ferrara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luciana Ferrara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ophthalmology Research, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luciana++Ferrara">Luciana Ferrara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ophthalmology Research, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Yang">Louis Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Byron Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Byron Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ophthalmology Research, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Byron++Li">Byron Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher S. Towler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher S. Towler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+S.++Towler">Christopher S. Towler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca C. Stacy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca C. Stacy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Medicine, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca+C.++Stacy">Rebecca C. Stacy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ganesh Prasanna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ganesh Prasanna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ophthalmology Research, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ganesh++Prasanna">Ganesh Prasanna</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Muneto Mogi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Muneto Mogi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>M.M.; e-mail, <a href="/cdn-cgi/l/email-protection#f9948c979c8d96d794969e90b997968f988b8d908ad79a9694"><span class="__cf_email__" data-cfemail="f79a8299928398d99a98909eb79998819685839e84d994989a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Muneto++Mogi">Muneto Mogi</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00007&amp;href=/doi/10.1021%2Facs.jmedchem.8b00007" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2552–2570</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 2, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 January 2018</li><li><span class="item_label"><b>Published</b> online</span>2 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00007" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00007</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2552%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTakeru%2BEhara%252C%2BChristopher%2BM.%2BAdams%252C%2BDoug%2BBevan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.8b00007%26title%3DThe%2BDiscovery%2Bof%2B%2528S%2529-1-%25286-%25283-%2528%25284-%25281-%2528Cyclopropanecarbonyl%2529piperidin-4-yl%2529-2-methylphenyl%2529amino%2529-2%252C3-dihydro-1H-inden-4-yl%2529pyridin-2-yl%2529-5-methyl-1H-pyrazole-4-carboxylic%2BAcid%252C%2Ba%2BSoluble%2BGuanylate%2BCyclase%2BActivator%2BSpecifically%2BDesigned%2Bfor%2BTopical%2BOcular%2BDelivery%2Bas%2Ba%2BTherapy%2Bfor%2BGlaucoma%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2570%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00007"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1788</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00007" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Takeru&quot;,&quot;last_name&quot;:&quot;Ehara&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;M. Adams&quot;},{&quot;first_name&quot;:&quot;Doug&quot;,&quot;last_name&quot;:&quot;Bevan&quot;},{&quot;first_name&quot;:&quot;Nan&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;L. Meredith&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;B. Belanger&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Powers&quot;},{&quot;first_name&quot;:&quot;Mitsunori&quot;,&quot;last_name&quot;:&quot;Kato&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Solovay&quot;},{&quot;first_name&quot;:&quot;Donglei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Capparelli&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Bolduc&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;E. Grob&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;H. Daniels&quot;},{&quot;first_name&quot;:&quot;Luciana&quot;,&quot;last_name&quot;:&quot;Ferrara&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Byron&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;S. Towler&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;C. Stacy&quot;},{&quot;first_name&quot;:&quot;Ganesh&quot;,&quot;last_name&quot;:&quot;Prasanna&quot;},{&quot;first_name&quot;:&quot;Muneto&quot;,&quot;last_name&quot;:&quot;Mogi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2552-2570&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00007&quot;},&quot;abstract&quot;:&quot;Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound (+)-23, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00007&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00007" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00007&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00007" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00007&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00007" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00007&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00007&amp;href=/doi/10.1021/acs.jmedchem.8b00007" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00007" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00007" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00007%26sid%3Dliteratum%253Aachs%26pmid%3D29498522%26genre%3Darticle%26aulast%3DEhara%26date%3D2018%26atitle%3DThe%2BDiscovery%2Bof%2B%2528S%2529-1-%25286-%25283-%2528%25284-%25281-%2528Cyclopropanecarbonyl%2529piperidin-4-yl%2529-2-methylphenyl%2529amino%2529-2%252C3-dihydro-1H-inden-4-yl%2529pyridin-2-yl%2529-5-methyl-1H-pyrazole-4-carboxylic%2BAcid%252C%2Ba%2BSoluble%2BGuanylate%2BCyclase%2BActivator%2BSpecifically%2BDesigned%2Bfor%2BTopical%2BOcular%2BDelivery%2Bas%2Ba%2BTherapy%2Bfor%2BGlaucoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2552%26epage%3D2570%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291749" title="Thiophenes">Thiophenes</a>,</li><li><a href="/action/doSearch?ConceptID=291719" title="Redox reactions">Redox reactions</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound <b>(+)-23</b>, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glaucoma, a neurodegenerative disease of the retina and optic nerve, is one of the leading causes of blindness in the world. The estimated number of glaucoma cases globally is over 60 million. In the USA alone, over 120 000 patients are legally blind from glaucoma.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The only accepted modifiable risk factor for glaucoma is the lowering of intraocular pressure (IOP), which is elevated in the most common form of glaucoma, primary open angle glaucoma (POAG). For each mmHg reduction in IOP, a 10% reduction in disease progression can be observed.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It is believed that the primary cause of increased IOP is inadequate drainage of intraocular fluid (aqueous humor) due to a dysfunctional outflow pathway. Dysfunctional outflow is thought to arise from extensive oxidative stress and extracellular matrix deposition, which can result in functional impairment of the trabecular meshwork (TM), the tissue that is the major site of resistance to aqueous humor outflow. The recent clinical success of Rhopressa (netarsudil, a rho kinase inhibitor)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and Vyzulta (latanoprostene bunod, a dual-action drug that produces nitric oxide and latanoprost),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> which improve conventional outflow facility (or trabecular outflow), have increased interest in targeting the TM.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Clinically and preclinically, nitric oxide (NO) can lead to a reduction in IOP by producing the vasorelaxant signaling molecule cyclic guanosine monophosphate (cGMP), presumably acting on the TM.<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> The endogenous receptor for NO is soluble guanylate cyclase (sGC). sGC is a heterodimer composed of either an α1 or an α2 subunit combined with the β1 subunit, which has a heme prosthetic group. Under physiological conditions, upon binding of NO to the reduced iron of the heme, the enzyme is activated and catalyzes the conversion of guanosine-5′-triphosphate (GTP) to cGMP.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Under pathological conditions involving oxidative stress, the heme moiety of sGC can become oxidized (from ferrous to ferric state) and become nonresponsive to NO. Furthermore, upon oxidation, the prosthetic heme can detach from the enzyme, leaving it incapable of catalyzing the conversion of GTP to cGMP.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">The NO/sGC/cGMP pathway has been implicated in a several different diseases, in particular cardiovascular and pulmonary diseases. This has led to identification of molecules that activate or stimulate sGC.<a onclick="showRef(event, 'cit7a ref9'); return false;" href="javascript:void(0);" class="ref cit7a ref9">(7a,9)</a> The greatest clinical success has been achieved using stimulators, with riociguat approved to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, stimulators require the heme of sGC to be present in the reduced state to afford an enhancement in cGMP production. Activators, on the other hand, preferentially bind to oxidized, or heme free, sGC and restore the enzyme’s catalytic activity. We hypothesized that in glaucoma, oxidative stress may lead to an increase in nonfunctional, oxidized sGC, and thus sGC activators may prove beneficial in reducing elevated IOP. Further evidence for the relevance of the NO/sGC/cGMP pathway comes from several reports of modulators of this pathway lowering IOP in preclinical glaucoma models.<a onclick="showRef(event, 'ref6 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref11">(6,11)</a></div><div class="NLM_p">At the start of our work, two sGC activators had been evaluated clinically for cardiovascular indications, cinaciguat and ataciguat, <b>1</b> and <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, to the best of knowledge, at the time our program was initiated, there were no reports of the development of topically administered sGC activators for the treatment of glaucoma.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported sGC activators tested in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>1</b> served as a useful tool to explore the potential of this mechanism to lower IOP. To this end, compound <b>1</b> was evaluated in our primary <i>in vivo</i> model, a laser-induced elevated IOP cynomolgus monkey model (cyno-IOP model).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In this model, a laser-induced trabeculoplasty of the TM in one eye leads to elevated IOP. Upon b.i.d. instillation of <b>1</b> employing topical eye drops, a modest reduction in IOP was observed (up to 10%). The need for twice-a-day dosing and substandard IOP lowering were clearly discouraging.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Compound <b>1</b> potently activates sGC (EC<sub>50</sub>/E-max; maximal cGMP produced from the dose response curve) in a high throughput Chinese hamster ovary (CHO) cell assay, which was used as our initial assay for compound evaluation. However, <b>1</b> proved to be a partial activator of sGC when evaluated in a potentially more relevant cell line, immortalized glaucomatous trabecular meshwork cells (GTM-3) expressing endogenous levels of sGC.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> We reasoned that an activator with greater <i>in vitro</i> efficacy (increase in E-max) in the GTM-3 cell assay may afford more robust IOP lowering. Therefore, we set out to identify sGC activators with excellent <i>in vitro</i> potency and efficacy, which were suitable for topical ocular administration.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An internal high-throughput screening (HTS) campaign identified <b>3</b><a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> as a potential starting point (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) with an EC<sub>50</sub> of 162 nM and an E-max of 105% in a CHO cell line overexpressing sGC. Pharmacophore modeling, which overlaid <b>3</b> with several literature described sGC activators,<a onclick="showRef(event, 'cit9c ref17'); return false;" href="javascript:void(0);" class="ref cit9c ref17">(9c,17)</a> guided our efforts to improve upon <b>3</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HTS hit (<b>3</b>), lead molecule (<b>4</b>), and pharmacophore model on <b>4</b>. Common feature points are carboxylic acid (red), hydrophobic groups (yellow and green), and a hydrogen bond acceptor (cyan), whereas occupancy of a tail group (purple dotted circle) varies depending on a molecule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This pharmacophore model suggested potency could be gained by elaborating <b>3</b> at the northern most ring. This led to the design of <b>4</b>, incorporating a thiophene ring to position the piperidine containing “tail” moiety in the appropriate orientation. We were pleased to see that upon synthesis, <b>4</b> afforded a ∼7-fold improvement in potency relative to <b>3.</b> Compound <b>4</b> served as a lead for our optimization campaign, which began with exploration of the substitution of the aryl ring of the “tail” (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Addition of a methyl group alpha to the oxygen (R<sup>2</sup> = Me, <b>5</b>) resulted in an enhancement in potency in the CHO cell assay. This improvement in potency warranted evaluation in the more relevant and stringent GTM cell assay. Gratifyingly, <b>5</b> afforded maximal efficacy (E-max = 97%) with an EC<sub>50</sub> of 370 nM. On the strength of this data, we evaluated <b>5</b> in the laser-induced elevated IOP cynomolgus monkey model (cyno-IOP model).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the Thiophene Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0009.gif" alt="" id="GRAPHIC-d55e572-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0010.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">(ND) = not determined.</p></div></div><div></div></div><div class="NLM_p">When a single 30 μL drop containing 100 μg of <b>5</b>, formulated as a suspension, was dosed in the cyno-IOP model, a modest 17% reduction in IOP was observed at 6 h and a 10% reduction was observed after 24 h. When a higher concentration of 300 μg in 30 μL was administered, mild hyperemia and ocular discharge were observed in the eyes of both rabbits and monkeys, limiting further evaluation at this dose. Although encouraged by the ability of <b>5</b> to demonstrate <i>in vivo</i> efficacy, there was room for further improvement. We initially focused on the piperidine of the tail (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), recognizing that this region offered one of the few areas to dramatically affect the physicochemical properties of the scaffold. Removal of the ethyl amide to reveal the free piperidine NH (<b>6</b>) afforded a dramatic loss of <i>in vitro</i> potency, as did N<i>-</i>alkylation (<b>7</b>). The amide appeared essential to retain potency, with a slight preference for cyclopropyl amide. We next explored the importance of substitution around the thiophene portion of the core. Installation of a methyl group at the 5-position (R<sup>4</sup>) improved CHO cellular potency (<b>8</b> vs <b>9</b>), and more importantly led to improved potency in the GTM-3 assay. Further exploration of the 5-position revealed that an electron withdrawing group or larger alkyl groups than methyl were less preferred (<b>10</b> and <b>11</b>) in the GTM-3 assay. Modification of the thiophene 4-position (e.g., R<sup>3</sup> in <b>12</b>–<b>14</b>) retained <i>in vitro</i> potency with addition of either methyl or ethyl groups. Recognizing that substitutions at both the 4 and 5 positions of the thiophene were tolerated or offered enhanced potency encouraged us to explore alternative core units to further increase the <i>in vitro</i> potency and also enrich the chemical diversity.</div><div class="NLM_p">We hypothesized that substitution at the 5 position may be filling a pocket within the protein, leading to the improved potency, while substitution at the 4 position may be altering the conformation of the piperidine tail to a more preferred orientation. These two hypotheses directed our efforts as we investigated replacements of the thiophene. Guided by our pharmacophore model, we identified 5- and 6-membered cycloalkenes and indanes as potential replacements for the thiophene (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cycloalkene and Indane Analogs Derived from <b>12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0011.gif" alt="" id="GRAPHIC-d55e654-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="/" /></col><col align="char" char="/" /></col><col align="left" /></col><col align="char" char="/" /></col><col align="char" char="/" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="/">CHO EC<sub>50</sub> (μM)/E-max (%)</th><th class="colsep0 rowsep0" align="center" char="/">GTM-3 EC<sub>50</sub> (μM)/E-max (%)</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="/">CHO EC<sub>50</sub> (μM)/E-max (%)</th><th class="colsep0 rowsep0" align="center" char="/">GTM-3 EC<sub>50</sub> (μM)/E-max (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="/">0.0025/101</td><td class="colsep0 rowsep0" align="char" char="/"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">(−)-<b>20</b></td><td class="colsep0 rowsep0" align="char" char="/">0.037/101</td><td class="colsep0 rowsep0" align="char" char="/">1.2/97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="/">0.00035/101</td><td class="colsep0 rowsep0" align="char" char="/">0.085/110</td><td class="colsep0 rowsep0" align="left">(+)-<b>21</b></td><td class="colsep0 rowsep0" align="char" char="/">0.001/101</td><td class="colsep0 rowsep0" align="char" char="/">0.055/85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-<b>17</b></td><td class="colsep0 rowsep0" align="char" char="/">0.001/102</td><td class="colsep0 rowsep0" align="char" char="/">0.006/85</td><td class="colsep0 rowsep0" align="left">(−)-<b>21</b></td><td class="colsep0 rowsep0" align="char" char="/">0.024/99</td><td class="colsep0 rowsep0" align="char" char="/"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-<b>17</b></td><td class="colsep0 rowsep0" align="char" char="/">0.009/100</td><td class="colsep0 rowsep0" align="char" char="/">0.17/63</td><td class="colsep0 rowsep0" align="left">(+)-<b>22</b></td><td class="colsep0 rowsep0" align="char" char="/">0.0025/103</td><td class="colsep0 rowsep0" align="char" char="/">0.32/70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="/">0.001/99</td><td class="colsep0 rowsep0" align="char" char="/">0.14/71</td><td class="colsep0 rowsep0" align="left">(+)-<b>23</b></td><td class="colsep0 rowsep0" align="char" char="/"><0.0005/104</td><td class="colsep0 rowsep0" align="char" char="/">0.005/106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-<b>19</b></td><td class="colsep0 rowsep0" align="char" char="/">0.001/102</td><td class="colsep0 rowsep0" align="char" char="/">0.01/100</td><td class="colsep0 rowsep0" align="left">(−)-<b>23</b></td><td class="colsep0 rowsep0" align="char" char="/">0.017/102</td><td class="colsep0 rowsep0" align="char" char="/">0.49/82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-<b>19</b></td><td class="colsep0 rowsep0" align="char" char="/">0.007/100</td><td class="colsep0 rowsep0" align="char" char="/"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">(+)-<b>24</b></td><td class="colsep0 rowsep0" align="char" char="/"><0.0005/101</td><td class="colsep0 rowsep0" align="char" char="/">0.009/120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-<b>20</b></td><td class="colsep0 rowsep0" align="char" char="/"><0.0005/100</td><td class="colsep0 rowsep0" align="char" char="/">0.003/89</td><td class="colsep0 rowsep0" align="left">(−)-<b>24</b></td><td class="colsep0 rowsep0" align="char" char="/">0.003/101</td><td class="colsep0 rowsep0" align="char" char="/"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">As anticipated, the cycloalkenes were tolerated, with a preference for the larger 6-membered ring system (<b>16</b>), consistent with substitution of the 5-position of the thiophene offering improved potency. Returning to the concept of altering the orientation of the piperidine tail, we then explored alkylation of the cyclohexene. A monomethyl substitution at the 3-position of the cyclohexene ring, somewhat mimicking substitution of the 4-position of the thiophene, proved beneficial, with the (+)-enantiomer of <b>17</b> furnishing a 14-fold improvement in potency relative to <b>16</b> in the GTM-3 assay. Interestingly, the other methyl enantiomer, or the gem-dimethyl analogue <b>18</b>, resulted in a decrease in potency relative to <b>16</b>. Of note, additional SAR (data not shown) indicated that substitution of the 2 position of the phenol (as in <b>16</b>) with a methyl group, or the 3 position with an ethyl group afforded similar activity, with a modest preference for the 3-ethyl motif. Highly encouraged by the ability to morph from the thiophene to the cyclohexene, we turned our attention to the indane concept.</div><div class="NLM_p">Replacement of the dialkyl thiophene of <b>12</b> with an indane led to compound <b>19</b>, which afforded similar potency in the GTM-3 cellular assay as <b>12</b>; of note, the corresponding enantiomer (−)-<b>19</b> was far less potent, supporting our previous observations about a preferred tail orientation. Although we were encouraged by the potency of (+)-<b>19</b>, there were concerns about the chemical stability of the benzylic ether linkage when considering that ideally a successful topical ocular molecule needs to be stable in an aqueous-based formulation for >12 months. Thus, we examined replacement of the potentially labile oxygen linker with a nitrogen (<b>20</b>), which proved equally potent. Aiming for further potency enhancement, we explored the 6 position of the indane core (R<sup>5</sup>), as that seemed to overlay with the 5-position of the thiophene core (e.g., <b>9</b>). Surprisingly, addition of a methyl to the indane core, (+)-<b>21</b>, decreased the GTM cellular potency by 18-fold relative to (+)-<b>20</b>.</div><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">4-Piperidylphenols and 4-piperidylaniline tail pieces were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Boronic ester <b>25</b> was coupled to the appropriate bromophenol utilizing Suzuki-type coupling conditions, followed by hydrogenation over Pd/C, to give 4-Boc-piperidylphenols <b>26</b>. Removal of the Boc protecting group and acylation with cyclopropylcarbonyl chloride gave rise to both N- and O-acylation, with the <i>O</i>-acyl group being selectively removed <i>in situ</i> with MeOH and K<sub>2</sub>CO<sub>3</sub>, to give free phenols <b>27</b>. Preparation of aniline <b>30</b> was accomplished using similar conditions to the 4-piperidylphenols, but the Boc removal and N<i>-</i>acylation were performed before reducing both the olefin and nitro group of <b>29</b> via hydrogenation over Pd/C.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Activator Tails<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromo-2-methyl phenol (for <b>26a</b>) or 4-chloro-3-ethylphenol (for <b>26b</b>), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct, aq. K<sub>3</sub>PO<sub>4</sub>, CH<sub>3</sub>CN, 80 °C; or SPhos-Pd (first generation), aq. K<sub>3</sub>PO<sub>4</sub>, DMF, 110 °C; (b) H<sub>2</sub>, Pd/C 5%, MeOH, rt; (c) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (2) cyclopropanecarbonyl chloride, <i>i-</i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (3) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) 4-bromo-2-methyl-1-nitrobenzene, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct, aq. K<sub>3</sub>PO<sub>4</sub>, CH<sub>3</sub>CN, 80 °C; (e) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (2) cyclopropanecarbonyl chloride, <i>i-</i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><div class="NLM_p">The general syntheses of activators <b>4</b>–<b>14</b> are outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The core was constructed starting with commercially available 2-bromo-6-hydrazinyl-pyridine (<b>31</b>) and ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate, which were reacted in EtOH at room temperature, followed by trituration with water, to provide <b>32</b>. A Suzuki coupling between <b>32</b> and (3-formylthiophen-2-yl)boronic acid was best achieved by employing ((<i>t</i>-Bu)<sub>3</sub>P)<sub>2</sub>Pd as the catalyst and potassium fluoride as the base in THF at room temperature followed by reduction of the aldehyde to give alcohol <b>33</b>. Coupling <b>33</b> with 4-piperidylphenol <b>26</b> was achieved by a Mitsunobu-type reaction, to afford phenoxyether <b>37</b>. When the piperidine nitrogen was protected with a Boc group, it was further functionalized by deprotection with TFA, followed by either acylation, coupling with a carboxylic acid, or alkylation. Finally, saponification of the ethyl ester afforded activators with the general structure of <b>38</b> (where R<sup>4</sup> = R<sup>5</sup> = H).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Activators <b>4</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate, EtOH, rt; (b) (3-formylthiophen-2-yl)boronic acid, KF, Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub>, THF, rt; (c) NaBH<sub>4</sub>, EtOH, 0 °C; (d) NBS, DMF, rt; or NCS, DMF; (e) corresponding dialkylzinc, Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub>, THF, rt; (f) <b>26</b>, DIAD, PPh<sub>3</sub>, THF; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) propionyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; or cyclopropylmethyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; or 2-cyclopropylacetic acid, HATU, <i>i-</i>Pr<sub>2</sub>NEt, DMF, rt; (i) LiOH, THF, MeOH, H<sub>2</sub>O, 50 °C.</p></p></figure><div class="NLM_p">Regioselective modification at the 5-position of the thiophene was achieved by treatment of <b>33</b> with <i>N</i>-bromosuccinimide (X<sup>1</sup> = Br) or <i>N</i>-chlorosuccinimide (X<sup>1</sup> = Cl), with only a single regioisomer observed. Converting the 5-bromothiophene <b>34</b> to 5-alkylthiophene <b>35</b> was accomplished with dimethyl or diethyl zinc in the presence of ((<i>t</i>-Bu)<sub>3</sub>P)<sub>2</sub>Pd in THF. Compound <b>35</b> was then successfully coupled with 4-piperidylphenol <b>26</b> under Mitsunobu-type reaction conditions, followed by saponification of the ethyl ester to give activators <b>38</b> (where R<sup>4</sup> = H and R<sup>5</sup> = alkyl or Cl). 5-Alkylthiophene <b>35</b> could be further functionalized at the 4 position by treating with NBS, followed by diethyl zinc, to give rise to 4,5-dialkyl thiophenes <b>36</b>, which could be carried forward as described above to <b>38</b> (where R<sup>4</sup> = Et and R<sup>5</sup> = Me). To selectively prepare activators with only substitution at the 4-position of the thiophene, we used previously described selective C–H functionalization.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Activators with the general structure of <b>41</b> were accessed via <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, starting with a two-step, one-pot Miyaura borylation and Suzuki coupling with either <b>32</b> or <b>39</b> (Y = H or Me) to afford the ketone intermediate <b>40</b>. Reductive amination followed by saponification afforded the final activators <b>41</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Indane Amine Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) bis(pinacolato)diboron, KOAc, SPhos–Pd (first generation), dioxane, 120 °C (microwave); (2) <b>42</b>, aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos–Pd (first generation), dioxane, 110 °C conventional heating (one pot); (b) (1) <b>30</b>, cat. TsOH, 130 °C with Dean–Stark apparatus; (2) NaBH<sub>4</sub>, EtOH, 0 °C to rt; (c) LiOH, MeOH/THF/H<sub>2</sub>O, 50 °C.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> outlines the synthesis of indane activators with an ether linkage. The 7-bromo-2,3-dihydro-1<i>H</i>-inden-1-one (<b>42</b>) was either reduced under standard NaBH<sub>4</sub> conditions to give the racemic indanol <b>43</b>, or <b>42</b> was reduced in an asymmetric fashion, using RuCl[(<i>R</i>,<i>R</i>)-Tsdpen](p-cymene), to give the enantiomerically enriched indanol <b>43</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The indanols underwent a Mitsunobu reaction with phenol <b>27</b> to afford ether <b>44</b>. A one pot Miyaura borylation–Suzuki coupling with pyridine halides <b>32</b> or <b>39</b> and saponification of the ester furnishes activators <b>45</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Indane Ether Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 0 °C to rt; or RuCl[(<i>R</i>,<i>R</i>)-Tsdpen](p-cymene), TEA·HC(O)OH, DMF, 60 °C; (b) <b>27</b>, azodicarboxylic dimorpholide, <i>n-</i>Bu<sub>3</sub>P, THF, rt; (c) bis(pinacolato)diboron, KOAc, SPhos-Pd (first generation), dioxane, 120 °C (microwave); (2) aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos-Pd (first generation), dioxane, 110 °C conventional heating (one pot); (d) LiOH, MeOH/THF/H<sub>2</sub>O, 50 °C.</p></p></figure><div class="NLM_p">The synthesis of cycloalkenyl activators is outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. TBS protected cycloalkenyl intermediates <b>46</b> were prepared from previously reported intermediates.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> A two step, one pot cross-coupling was performed to couple <b>46</b> and 2-bromo pyridyl <b>32</b> or <b>39</b>. Removal of the TBS group using TBAF in THF afforded <b>47</b>. The free alcohols <b>47</b> were then coupled with 4-piperidylphenol <b>27</b> via a Mitsunobu-type reaction, followed by saponification, to provide activators <b>48</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Cycloalkenyl Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) bis(pinacolato)diboron, potassium acetate, SPhos–Pd (first generation), dioxane, 110 °C; (2) corresponding cycloalkene intermediate, aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos–Pd (first generation) (one pot); (b) TBAF, THF, rt; (c) <b>27</b>, DIAD, PPh<sub>3</sub>, THF; (d) LiOH, THF, MeOH, H<sub>2</sub>O, 50 °C.</p></p></figure></div><div id="sec2-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>In Vivo</i> Pharmacology</h3><div class="NLM_p">With acceptable potency and efficacy observed in the GTM-3 cellular assay for the thiophene, cyclohexene, and indane cores, we next selected representative examples from each scaffold for <i>in vivo</i> evaluation. Compounds <b>12</b>, (+)-<b>17</b>, and (+)-<b>20</b> were profiled first in an acute rabbit ocular tolerability study to assess the maximum dose that afforded acceptable ocular tolerability. Each compound was formulated at 1%, 0.3%, and 0.1% concentrations (300 μg, 100 μg, and 30 μg, respectively) in a 30 μL drop to test in the rabbit ocular tolerability study to identify a suitable dose to evaluate in the cyno-IOP model. Thiophene <b>12</b> was sufficiently tolerated up to 300 μg, although mild ocular discharge was noted in the majority of animals. In the cyno-IOP model, thiophene <b>12</b> afforded improved IOP lowering compared to progenitor compound <b>5</b>; however a 3-fold higher dose was required; furthermore some mild ocular irritation was noted in a subset of animals (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">3</a></a>). In the case of cyclohexene (+)-<b>17</b> and indane (+)-<b>20</b>, even a dose as low as 30 μg afforded suboptimal tolerability with hyperemia and excessive blinking observed in subsets of rabbits. The fact that ocular tolerability limited dosing to <30 μg for (+)-<b>17</b> and (+)-<b>20</b> and that several of the compounds evaluated (e.g., <b>5</b> and <b>12</b>) also exhibited signs of irritation was a concern. While it was not clear what was causing the acute ocular tolerability issues, one hypothesis was the relatively acidic 5-(trifluoromethyl)-pyrazole-4-carboxylic acid moiety that was common to most compounds across scaffolds, for example, the p<i>K</i><sub>a</sub> of the carboxylic acid of (+)-<b>21</b> was determined to be only 3.1. Replacing the electron withdrawing CF<sub>3</sub> moiety with a methyl as in (+)-<b>23</b> raises the p<i>K</i><sub>a</sub> over a full log unit to 4.3, without impacting cellular activity. Of note, completely removing substitution at the 5-position of the pyrazole led to a substantial loss in cellular activity (e.g., (+)-<b>22</b>). When (+)-<b>23</b> was evaluated in an acute rabbit tolerability study, we were delighted to see that at a dose of 300 μg (1%), the highest dose tested, this molecule was well tolerated. Performing the same transformation on cyclohexene (+)-<b>17</b> afforded (+)-<b>24</b>; this also afforded a much improved rabbit ocular tolerability profile, up to a dose of 300 μg. While we recognize that ocular tolerability is almost certainly governed by a wide range of parameters and that there may not be a general strict correlation of p<i>K</i><sub>a</sub> to tolerability, in this instance, empirically, it appears to be a factor.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> With (+)-<b>23</b> and (+)-<b>24</b> offering improved dose flexibility, they were evaluated in the cyno-IOP model. Both (+)-<b>23</b> and (+)-<b>24</b> afforded robust IOP lowering with excellent ocular tolerability at a dose of 30 μg (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">3</a></a>). However, what differentiated indane (+)-<b>23</b> from cyclohexene (+)-<b>24</b> was the trend that for (+)-<b>23</b> the reduction in IOP was maintained or even increased from 6 h to 24 h time points, whereas there was a clear attenuation in efficacy for (+)-<b>24</b> in going from 6 to 24 h time point. The importance of being able to maintain effective IOP lowering over a 24 h time period, and the ability to lower IOP to levels that compare favorably to other approved therapies in this model,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> led to the selection of compound (+)-<b>23</b> for clinical evaluation.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. IOP reduction (%) in the cynomolgus monkey laser-induced hypertensive model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, SAR development starting from <b>4</b> identified <i>in vitro</i> potent thiophene containing sGC activators, which afforded modest <i>in vivo</i> efficacy in a cynomolgus monkey model of elevated IOP. Subsequent core modifications led to the identification of cyclohexene and indane scaffolds. Further refinement addressed ocular tolerability concerns and led to well tolerated molecules with robust IOP lowering in the cyno-IOP model. These efforts culminated with the discovery of (+)-<b>23</b>, an sGC activator specifically designed for once a day topical ocular dosing for the treatment of elevated IOP associated with glaucoma. Additional preclinical and clinical pharmacology and safety studies with (+)-<b>23</b> will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacophore Modeling</h3><div class="NLM_p">Eight representative sGC activators from the literature<a onclick="showRef(event, 'cit9c ref17'); return false;" href="javascript:void(0);" class="ref cit9c ref17">(9c,17)</a> were selected to maximize chemical dissimilarity and presumable maintenance of a similar binding site based on their electronic and steric features as well as reported SAR. The activators employed are described in refs <a onclick="showRef(event, 'cit9c'); return false;" href="javascript:void(0);" class="ref cit9c">(9c)</a> and <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> are 5-(trifluoro-methyl)-1-(6-(2-((4-(4-(trifluoro-methyl)-cyclohexyl)-phenyl)-methoxy)-phenyl)-pyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylic acid, 1-(4-(2-((4-(4-cyano-phenyl)-2-methyl-phenyl)-methoxy)-5-methyl-phenyl)-pyrimidin-2-yl)-piperidine-4-carboxylic acid, 1-(6-(3-chloro-phenyl)-pyridin-2-yl)-5-(trifluoro-methyl)-1<i>H</i>-pyrazole-4-carboxylic acid, 1-((5-methyl-2-(3-(trifluoro-methyl)-phenyl)-thiazol-4-yl)-methyl)-1<i>H</i>-pyrazole-4-carboxylic acid, 1-(3-(2-cyclopentyl-2-(4-((2-fluoro-7-oxo-8-aza-bicyclo[4.3.0]nona-1(6),2,4-trien-8-yl)-methyl)-phenyl)-acetylamino)-benzyl)-cyclopropanecarboxylic acid, 3-(4-chloro-3-(2-(4-chloro-phenyl)-4,4,4-trifluoro-3-methyl-butyrylamino)-phenyl)-4-cyclopropyl-butanoic acid, 1-(3-(2-(4-chloro-phenyl)-2-cyclopentyl-acetylamino)-benzyl)-cyclopropanecarboxylic acid, and 1-(6-(5-chloro-2-(4-(4-(2,2,2-trifluoro-ethyl)-piperazin-1-yl)-phenyl)-phenyl)-pyridin-2-yl)-5-(trifluoro-methyl)-1<i>H</i>-pyrazole-4-carboxylic acid.</div><div class="NLM_p last">Low energy conformations of these molecules were generated with MacroModel v9.6,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> followed by B3LYP/6-31+G(d,p) with a continuum water model with Gaussian 03.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> An initial overlay model was built based on similarity of local molecular size, shape, electronic properties, and reported SAR within low energy conformations of these molecules. The model was further refined with MOE flexible alignment.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Vitro</i> Cellular Assays</h3><div id="sec4-2-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> CHO Cellular Assay</h4><div class="NLM_p last">CHO cells overexpressing sGC were generated to test the effect of sGC activators in a cellular context. Human cDNAs for GUCYA3 (the Reference Sequence <a href="https://NM_000856.3" class="ext-link">NM_000856.3</a>) and GUCYB3 (the Reference Sequence <a href="https://NM_000857.1" class="ext-link">NM_000857.1</a>) were amplified by PCR from a HUVEC (human umbilical vein endothelial cells) cDNA library and cloned into mammalian expression vectors. CHO K1 cells (ATCC CCL-61) were transfected using Lipofectamine 2000 following manufacturer’s instructions and stably expressing clones were identified by antibiotic selection. CHO GUCY clone 8E10 was used for subsequent experiments. Cells were seeded at a density of 3000 cells/well in white 384-well proxyplates (PerkinElmer) and incubated overnight, then the medium was removed, and cells were washed with assay buffer (Hanks’ balanced salt solution (HBSS), 0.1% BSA, 1 mM IBMX, 20 μM ODQ). sGC activators were serially diluted in DMSO, then diluted in assay buffer prior to adding to cells (10 μL/well, final DMSO concentration 0.5%). Cells were incubated with compounds for 1 h at room temperature and then assayed for cGMP production using Cisbio cGMP HTRF kit (62GM2PEC) according to manufacturer’s instructions. The EC<sub>50</sub> values are calculated based on the amount of cGMP interpolated from the standard curve, using a 4-parameter sigmoidal dose–response. The % E-max (maximal cGMP produced) was calculated in reference to 1-{6-[5-chloro-2-({4-[<i>trans</i>-4-(trifluoromethyl)cyclohexyl]-benzyl}oxy)phenyl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylic acid.<a onclick="showRef(event, 'cit9c ref26'); return false;" href="javascript:void(0);" class="ref cit9c ref26">(9c,26)</a></div></div><div id="sec4-2-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> GTM-3 Cellular Assay</h4><div class="NLM_p">GTM-3 cells (SV40-transformed human GTM cells, Alcon Laboratories) were used for additional profiling of selected sGC activators. Cells were plated in 96-well plates at a density of 50 000 cells/well and incubated overnight. Medium was removed, and cells were incubated with assay buffer (Dulbecco’s modified Eagle’s medium (DMEM), 1 mM IBMX, 0.1% BSA, 20 μM ODQ) for 15 min, then sGC activators serially diluted in DMSO were added (final DMSO concentration 0.1%). Cells were incubated 30 min at 37 °C, then cGMP was quantitated using CatchPoint Cyclic-GMP Fluorescent Assay Kit (Molecular Devices) following manufacturer’s instructions.</div><div class="NLM_p last">The EC<sub>50</sub> values are calculated based on the amount of cGMP interpolated from the standard curve, using a 4-parameter sigmoidal dose–response. The % E-max (maximal cGMP produced) was calculated in reference to 1-{6-[5-chloro-2-({4-[<i>trans</i>-4-(trifluoromethyl)cyclohexyl]-benzyl}oxy)phenyl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylic acid.<a onclick="showRef(event, 'cit9c ref26'); return false;" href="javascript:void(0);" class="ref cit9c ref26">(9c,26)</a></div></div></div><div id="sec4-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vivo</i> Pharmacology Experiments</h3><div class="NLM_p">All animal related procedures were conducted under Novartis Institutional Animal Care and Use Committee (IACUC) approved protocols in compliance with Animal Welfare Act (AWA) regulations and the Guide for the Care and Use of Laboratory Animals.</div><div id="sec4-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Determination of IOP in Lasered (Hypertensive) Eyes of Cynomolgus Monkeys</h4><div class="NLM_p last">The induction of elevated IOP in cynomolgus monkeys and the determination of IOP have been described in detail in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>. However, in brief, conscious IOP was determined with an Alcon Pneumatonometer (Alcon Laboratories, Inc., Fort Worth, TX.) after light corneal anesthesia with 0.25% proparacaine. Right eyes were hypertensive as a result of laser trabeculoplasty. Left eyes were intact and with normal IOP. After a baseline IOP measurement, the animals were randomly divided into two groups with similar group mean of IOP. Compound-containing formulation was administered as a single 30 μL topical ocular drop to both eyes in 8–9 conscious ocular hypertensive cynomolgus monkeys. Vehicle was instilled in both eyes of 8–9 additional animals as control. Subsequent IOP measurements were taken at prescribed time points. Average baseline IOP in the hypertensive eye ranged from 35 to 40 mmHg (<i>n</i> = 9–10 animals/group). Group mean and standard error of the mean (SEM) were calculated. Statistical significance of IOP change from baseline and also versus treatment groups were determined by repeated measures ANOVA and Bonferroni <i>t</i> test at <i>p</i> < 0.05. For this manuscript the formulation employed in all instances was comprised of: hydroxypropyl methylcellulose USP 2910 E4M (0.5%), dibasic sodium phosphate anhydrous (0.2%), sodium chloride (0.65%), polysorbate 80 (0.05%), sodium hydroxide and hydrochloric acid (to adjust to pH 7.4), and purified water (q.s. 100%).</div></div><div id="sec4-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Rabbit Ocular Tolerability Assessments Following Topical Ocular Dosing</h4><div class="NLM_p last">The compound was instilled as a single 30 μL topical ocular drop on the cornea of New Zealand albino rabbits employing concentrations as specified. Conjunctival hyperemia (mild, medium, and severe, based on area of blood vessel coverage), conjunctival discharge (mild, inner portion of eye; moderate, around eyelid/hair; severe, marked discharge around periocular skin), and swelling (mild or moderate, lid misalignment; severe, eversion) were assessed up to 2 h postdose and followed up at 24 h after dosing. Up to 20 rabbits (10 eyes/dose) were evaluated following a single topical ocular dose. Percent of eyes with varying degrees of ocular tolerability were noted for each dose and compared with that observed following vehicle treatment.</div></div></div><div id="sec4-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthetic Methods and Procedures</h3><div id="sec4-6-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Chemical Methods</h4><div class="NLM_p last">Starting materials, reagents, and solvents were obtained from commercial sources and used as received. THF and diethyl ether were anhydrous grade. Progress of the reactions was monitored by analytical LC-MS using an Agilent 1100 series with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters ZQ single quad mass detector. Progress of the reactions was also monitored by analytical LC-MS using a Waters Classic AcQuity UPLC with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a Waters SQ single quad mass detector. Purification of intermediates and final products was carried out using CombiFlash Companion from Teledyne Isco, Inc., and RediSep Rf disposable normal phase silica gel columns (4–300 g). HPLC was performed on a Waters preparative HPLC system controlled by MassLynx. Systems were run with acetonitrile/water gradient with 10 mM NH<sub>4</sub>OH modifier on X-Bridge C18 5 μm particle column (RP-HPLC-B) or 0.1% TFA modifier on SunFire C18 μm particle column (RP-HPLC-A). Preparative supercritical fluid chromatography (SFC) was performed employing WatersThar-80 system with UV detection based collection. In the case of racemic samples, including intermediates, enantiomers were separated by SFC using a chiral stationary phase with the provided conditions. Optical rotations were measured at the sodium D line with a Jasco P-2000 digital polarimeter in a qualitative manner. NMR spectra were recorded on a Bruker Avance II 400 MHz spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane or deuterated solvent as the internal standard. The following abbreviations are used to denote signal patterns: s = singlet, d = doublet, t = triplet, m = multiplet, and br = broad. The purity of all exemplified compounds was ≥95%, as determined by both <sup>1</sup>H NMR and HPLC-UV at a wavelength of 214 nm.</div></div><div id="sec4-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for the Saponification</h4><div class="NLM_p">Method A. A mixture of ethyl ester (1 equiv) and LiOH (10 equiv) in 1:1 THF/H<sub>2</sub>O (0.5 M) was stirred at 40 °C for 16 h, and then partially concentrated. The resulting residue was rendered pH ≈ 5 with 2 N aq. HCl and then extracted twice with EtOAc. The combined organic extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and then concentrated.</div><div class="NLM_p">Method B. A mixture of ethyl ester (1 equiv) and 1 M aq LiOH (3 equiv) in acetonitrile (0.02 M) was stirred at 50 °C for 2 h. Aqueous HCl (3.3 equiv of 1 M) was added to resulting precipitates, which were collected and then washed with H<sub>2</sub>O and MeOH to furnish the title compound. In some instances, further HPLC purification was performed under the provided conditions.</div><div class="NLM_p last">Method C. A mixture of ethyl ester (1 equiv) and 1 M aq LiOH (10 equiv) in 1:1 THF/MeOH (0.02 M) was stirred at rt for 1.5 h and then rendered acidic with 1 N aq HCl. The mixture was then extracted with EtOAc. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated.</div></div><div id="sec4-8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure for the Mitsunobu-type Reaction</h4><div class="NLM_p">Method D. To a solution of alcohol (1.1 equiv), phenol (1 equiv), and PPh<sub>3</sub> (1.1 equiv) in THF (0.2 M) at 0 °C was added diisopropyl azodicarboxylate (DIAD, 1.1 equiv). The mixture was stirred at rt for 16 h and then concentrated.</div><div class="NLM_p last">Method E. A mixture of alcohol (1 equiv), phenol (1.5 equiv), and 2-(tributylphosphoranylidene)acetonitrile (2 equiv) in toluene (1 M) was stirred at 80 °C for 4 h. The reaction mixture was then concentrated.</div></div><div id="sec4-9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure for a Pd Mediated Cross Coupling with Corresponding Zincate</h4><div class="NLM_p last">Method F. To a solution aryl halide (1 equiv) in THF (10 mL) was added dialkylzinc (4 equiv as a solution), followed by Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub> (10 mol %). The mixture was stirred at rt for 16 h and then quenched with EtOH. The mixture was diluted with EtOAc. The mixture was filtered through a plug of silica gel, which was rinsed with EtOAc. The filtrate was then concentrated.</div></div><div id="sec4-10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure of a Pd Mediated Two-Step One-Pot Cross-Coupling</h4><div class="NLM_p">Method G. Step 1. 2-Halo pyridine (1 equiv), bis(pinacolato)diboron (1 equiv), and KOAc (1.5 equiv) were added to a microwave vial with a stir bar and dioxane (0.2 M). S-Phos Pd G1 (CAS registry number 1028206-58-7, 10 mol %) was added, and the head space was purged with N<sub>2</sub>. The vial was sealed and heated to 120 °C under microwave irradiation for 45 min.</div><div class="NLM_p">Step 2. Aryl halide (1.2 equiv) in dioxane (0.2 M) was added to the reaction mixture, followed by 1 M aq Na<sub>2</sub>CO<sub>3</sub> (3 equiv) and S-Phos Pd G1 (10 mol %). The reaction mixture was heated to 110 °C under microwave irradiation for 30 min. The reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O before the organic phase was passed through an Isolute Phase Separator and concentrated.</div><div id="sec4-10-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 1-(6-(3-((4-(1-Propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>4</b>)</h5><div class="NLM_p last">Step 1. A mixture of 2-bromo-3-(bromomethyl)-thiophene (1.50 g, 5.9 mmol), <i>tert-</i>butyl 4-(4-hydroxyphenyl)piperidine-1-carboxylate (0.93 g, 5.9 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.81 g, 5.9 mmol) in DMF (56 mL) was stirred at 70 °C for 22 h. The reaction mixture was cooled to rt, and then diluted with EtOAc. The organic layer was then washed twice with H<sub>2</sub>O. The organic layer was further washed with brine, and then dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (20% EtOAc in heptane) to afford <i>tert</i>-butyl 4-(4-((2-bromothiophen-3-yl)methoxy)phenyl)piperidine-1-carboxylate (0.65 g, 24% yield). MS (ESI+) <i>m</i>/<i>z</i> 395.1 (M – <i>t</i>Bu + 2H). Step 2. To a suspension of <b>32</b> (500 mg, 1.373 mmol), bis(pinacolato)diboron (384 mg, 1.51 mmol), potassium acetate (404 mg, 4.12 mmol), and X-Phos (98 mg, 0.21 mmol) in dioxane (13 mL) was added Pd(OAc)<sub>2</sub> (12 mg, 0.053 mmol). The mixture was then stirred at 100 °C for 3 h and cooled to rt. The mixture was then filtered through a plug of Celite. The filtrate was then concentrated. The resulting residue was suspended in 1,4-dioxane (12 mL). To the suspension were added <i>tert</i>-butyl 4-(4-((2-bromothiophen-3-yl)methoxy)phenyl)piperidine-1-carboxylate (500 mg, 1.1 mmol), 2 M aq. sodium carbonate (2.21 mL, 4.4 mmol), and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> adduct. The mixture was stirred at 80 °C for 30 h and then cooled to rt. The mixture was diluted with EtOAc and then washed successively with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (20% EtOAc in heptane) to afford <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophen-3-yl)methoxy)phenyl)piperidine-1-carboxylate (0.30 g, 42%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.18 (t, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.5 Hz, 1H), 7.72–7.70 (m, 2H), 7.26 (d, <i>J</i> = 5.1 Hz, 1H), 7.13–7.10 (m, 2H), 6.90–6.87 (m, 2H), 5.28 (s, 2H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 4.06–4.00 (m, 2H), 2.82–2.75 (m, 2H), 2.65–2.55 (m, 1H), 1.72–1.68 (m, 2H), 1.45–1.40 (m, 1H), 1.39 (s, 9H), 1.29 (t, <i>J</i> = 7.2 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 657.4 (M + H). Step 3. Deprotection of the Boc group on <i>tert-</i>butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophen-3-yl)methoxy)phenyl)piperidine-1-carboxylate was achieved by a similar method as described for the synthesis of <b>27a</b> to afford ethyl 1-(6-(3-((4-(piperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, which was used in the next step without any further purification (crude yield). MS (ESI+) <i>m</i>/<i>z</i> 557.3 (M + H). Step 4. To a solution of ethyl 1-(6-(3-((4-(piperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (0.25 g, 0.45 mmol) and Et<sub>3</sub>N (0.15 mL, 1.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added propionyl chloride (0.05 mL, 0.054 mmol). The mixture was stirred at rt for ca. 80 min and then diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed successively with H<sub>2</sub>O (three times) and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (50% EtOAc in heptane) to afford ethyl 1-(6-(3-((4-(1-propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (0.20 g, 74% yield). <sup>1</sup>H NMR (300 MHz, DMSO- <i>d</i><sub>6</sub>) δ 8.20 (s, 1H), 8.18 (t, <i>J</i> = 8.1 Hz, 1H), 7.84 (d, <i>J</i> = 7.2 Hz, 1H), 7.72–7.69 (m, 2H), 7.26 (d, <i>J</i> = 5.1 Hz, 1H), 7.13–7.11 (m, 2H), 6.90–6.88 (m, 2H), 5.28 (s, 2H), 4.58–4.52 (m, 1H), 4.31 (q, <i>J</i> = 6.9 Hz, 2H), 3.94–3.89 (m, 1H), 3.04–3.00 (m, 2H), 2.70–2.63 (m, 1H), 2.56–2.50 (m, 1H), 2.31 (q, <i>J</i> = 7.5 Hz, 2H), 1.80–1.70 (m, 2H), 1.58–1.48 (m, 2H), 1.29 (t, <i>J</i> = 6.9 Hz, 3H), 0.98 (t, <i>J</i> = 7.5 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 613.4 (M + H). Step 5. Method A employing ethyl 1-(6-(3-((4-(1-propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate afforded <b>4</b> (0.09 g, 82% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.15 (s, 1H), 8.07 (dd, <i>J</i> = 7.80, 8.00 Hz, 1H), 7.84 (dd, <i>J</i> = 0.60, 8.00 Hz, 1H), 7.59 (dd, <i>J</i> = 0.60, 8.00 Hz, 1H), 7.53 (d, <i>J</i> = 5.26 Hz, 1H), 7.26 (d, <i>J</i> = 5.13 Hz, 1H), 7.08–7.13 (m, 2H), 6.82–6.88 (m, 2H), 5.31 (s, 2H), 4.63–4.70 (m, 1H), 4.01–4.09 (m, 1H), 3.14–3.22 (m, 1H), 2.64–2.79 (m, 2H), 2.45 (q, <i>J</i> = 7.54 Hz, 2H), 1.80–1.92 (m, 2H), 1.46–1.66 (m, 2H), 1.14 (t, <i>J</i> = 7.46 Hz, 3H). HRMS calculated for C<sub>29</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 585.1783, found 585.1808.</div></div><div id="sec4-10-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 1-(6-(3-((2-Methyl-4-(1-propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>5</b>)</h5><div class="NLM_p last">Step 1. Method D employing <b>33</b> and <b>26a</b>, followed by FCC purification (0–30% EtOAc/heptane) afforded <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophen-3-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate (2.4 g, 71% yield). MS (ESI+) <i>m</i>/<i>z</i> 615.2 (M – <i>t</i>Bu + 2H). Step 2. Following the procedure as described for the preparation of <b>29</b>, a reaction of <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophen-3-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate with propionyl chloride in place of cyclopropane carbonyl chloride afforded ethyl 1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (160 mg, 98% yield). MS (ESI+) <i>m</i>/<i>z</i> 627.3 (M + H). Step 3. Method B employing ethyl 1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate, followed by RP-HPLC-B purification, afforded <b>5</b> (23 mg, 15% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.03 (dd, <i>J</i> = 7.8, 8.0 Hz, 1H), 8.00 (s, 1H), 7.78 (d, <i>J</i> = 7.8 Hz, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.52 (d, <i>J</i> = 5.1 Hz, 1H), 7.26 (d, <i>J</i> = 5.1 Hz, 1H), 6.97–7.00 (m, 1H), 6.92–6.96 (m, 1H), 6.80 (d, <i>J</i> = 8.4 Hz, 1H), 5.33 (s, 2H), 4.62–4.70 (m, 1H), 4.02–4.08 (m, 1H), 3.12–3.22 (m, 1H), 2.66–2.75 (m, 2H), 2.44 (q, <i>J</i> = 7.5 Hz, 2H), 2.14 (s, 3H), 1.79–1.91 (m, 2H), 1.46–1.65 (m, 2H), 1.14 (t, <i>J</i> = 7.5 Hz, 3H). HRMS calculated for C<sub>30</sub>H<sub>30</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 599.1940, found 599.1999.</div></div><div id="sec4-10-3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 1-(6-(3-((2-Methyl-4-(piperidin-4-yl)phenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>6</b>)</h5><div class="NLM_p last">Deprotection of the Boc group on <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophen-3-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate was achieved by a similar method as described for the synthesis of <b>27a</b> and was followed by method B affording <b>6</b> (30 mg, quantitative yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.16 (d, <i>J</i> = 0.7 Hz, 1H), 8.07 (t, <i>J</i> = 7.9 Hz, 1H), 7.85 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.59 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 7.54 (d, <i>J</i> = 5.2 Hz, 1H), 7.27 (d, <i>J</i> = 5.2 Hz, 1H), 7.01 (d, <i>J</i> = 2.3 Hz, 1H), 6.95 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 6.81 (d, <i>J</i> = 8.4 Hz, 1H), 5.36 (s, 2H), 3.50–3.43 (m, 2H), 3.15–3.05 (m, 2H), 2.84–2.73 (m, 1H), 2.14 (s, 3H), 2.08–1.99 (m, 2H), 1.90–1.77 (m, 2H). HRMS calculated for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup> 543.1678, found 543.1687.</div></div><div id="sec4-10-4" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 1-(6-(3-((4-(1-(Cyclopropylmethyl)piperidin-4-yl)-2-methylphenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>7</b>)</h5><div class="NLM_p last">To a solution of <b>6</b> (60 mg, 0.105 mmol) in DMF (1 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (103 mg, 0.315 mmol), followed by (bromomethyl)cyclopropane (28.4 mg, 0.210 mmol). The mixture was stirred at 50 °C for 16 h, and then insoluble materials were filtered off. To the DMF solution was added a solution of 1 M aq. LiOH (0.52 mL), and then the mixture was stirred at for 50 °C for 2 h. The reaction mixture was rendered acidic by aq. HCl, and resulting precipitates were removed by filtration. The filtrate was then directly purified by RP-HPLC-B to afford <b>7</b> (7 mg, 10% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.02 (t, <i>J</i> = 7.9 Hz, 1H), 7.94–7.88 (m, 1H), 7.77 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.58–7.49 (m, 2H), 7.29 (d, <i>J</i> = 5.2 Hz, 1H), 6.96 (d, <i>J</i> = 9.2 Hz, 2H), 6.79 (d, <i>J</i> = 8.2 Hz, 1H), 5.37 (s, 2H), 3.67 (d, <i>J</i> = 12.2 Hz, 2H), 2.98 (d, <i>J</i> = 7.0 Hz, 4H), 2.72 (s, 1H), 2.13 (s, 3H), 2.04 (d, <i>J</i> = 14.3 Hz, 2H), 1.93 (t, <i>J</i> = 13.4 Hz, 2H), 1.20–1.07 (m, 1H), 0.81–0.73 (m, 2H), 0.48–0.37 (m, 2H). HRMS calculated for C<sub>31</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S (M + H) 597.2147, found 597.2151.</div></div><div id="sec4-10-5" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>8</b>)</h5><div class="NLM_p last">Step 1. A solution of cyclopropane-carboxylic acid (19.6 mg, 0.23 mmol) and HATU (66.6 mg, 0.175 mmol) in DMF (2 mL) was stirred at rt for 30 min. To the mixture were added <b>6</b> (100 mg, 0.175 mmol) and diisopropylethylamine (0.061 mL, 0.350 mmol), and then the mixture was stirred at rt for 16 h. The reaction mixture was filtered, and the filtrate was directly purified by RP-HPLC-B to afford ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (90 mg, 80% yield). MS (ESI+) <i>m</i>/<i>z</i> 639.1 (M + H). Step 2. The obtained ethyl ester was saponified by utilizing method B to provide <b>8</b> after RP-HPLC-B purification (52 mg, 60% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.07–7.98 (m, 2H), 7.78 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.58 (dd, <i>J</i> = 8.0, 0.7 Hz, 1H), 7.52 (d, <i>J</i> = 5.1 Hz, 1H), 7.26 (d, <i>J</i> = 5.2 Hz, 1H), 6.99 (d, <i>J</i> = 2.2 Hz, 1H), 6.95 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.80 (d, <i>J</i> = 8.3 Hz, 1H), 5.32 (s, 2H), 4.63 (d, <i>J</i> = 12.9 Hz, 1H), 4.44 (d, <i>J</i> = 13.6 Hz, 1H), 3.28–3.18 (m, 1H), 2.73 (tt, <i>J</i> = 11.0, 3.3 Hz, 2H), 2.15 (s, 3H), 2.05–1.95 (m, 1H), 1.95–1.75 (m, 2H), 1.72–1.44 (m, 2H), 0.95–0.75 (m, 4H). HRMS calculated for C<sub>31</sub>H<sub>30</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 611.1940, found 611.1934.</div></div><div id="sec4-10-6" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>9</b>)</h5><div class="NLM_p last">Step 1. A solution of <b>33</b> (2 g, 5.03 mmol) and NBS (1.1 g, 6.18 mmol) in DMF (20 mL) was stirred at rt for 14 h. The reaction mixture was diluted with H<sub>2</sub>O. The whole mixture was stirred at rt for 0.5 h. The resulting solid was collected by filtration. The collected solid was purified by FCC (heptane/EtOAc = 8/2 to 6/4) to afford ethyl 1-(6-(5-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (2.0 g, 83% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 8.23 (t, <i>J</i> = 8.0 Hz, 1H), 7.91 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 7.74 (dd, <i>J</i> = 8.0, 0.7 Hz, 1H), 7.31 (s, 1H), 5.53 (t, <i>J</i> = 5.5 Hz, 1H), 4.67 (d, <i>J</i> = 5.5 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 475.9 (M + H). Step 2. Following method F, ethyl 1-(6-(5-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate and dimethylzinc (2 M in toluene) afforded ethyl 1-(6-(3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (heptane/EtOAc = 67/33) (1.0 g, 77% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (d, <i>J</i> = 0.6 Hz, 1H), 8.16 (t, <i>J</i> = 7.9 Hz, 1H), 7.85 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.64 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 6.94 (d, <i>J</i> = 1.2 Hz, 1H), 5.34 (t, <i>J</i> = 5.5 Hz, 1H), 4.62 (d, <i>J</i> = 5.5 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 2.46 (d, <i>J</i> = 1.1 Hz, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 412.1. Step 3. Following method E, ethyl 1-(6-(3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate and <b>27a</b> afforded ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (15–40% EtOAc/heptane) (30 mg, 63% yield). MS (ESI+) <i>m</i>/<i>z</i> 653.1 (M + H). Step 4. Method C was employed for the hydrolysis, followed by RP-HPLC-A purification to afford <b>9</b> (11 mg, 21% yield over 2 steps). <sup>1</sup>H NMR (+5 μL TFA, 400 MHz, CD<sub>3</sub>OD) δ 8.15 (s, 1H), 8.02 (t, <i>J</i> = 7.9 Hz, 1H), 7.74 (dd, <i>J</i> = 0.6, 7.9 Hz, 1H), 7.52 (dd, <i>J</i> = 0.6, 7.9 Hz, 1H), 6.95–7.01 (m, 2H), 6.92 (dd, <i>J</i> = 2.3, 8.4 Hz, 1H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 5.25 (s, 2H), 4.58–4.69 (m, 1H), 4.39–4.51 (m, 1H), 3.17–3.26 (m, 1H), 2.65–2.79 (m, 2H), 2.50 (d, <i>J</i> = 1 Hz, 3H), 2.13 (s, 3H), 1.95–2.05 (m, 1H), 1.76–1.94 (m, 2H), 1.44–1.70 (m, 2H), 0.74–0.94 (m, 4H). HRMS calculated for C<sub>32</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 625.2096, found 625.2115.</div></div><div id="sec4-10-7" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-(6-(5-Chloro-3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>10</b>)</h5><div class="NLM_p last">Step 1. Ethyl 1-(6-(5-chloro-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate was synthesized by a similar method as described for the synthesis of ethyl 1-(6-(5-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, starting with NCS in the place of NBS. MS (ESI+) <i>m</i>/<i>z</i> 432.2 (M + H). Step 2. Following method E, <b>34</b> (X<sub>1</sub> = Cl, prepared in the step 1 above) and <b>27a</b> afforded ethyl 1-(6-(5-chloro-3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate. MS (ESI+) <i>m</i>/<i>z</i> 673.4 (M + H). Step 3. Method C, followed by HPLC purification (RP-HPLC-A), afforded <b>10</b> (3% yield over 3 steps). <sup>1</sup>H NMR (TFA salt, 400 MHz, CD<sub>3</sub>OD) δ 8.17 (s, 1H), 8.07 (dd, <i>J</i> = 7.80, 8.00 Hz, 1H), 7.75–7.80 (m, 1H), 7.63 (d, <i>J</i> = 7.96 Hz, 1H), 7.15 (s, 1H), 7.00–7.04 (m, <i>J</i> = 2.00 Hz, 1H), 6.94–6.99 (m, 1H), 6.82 (d, <i>J</i> = 8.34 Hz, 1H), 5.25 (s, 2H), 4.60–4.69 (m, 1H), 4.39–4.50 (m, 1H), 3.20–3.29 (m, 1H), 2.67–2.79 (m, 2H), 2.14 (s, 3H), 1.96–2.03 (m, 1H), 1.87–1.95 (m, 1H), 1.78–1.87 (m, 1H), 1.46–1.70 (m, 2H), 0.75–0.93 (m, 4H). HRMS calculated for C<sub>31</sub>H<sub>29</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 645.1550, found 645.1581.</div></div><div id="sec4-10-8" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-5-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>11</b>)</h5><div class="NLM_p last">Step 1. Following method F, ethyl 1-(6-(5-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate and diethylzinc (1 M in hexane), followed by FCC purification (0–30% EtOAc in heptane), afforded ethyl 1-(6-(5-ethyl-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (136 mg, 66% yield). MS (ESI+) <i>m</i>/<i>z</i> 425.90 (M + H). Step 2. To a solution of ethyl 1-(6-(5-ethyl-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (220 mg, 0.517 mmol) and diisopropylethylamine (270 μL, 1.55 mmol) in anhydrous DCM (5 mL) at rt was added methanesulfonyl chloride (72 μL, 0.931 mmol), and then the mixture was stirred at rt for 18 h. The reaction mixture was then washed with H<sub>2</sub>O. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was used in the next step without any further purification. MS (ESI+) <i>m</i>/<i>z</i> 443.8 (M + H). Step 3. To a solution of the resulting residue above (230 mg as a crude, 0.52 mmol) in anhydrous DMF (6 mL) was added potassium carbonate (239 mg, 1.73 mmol), followed by <b>26a</b> (151 mg, 0.52 mmol). The mixture was stirred at 50 °C for 18 h. The reaction mixture was diluted with EtOAc, which was then washed with H<sub>2</sub>O. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (100% heptane) to afford <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)-5-ethylthiophen-3-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate (330 mg, 91% yield). MS (ESI+) <i>m</i>/<i>z</i> 699.8 [M + H]<sup>+</sup>. Step 4. Deprotection of the Boc group of <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)-5-ethylthiophen-3-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate and subsequent acylation were achieved by a similar method as described for the synthesis of <b>27a</b> to furnish ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-5-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (240 mg, 76% yield). MS (ESI+) <i>m</i>/<i>z</i> 667.0 (M + H). Step 5. Following method C, ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-5-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate afforded <b>11</b>, after RP-HPLC-A purification (100 mg, 98% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97 (t, <i>J</i> = 8.0 Hz, 1H), 7.91 (s, 1H), 7.68 (dd, <i>J</i> = 0.7, 7.9 Hz, 1H), 7.52 (dd, <i>J</i> = 0.7, 8.0 Hz, 1H), 6.93–7.01 (m, 3H), 6.80 (d, <i>J</i> = 8.4 Hz, 1H), 5.27 (s, 2H), 4.58–4.68 (m, 1H), 4.40–4.49 (m, 1H), 3.19–3.26 (m, 1H), 2.87 (dq, <i>J</i> = 0.9, 7.6 Hz, 2H), 2.67–2.79 (m, 2H), 2.17 (s, 3H), 1.96–2.04 (m, 1H), 1.87–1.95 (m, 1H), 1.77–1.86 (m, 1H), 1.46–1.70 (m, 2H), 1.33 (t, <i>J</i> = 7.6 Hz, 3H), 0.77–0.93 (m, 4H). HRMS calculated for C<sub>33</sub>H<sub>34</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 639.2253, found 639.2275.</div></div><div id="sec4-10-9" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-ethyl-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>12</b>)</h5><div class="NLM_p last">Step 1. The bromination of ethyl 1-(6-(3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate was achieved by a similar method as described for the synthesis of ethyl 1-(6-(5-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–40% EtOAc/heptane). MS (ESI+) <i>m</i>/<i>z</i> 489.9 (M + H). Step 2. Following method F, ethyl 1-(6-(4-bromo-3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate and diethylzinc (1 M in hexane) afforded ethyl 1-(6-(4-ethyl-3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (35% EtOAc/heptane) (78% yield over 2 steps). MS (ESI+) <i>m</i>/<i>z</i> 440.3 (M + H). Step 3. Method E employing <b>27a</b> and ethyl 1-(6-(4-ethyl-3-(hydroxymethyl)-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, followed by FCC purification (16–67% EtOAc/heptane), afforded ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-ethyl-5-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (65 mg, 28% yield). MS (ESI+) <i>m</i>/<i>z</i> 681.3 (M + H). Step 4. Method C employing the product in the step 4 above, followed by RP-HPLC-A purification, afforded <b>12</b> (25 mg, 35% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.09 (s, 1H), 7.96 (dd, <i>J</i> = 7.80, 8.00 Hz, 1H), 7.69 (dd, <i>J</i> = 0.67, 7.89 Hz, 1H), 7.53 (dd, <i>J</i> = 0.67, 7.89 Hz, 1H), 6.94–7.00 (m, 2H), 6.89–6.93 (m, 1H), 5.12 (s, 2H), 4.59–4.69 (m, 1H), 4.40–4.51 (m, 1H), 3.21–3.27 (m, 1H), 2.70–2.80 (m, 2H), 2.61–2.70 (m, 2H), 2.46 (s, 3H), 2.07 (s, 3H), 1.97–2.05 (m, 1H), 1.89–1.97 (m, 1H), 1.80–1.89 (m, 1H), 1.47–1.71 (m, 2H), 1.15 (t, <i>J</i> = 7.52 Hz, 3H), 0.77–0.95 (m, 4H). HRMS calculated for C<sub>34</sub>H<sub>36</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 653.2404, found 665.2424.</div></div><div id="sec4-10-10" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>13</b>)</h5><div class="NLM_p last">Step 1. To a solution of 1 M LDA in THF (14.77 mL, 14.77 mmol) at −78 °C was added a solution of 4-methylthiophene-3-carboxylic acid (1 g, 7.03 mmol) in THF (5 mL) over 0.25 h, and then the mixture was stirred at −78 °C for 0.5 h. To the solution was then added a solution of CBr<sub>4</sub> (2.57 g, 7.74 mmol) in THF (8 mL) dropwise over 15 min. The mixture was stirred at −78 °C for 0.5 h, and then allowed to warm to rt over 1 h. The reaction mixture was then rendered acidic with 1 M aq. HCl to a pH of 1. The mixture was then extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The resulting residue was purified by FCC (0–100% EtOAc in heptane) to afford 2-bromo-4-methylthiophene-3-carboxylic acid (1.2 g, 71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.92 (s, 1H), 2.45 (s, 3H). Step 2. To a solution of 2-bromo-4-methylthiophene-3-carboxylic acid (1.22 g, 5.52 mmol) in THF (8 mL) at rt was added BH<sub>3</sub>-THF in THF (16.56 mL, 16.56 mmol). The mixture was then stirred at rt for 2 h. The reaction was quenched with MeOH. The mixture was then concentrated. The resulting residue was purified by FCC (0–30% EtOAc in heptane) to afford (2-bromo-4-methylthiophen-3-yl)methanol (920 mg, 81% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.02 (d, <i>J</i> = 1.0 Hz, 1H), 4.45–4.60 (m, 2H), 2.29 (d, <i>J</i> = 1.0 Hz, 3H). Step 3. Following method D, (2-bromo-4-methylthiophen-3-yl)methanol and <b>27a</b>, followed by FCC purification (0–100% EtOAc/heptane), afforded (4-(4-((2-bromo-4-methylthiophen-3-yl)methoxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone (80 mg, 35% yield). MS (ESI+) <i>m</i>/<i>z</i> 448.0 (M + H). Step 4. Following method G, <b>32</b> and (4-(4-((2-bromo-4-methylthiophen-3-yl)methoxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone, followed by FCC purification (0–50% EtOAc/heptane), afforded ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (54 mg, 46% yield). MS (ESI+) <i>m</i>/<i>z</i> 448.0 (M + H). Step 5. Method C employing ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-methylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate afforded <b>13</b>, without any further purification (22 mg, 43% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.08 (d, <i>J</i> = 0.8 Hz, 1H), 8.00 (t, <i>J</i> = 7.9 Hz, 1H), 7.74 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 7.59 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.22 (d, <i>J</i> = 1.1 Hz, 1H), 6.98 (d, <i>J</i> = 2.2 Hz, 1H), 6.95 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 5.19 (s, 2H), 4.64 (d, <i>J</i> = 13.1 Hz, 1H), 4.45 (d, <i>J</i> = 13.7 Hz, 1H), 3.27–3.20 (m, 1H), 2.74 (tt, <i>J</i> = 12.2, 3.7 Hz, 2H), 2.30 (d, <i>J</i> = 1.0 Hz, 3H), 2.07 (s, 3H), 2.00 (tt, <i>J</i> = 8.0, 4.8 Hz, 1H), 1.96–1.87 (m, 1H), 1.83 (d, <i>J</i> = 13.2 Hz, 1H), 1.71–1.45 (m, 2H), 0.94–0.86 (m, 2H), 0.85–0.78 (m, 2H). HRMS calculated for C<sub>32</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 625.2018, found 625.2121.</div></div><div id="sec4-10-11" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>14</b>)</h5><div class="NLM_p last">Step 1. A mixture of thiophene-3-carboxylic acid (2.24 g, 17.5 mmol), propylphosphonic anhydride (T<sub>3</sub>P, 2 M in DMF, 12.5 mL, 25 mmol), diisopropylethylamine (6.2 mL, 35.5 mmol) and 2,3,5,6-tetrafluoro-4-(trifluoromethyl)aniline (4.45 g, 19.1 mmol) was stirred at 100 °C for 18 h and then cooled to rt. The reaction mixture was poured into saturated aq. NH<sub>4</sub>Cl and then stirred for 0.5 h. The resulting precipitates were collected by filtration. The precipitates were triturated with CH<sub>2</sub>Cl<sub>2</sub> (ca. 60 mL). The solids were collected by filtration and rinsed with CH<sub>2</sub>Cl<sub>2</sub> to afford <i>N</i>-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)thiophene-3-carboxamide (3.7 g, 62% yield). MS (ESI+) <i>m</i>/<i>z</i> 344.0 (M + H). Step 2. A mixture of <i>N</i>-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)thiophene-3-carboxamide (2.33 g, 6.8 mmol), <b>32</b> (1.98 g, 5.43 mmol), Pd(OAc)<sub>2</sub> (121 mg, 0.54 mmol), Cs<sub>2</sub>CO<sub>3</sub> (5.31 g, 16.30 mmol), and triphenylphosphine (547 mg, 2.09 mmol) in toluene (9.9 mL) was sparged with N<sub>2</sub>, and then the mixture was stirred at 100 °C for 1.5 h. The reaction mixture was cooled to rt and then diluted with EtOAc and saturated aq. NH<sub>4</sub>Cl. The organic layer was separated and then successively washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (15–40% EtOAc/heptane) to afford ethyl 1-(6-(3-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)carbamoyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (2.5 g, 74% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.20 (s, 1H), 8.36 (s, 1H), 8.18 (t, <i>J</i> = 7.9 Hz, 1H), 7.92 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (d, <i>J</i> = 5.3 Hz, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 5.1 Hz, 1H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 627.0 (M + H). Step 3. To a mixture of ethyl 1-(6-(3-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)carbamoyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (503.8 mg, 0.804 mmol), potassium acetate (281.7 mg, 2.87 mmol), and NBS (217.1 mg, 1.220 mmol) in DCE (5 mL) was added bis[(pentamethylcyclopentadienyl)dichloro-rhodium] (25.4 mg, 0.041 mmol). The mixture was then stirred at 80 °C for 1 h. To the mixture was then added an additional amount of NBS (168.2 mg, 0.945 mmol), and the mixture continued to be stirred at 80 °C for 0.5 h. To the mixture was then added bis[(pentamethylcyclopentadienyl)dichloro-rhodium] (33.2 mg, 0.054 mmol) and stirred at 80 °C for 0.5 h. The reaction mixture was then cooled to rt and filtered through a plug of Celite, which was rinsed with EtOAc. The filtrate was then concentrated. The resulting residue was purified by FCC (15–30% EtOAc/heptane) to afford ethyl 1-(6-(4-bromo-3-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)carbamoyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (254 mg, 45% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.52 (s, 1H), 8.37 (s, 1H), 8.25 (t, <i>J</i> = 7.9 Hz, 1H), 8.06 (s, 1H), 7.88 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 704.8 (M + H). Step 4. A mixture of ethyl 1-(6-(4-bromo-3-((2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)carbamoyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (1.47 g, 2.08 mmol) and MsOH (7.5 mL) was stirred at 70 °C for 2.25 h and then cooled to rt. The mixture was poured into ice/H<sub>2</sub>O and then stirred for 0.75 h. The resulting precipitate was collected by filtration to furnish 4-bromo-2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophene-3-carboxylic acid (469 mg, 46% yield). MS (ESI+) <i>m</i>/z 489.9 (M + H). Step 5. To a solution of BH<sub>3</sub>-THF complex (6.6 mL, 6.60 mmol) at 4 °C was added a solution of 4-bromo-2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)thiophene-3-carboxylic acid (644 mg, 1.31 mmol) in THF (5 mL). The mixture was then stirred for 3 h at rt. To the mixture was added additional BH<sub>3</sub>-THF complex (6.6 mL, 6.6 mmol), and then the mixture was stirred at rt for an additional 3 h. The reaction was quenched with MeOH (6.0 mL). The mixture was then concentrated. The resulting residue was purified by FCC (15–40% EtOAc/heptane) to afford ethyl 1-(6-(4-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (250 mg, 40% yield). MS (ESI+) <i>m</i>/<i>z</i> 475.9 (M + H). Step 6. Following method F, ethyl 1-(6-(4-bromo-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (370 mg, 0.777 mmol) and diethylzinc (1 M in hexane, 1.5 mL), followed by FCC purification (33% isocratic EtOAc/heptane), afforded ethyl 1-(6-(4-ethyl-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (190 mg, 57% yield). MS (ESI+) <i>m</i>/<i>z</i> 426.2 (M + H). <i>Step 7.</i> To a solution of ethyl 1-(6-(4-ethyl-3-(hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate (150 mg, 0.353 mmol) and CBr<sub>4</sub> (150 mg, 0.452 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at rt was added PPh<sub>3</sub> (150 mg, 0.572 mmol). The reaction mixture was then stirred at rt for 1.5 h. To the reaction mixture were added <b>27a</b> (140 mg, 0.540 mmol) and K<sub>2</sub>CO<sub>3</sub> (140 mg, 1.013 mmol), and then the reaction mixture was diluted with DMF (3 mL). The reaction mixture was then stirred at rt for 16 h. The reaction mixture was diluted with EtOAc, and the organic layer was washed successively with half saturated aq. KHSO<sub>4</sub>, H<sub>2</sub>O, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The residue was purified by FCC (2–7% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to afford ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (140 mg, 60% yield). MS (ESI+) <i>m</i>/<i>z</i> 667.4 (M + H). Step 8. Method C employing ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)-4-ethylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate afforded <b>14</b> without any further purification (110 mg, 80% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.94–8.01 (m, 2H), 7.71 (dd, <i>J</i> = 0.67, 7.89 Hz, 1H), 7.59 (dd, <i>J</i> = 0.61, 7.95 Hz, 1H), 7.26 (s, 1H), 6.95–7.01 (m, 2H), 6.90 (d, <i>J</i> = 8.20 Hz, 1H), 5.16 (s, 2H), 4.59–4.68 (m, 1H), 4.40–4.50 (m, 1H), 3.20–3.27 (m, 1H), 2.66–2.80 (m, 4H), 2.08 (s, 3H), 1.97–2.05 (m, 1H), 1.89–1.96 (m, 1H), 1.79–1.88 (m, 1H), 1.47–1.72 (m, 2H), 1.28 (t, <i>J</i> = 7.52 Hz, 3H), 0.76–0.95 (m, 4H). HRMS calculated for C<sub>33</sub>H<sub>34</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S (M + H) 639.2253, found 639.2253.</div></div><div id="sec4-10-12" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>15</b>)</h5><div class="NLM_p last">Step 1. To a solution of (2-bromocyclopent-1-en-1-yl)methanol (1.95 g, 11.01 mmol) and imidazole (0.86 g, 12.7 mmol) in DMF (10 mL) was added TBS-Cl (1.83 g, 12.12 mmol). The mixture was stirred at rt for 18 h. The reaction was quenched with a mixture of H<sub>2</sub>O and saturated aq NH<sub>4</sub>Cl. The mixture was extracted with a solvent mixture of EtOAc/heptane (ca. 2/1). The organic layer was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic layer was filtered and concentrated to afford ((2-bromocyclopent-1-en-1-yl)methoxy)(<i>tert</i>-butyl)dimethylsilane (3.04 g, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.19 (s, 2H), 2.60–2.53 (m, 2H), 2.35 (t, <i>J</i> = 7.2 Hz, 2H), 1.86 (app. quin, <i>J</i> = 7.6 Hz, 2H), 0.82 (s, 9H), 0.00 (s, 6H). Step 2. Following method G, <b>32</b> and ((2-bromocyclopent-1-en-1-yl)methoxy)(<i>tert</i>-butyl)dimethylsilane, followed by FCC purification (0–75% EtOAc in heptane), afforded ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (34% yield). MS (ESI+) <i>m</i>/<i>z</i> 496.3 (M + H). Step 3. To a solution of ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (0.19 g, 0.383 mmol) in THF (5 mL) at rt was added TBAF (1 M in THF; 0.65 mL, 0.65 mmol). The mixture was stirred at rt for 30 min. The reaction mixture was diluted with EtOAc. The organic layer was then washed with saturated aq NH<sub>4</sub>Cl, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (0–30% EtOAc/DCM) to afford ethyl 1-(6-(2-(hydroxymethyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (134 mg, 92% yield). MS (ESI+) <i>m</i>/<i>z</i> 382.2 (M + H). Step 4. Following method E, a reaction of <b>27a</b> with ethyl 1-(6-(2-(hydroxymethyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, followed by FCC purification (0–20% EtOAc/DCM), afforded ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate. MS (ESI+) <i>m</i>/<i>z</i> 623.3 (M + H). Step 5. Method A employing ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclopent-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, followed by RP-HPLC-B purification, afforded <b>15</b> (64 mg, 55% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 13.44 (br. s., 1H), 8.29 (s, 1H), 8.14 (t, <i>J</i> = 7.9 Hz, 1H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.00 (d, <i>J</i> = 1.8 Hz, 1H), 6.87 (dd, <i>J</i> = 2.1, 8.3 Hz, 1H), 6.62 (d, <i>J</i> = 8.4 Hz, 1H), 5.04 (s, 2H), 4.49 (d, <i>J</i> = 12.1 Hz, 1H), 4.34 (d, <i>J</i> = 12.2 Hz, 1H), 3.12 (t, <i>J</i> = 12.1 Hz, 1H), 2.88 (t, <i>J</i> = 7.2 Hz, 2H), 2.73 (t, <i>J</i> = 7.2 Hz, 2H), 2.69–2.61 (m, 2H), 2.11 (s, 3H), 2.02–1.88 (m, 3H), 1.82–1.66 (m, 2H), 1.55–1.31 (m, 2H), 0.80–0.66 (m, 4H). HRMS calculated for C<sub>32</sub>H<sub>34</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> (M + H) 595.2532, found 595.2549.</div></div><div id="sec4-10-13" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>16</b>)</h5><div class="NLM_p last">Step 1. Following method G, a reaction of <b>32</b> (1.43 g, 3.93 mmol) with ((2-bromocyclohex-1-en-1-yl)methoxy)(<i>tert</i>-butyl)dimethylsilane (1 g, 3.28 mmol), followed by FCC purification (0–10% EtOAc in heptane), afforded ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (569 mg, 34% yield). MS (ESI+) <i>m</i>/<i>z</i> 510.3 (M + H). Step 2. Deprotection of the TBS group on ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate was achieved by a similar method as described for the synthesis of <b>15</b>, followed by purification by FCC (0–100% EtOAc/heptane), to afford ethyl 1-(6-(2-(hydroxymethyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (2.26 g, 92% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.33 (d, <i>J</i> = 0.6 Hz, 1H), 8.08 (t, <i>J</i> = 7.8 Hz, 1H), 7.65 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.57 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H), 4.74 (t, <i>J</i> = 5.3 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 3.83 (d, <i>J</i> = 5.3 Hz, 2H), 2.40–2.31 (m, 2H), 2.31–2.18 (m, 2H), 1.65 (t, <i>J</i> = 3.2 Hz, 4H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 396.2 (M + H). Step 3. Following method D, a reaction of ethyl 1-(6-(2-(hydroxymethyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate with <b>26a</b>, followed by FCC purification (0–25% EtOAc in heptane), afforded <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)cyclohex-1-en-1-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate (566 mg, 69% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (s, 1H), 8.09 (t, <i>J</i> = 7.8 Hz, 1H), 7.71–7.65 (m, 1H), 7.53–7.48 (m, 1H), 6.99–6.96 (m, 1H), 6.87 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.60 (d, <i>J</i> = 8.5 Hz, 1H), 4.40 (s, 2H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 4.07–3.99 (m, 2H), 3.29 (s, 2H), 2.45–2.38 (m, 2H), 2.34–2.28 (m, 2H), 2.11 (s, 3H), 1.74–1.63 (m, 6H), 1.46–1.35 (m, 12H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 669.3 (M + H). Step 4. To a solution of <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)cyclohex-1-en-1-yl)methoxy)-3-methylphenyl)piperidine-1-carboxylate (396 mg, 0.592 mmol) in DCM (5 mL) at 0 °C was added TFA (5 mL, 64.9 mmol) dropwise. The mixture was then stirred for 30 min at 0 °C. Acetonitrile (10 mL) was added to the mixture, which was then was concentrated. The resulting residue was diluted with DCM and saturated. aq. NaHCO<sub>3</sub> and then passed through an ISOLUTE Phase Separator. The organic layer was concentrated to furnish ethyl 1-(6-(2-((2-methyl-4-(piperidin-4-yl)phenoxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (337 mg, quantitative yield). MS (ESI+) <i>m</i>/<i>z</i> 569.4 (M + H). Step 5. To a solution of ethyl 1-(6-(2-((2-methyl-4-(piperidin-4-yl)phenoxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (38 mg, 0.067 mmol) and diisopropylethylamine (0.035 mL, 0.200 mmol) in DCM (2 mL) at 0 °C was added cyclopropylcarbonyl chloride (6 μL, 0.100 mmol). The mixture was stirred for 30 min at 0 °C, and then H<sub>2</sub>O was added. The mixture was then passed through an ISOLUTE Phase Separator. The organics were concentrated. The resulting residue was purified by FCC (heptane to 50% EtOAc in heptane) to afford ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (36 mg, 85% yield). MS (ESI+) <i>m</i>/<i>z</i> 637.3 (M + H). Step 6. Method C employing ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)methyl)cyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate, followed by RP-HPLC-B purification, afforded <b>16</b> (10 mg, 44% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.44 (s, 1H), 8.28 (s, 1H), 8.08 (t, <i>J</i> = 7.8 Hz, 1H), 7.67 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.50 (dd, <i>J</i> = 7.8, 0.9 Hz, 1H), 7.00 (d, <i>J</i> = 2.2 Hz, 1H), 6.89 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.60 (d, <i>J</i> = 8.4 Hz, 1H), 4.53–4.43 (m, 1H), 4.40 (s, 2H), 4.38–4.30 (m, 1H), 3.12 (t, <i>J</i> = 12.8 Hz, 1H), 2.71–2.53 (m, 2H), 2.43 (s, 2H), 2.32 (dd, <i>J</i> = 5.0, 2.5 Hz, 2H), 2.11 (s, 3H), 2.04–1.92 (m, 1H), 1.79–1.66 (m, 6H), 1.49 (d, <i>J</i> = 13.1 Hz, 1H), 1.37 (s, 1H), 0.77–0.65 (m, 4H). HRMS calculated for C<sub>33</sub>H<sub>36</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> (M + H) 609.2689, found 609.2682.</div></div><div id="sec4-10-14" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (+)-1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)-<b>17</b>)</h5><div class="NLM_p last">Step 1. Methyl acetoacetate (1.85 mL, 17.2 mmol) was added dropwise to a suspension of NaH (0.76 g, 18.9 mmol, 60% in mineral oil) and THF (60 mL) at 0 °C. After 10 min, <i>n</i>-BuLi (7.58 mL, 18.9 mmol, 2.5 M in heptane) was added dropwise. After an additional 10 min, crotonyl bromide (1.77 mL, 17.2 mmol) was added, and the reaction was allowed to slowly warm to rt. After 2 h, the reaction was quenched with 1 M aq. HCl, and the mixture was extracted with Et<sub>2</sub>O (200 mL). The organic layer was then dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by FCC (5% EtOAc/heptane) to give methyl 3-oxooct-6-enoate as a mixture of <i>E</i>- and <i>Z</i>-isomers (2.7 g, 84% yield). MS (ESI+) <i>m</i>/<i>z</i> 171.1 (M + H). Step 2. A mixture of methyl 3-oxooct-6-enoate (4.35 g, 25.6 mmol), ytterbium(III) trifluoromethanesulfonate (4.76 g, 7.67 mmol), and dichlorobis(acetonitrile)palladium(II) (0.66 g, 2.56 mmol) in dioxane (250 mL) was stirred at 50 °C for 30 h and then concentrated. The resulting residue was passed through a silica gel plug, eluting with 30% EtOAc/heptane, to furnish <i>rac</i>-methyl 2-methyl-6-oxocyclohexanecarboxylate, which was used without any further purification (3.2 g, 74% yield). MS (ESI+) <i>m</i>/<i>z</i> 171.1 (M + H). Step 3. To a solution of <i>rac</i>-methyl 2-methyl-6-oxocyclohexanecarboxylate (1.00 g, 5.88 mmol) in DCM (30 mL) at 0 °C was added NaH (0.305 g, 7.64 mmol, 60% in mineral oil). The suspension was allowed to warm to rt and stir for 10 min. The reaction mixture was then cooled to −78 °C. To the mixture at −78 °C was added triflic anhydride (1.29 mL, 14.1 mmol), and the mixture was allowed to gradually warm to rt. After 1 h, the reaction at rt was quenched with the slow addition of 10% aq. citric acid. The mixture was then diluted with DCM and H<sub>2</sub>O. The layers were mixed and then separated. The aqueous layer was further extracted with DCM. The combined organic layers were then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (0–10% EtOAc/heptane) to afford <i>rac</i>-methyl 6-methyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-enecarboxylate (1.55 g, 87% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.74 (s, 3H), 2.91–2.78 (m, 1H), 2.40–2.21 (m, 2H), 1.85–1.73 (m, 1H), 1.73–1.62 (m, 2H), 1.45–1.35 (m, 1H), 1.02 (d, <i>J</i> = 6.9 Hz, 3H). Step 4. To a solution of <i>rac-</i>methyl 6-methyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-enecarboxylate (5.1 g, 16.9 mmol) in DCM (170 mL) at −78 °C was added a THF solution of 1 M DIBAL-H (35.4 mL, 35.4 mmol). The reaction was allowed to slowly warm to rt over 1 h, at which point the reaction showed complete conversion according to TLC (25% EtOAc/heptane, KMnO<sub>4</sub> stain). The reaction was then quenched with an addition of 2.1 mL of H<sub>2</sub>O with vigorous stirring at rt over 0.25 h, followed by addition of 2.1 mL of 15% aqueous NaOH. The mixture was vigorously stirred until solids formed. The solids were removed by filtration, and the filtrate was concentrated to afford <i>rac</i>-2-(hydroxymethyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate, which was used without any further purification (2.45 g, 53% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.40 (d, <i>J</i> = 12.8 Hz, 1H), 4.05 (d, 1H), 2.62–2.76 (m, 1H), 2.30–2.39 (m, 2H), 1.64–1.95 (m, 3H), 1.37–1.50 (m, 1H), 1.15 (d, <i>J</i> = 7.0 Hz, 3H). Step 5. To a solution of <i>rac</i>-2-(hydroxymethyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate (6.0 g, 21.9 mmol) in DMF (220 mL) were added imidazole (1.71 g, 25.2 mmol) and TBS-Cl (3.63 g, 24.1 mmol) at rt. The mixture was then stirred at rt for 3 h. The reaction mixture was filtered through a pad of Celite, which was rinsed with 25% EtOAc–heptane. The resulting solution was concentrated. The resulting residue was suspended in H<sub>2</sub>O and then extracted with ca. 1/1 mixture of EtOAc/heptane. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford <i>rac</i>-2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate, which was used in the next reaction without any further purification (5.9 g, 69% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.40 (d, <i>J</i> = 12.4 Hz, 1H), 4.07–4.14 (m, 1H), 2.55–2.67 (m, 1H), 2.18–2.30 (m, 2H), 1.72–1.85 (m, 1H), 1.57–1.72 (m, 2H), 1.30–1.41 (m, 1H), 1.06 (d, <i>J</i> = 7.0 Hz, 3H), 0.83 (s, 9H), 0.01 (d, <i>J</i> = 5.2 Hz, 6H). Step 6. Following method G, <b>32</b> and <i>rac-</i>2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate (534 mg, 1.37 mmol) afforded <i>rac</i>-ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–100% EtOAc in heptane) (141 mg, 20% yield). MS (ESI+) <i>m</i>/<i>z</i> 524.3 (M + H). Step 7. To a solution of <i>rac</i>-ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (1.0 g, 1.92 mmol) in THF (19.3 mL) at room temperature was added a solution of TBAF in THF (1 M, 2.9 mL, 2.9 mmol). The mixture was stirred at room temperature for 3 h, and then diluted with EtOAc. The mixture was washed successively with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The resulting residue was purified by FCC (0–100 EtOAc/heptane) to afford <i>rac</i>-ethyl 1-(6-(2-(hydroxymethyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (546 mg, 69% yield). MS (ESI+) <i>m</i>/<i>z</i> 410.6 (M + H). Step 8. Following method D, <b>27b</b> and <i>rac</i>-ethyl 1-(6-(2-(hydroxymethyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate afforded <i>rac-</i>ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–100% EtOAc in heptane) (230 mg, 46% yield). MS (ESI+) <i>m</i>/<i>z</i> 665.3 (M + H). Step 9. Resolution of the racemate was achieved by chiral SFC using Daicel CHIRALPAK AD-H column with a gradient 5–55% MeOH in CO<sub>2</sub> to afford ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (enantiomer 1, <i>t</i><sub>R</sub> = 2.3 min, >99% ee) and ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (enantiomer 2, <i>t</i><sub>R</sub> = 2.5 min, >99% ee). Step 10. Method C employing ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (enantiomer 1, <i>t</i><sub>R</sub> = 2.3 min) afforded (+)-<b>17</b> without any further purification (79 mg, 86% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.06 (s, 1H), 7.95 (t, <i>J</i> = 7.8 Hz, 1H), 7.56 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.45 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H), 6.96–7.05 (m, 1H), 6.52–6.63 (m, 2H), 4.64 (d, <i>J</i> = 13.1 Hz, 1H), 4.32–4.54 (m, 3H), 2.93–3.07 (m, 1H), 2.68–2.80 (m, 1H), 2.50–2.67 (m, 4H), 2.31–2.44 (m, 1H), 2.27 (t, <i>J</i> = 7.4 Hz, 1H), 1.93–2.06 (m, 1H), 1.46–1.92 (m, 8H), 1.21 (d, <i>J</i> = 7.0 Hz, 3H), 1.14 (t, <i>J</i> = 7.5 Hz, 3H), 0.75–0.99 (m, 4H). HRMS calculated for C<sub>35</sub>H<sub>40</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> (M + H) 637.2996, found 637.3014.</div></div><div id="sec4-10-15" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (−)-1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((−)-<b>17</b>)</h5><div class="NLM_p last">Method C employing ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (enantiomer 2, <i>t</i><sub>R</sub> = 2.5 min) afforded (−)-<b>17</b> without any further purification (9 mg, 93% yield). The analytical data were substantially identical to (+)-<b>17</b>.</div></div><div id="sec4-10-16" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid (<b>18</b>)</h5><div class="NLM_p last">Step 1. A TBS protection of 2-(hydroxymethyl)-3,3-dimethylcyclohex-1-en-1-yl trifluoromethanesulfonate was achieved by a similar method as described for the synthesis of 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate to afford 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl trifluoromethanesulfonate (7.4 g, 79% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.30 (t, <i>J</i> = 1.0 Hz, 2H), 2.36 (t, <i>J</i> = 6.4 Hz, 2H), 1.77–1.88 (m, 2H), 1.46–1.54 (m, 2H), 1.19 (d, <i>J</i> = 2.0 Hz, 6H), 0.91 (d, <i>J</i> = 1.6 Hz, 9H), 0.10 (s, 6H). Step 2. Following method G, <b>32</b> and 2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl trifluoromethanesulfonate afforded ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–100% EtOAc in heptane) (257 mg, 6% yield). MS (ESI+) <i>m</i>/<i>z</i> 538.3 (M + H). Step 3. Deprotection of the TBS group on ethyl 1-(6-(2-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate was achieved by a similar method as described for the synthesis of <b>15</b> to afford ethyl 1-(6-(2-(hydroxymethyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–100% EtOAc in heptane) (45 mg, 22% yield). (ESI+) <i>m</i>/<i>z</i> 424.4 (M + H). Step 4. Following method D, ethyl 1-(6-(2-(hydroxymethyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate and <b>26b</b> afforded <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)-6,6-dimethylcyclohex-1-en-1-yl)methoxy)-2-ethylphenyl)piperidine-1-carboxylate after FCC purification (0–100% EtOAc in heptane) (62 mg, 82% yield). (ESI+) <i>m</i>/<i>z</i> 711.5 (M + H). Step 5. Deprotection of the Boc group on <i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H-</i>pyrazol-1-yl)pyridin-2-yl)-6,6-dimethylcyclohex-1-en-1-yl)methoxy)-2-ethylphenyl)piperidine-1-carboxylate was achieved by a similar method as described for the synthesis of <b>27a</b> to afford ethyl 1-(6-(2-((3-ethyl-4-(piperidin-4-yl)phenoxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–20% MeOH/DCM) (34 mg, 64% yield). MS (ESI+) <i>m</i>/<i>z</i> 611.5 (M + H). Step 6. To a solution of ethyl 1-(6-(2-((3-ethyl-4-(piperidin-4-yl)phenoxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate (35 mg, 0.057 mmol) and diisopropylethylamine (0.03 mL, 0.17 mmol) in DCM (3 mL) was added cyclopropanecarbonyl chloride (0.01 mL, 0.110 mmol). The mixture was stirred at rt for 1 h. The reaction mixture was directly loaded onto silica gel and was purified by FCC (20% EtOAc in heptane) to afford ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (35 mg, 91% yield). MS (ESI+) <i>m</i>/<i>z</i> 679.5 (M + H). Step 7. Method C employing ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3,3-dimethylcyclohex-1-en-1-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate afforded <b>18</b> without any further purification (12 mg, 32% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.11 (s, 1H), 7.87 (t, <i>J</i> = 7.8 Hz, 1H), 7.56 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H), 7.51 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 6.98–7.07 (m, 1H), 6.59 (dt, <i>J</i> = 4.4, 2.4 Hz, 2H), 4.65 (d, <i>J</i> = 13.3 Hz, 1H), 4.46 (d, <i>J</i> = 13.3 Hz, 1H), 4.30 (s, 2H), 3.01 (t, <i>J</i> = 12.0 Hz, 1H), 2.74 (t, <i>J</i> = 12.9 Hz, 1H), 2.65 (q, <i>J</i> = 7.5 Hz, 2H), 2.48 (t, <i>J</i> = 6.3 Hz, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 1H), 1.95–2.07 (m, 1H), 1.49–1.93 (m, 9H), 1.21 (s, 6H), 1.17 (t, <i>J</i> = 7.5 Hz, 3H), 0.73–0.99 (m, 4H). HRMS calculated for C<sub>36</sub>H<sub>42</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> (M + H) 651.3153, found 651.3165.</div></div><div id="sec4-10-17" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)-<b>19</b>)</h5><div class="NLM_p last">Step 1. Sodium borohydride (0.090 g, 2.369 mmol) was added to a solution of <b>42</b> (0.5 g, 2.369 mmol) in MeOH (24 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h then let warm to rt. After 2 h, TLC indicated complete consumption of the starting material. The reaction mixture was diluted with H<sub>2</sub>O and DCM, and then saturated aq. NH<sub>4</sub>Cl was added to neutralize the aqueous layer to a pH of 7. The mixture was passed through an ISOLUTE Phase Separator, and the organic phase was concentrated to afford <i>rac</i>-7-bromo-2,3-dihydro-1<i>H</i>-inden-1-ol (505 mg, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41–7.33 (m, 1H), 7.25–7.20 (m, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 5.41–5.34 (m, 1H), 3.30–3.17 (m, 1H), 2.97–2.84 (m, 1H), 2.51–2.35 (m, 1H), 2.20–2.09 (m, 1H). Step 2. To a solution of <i>rac</i>-7-bromo-2,3-dihydro-1<i>H</i>-inden-1-ol (335 mg, 1.57 mmol), <b>27a</b> (489 mg, 1.89 mmol), and tri-<i>n</i>-butylphosphine (490 μL, 1.89 mmol) in THF (6.3 mL), azodicarboxylic dimorpholide (483 mg, 1.89 mmol) was added at rt, and the reaction mixture was stirred for 2 h. The reaction mixture was diluted with DCM and H<sub>2</sub>O and then passed through a phase separator and concentrated. The residue was purified by FCC (0–50% EtOAc/heptane) to afford <i>rac</i>-(4-(4-((7-bromo-2,3-dihydro-1<i>H</i>-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone (248 mg, 34.7% yield). MS (ESI+) <i>m</i>/<i>z</i> 456.2 (M + H). Step 3. Following method G, <i>rac</i>-(4-(4-((7-bromo-2,3-dihydro-1<i>H</i>-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone and <b>32</b> afforded <i>rac</i>-ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–50% EtOAc/heptane gradient) (55% yield). MS (ESI+) <i>m</i>/<i>z</i> 659.4 (M + H). Step 4. Resolution of the racemate was achieved by chiral SFC using Daicel CHIRALCEL OJ-H column with a gradient 5% to 55% MeOH in CO<sub>2</sub> to give (+)-ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 2.02 min) and (−)-ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 2.19 min). Step 5. Method C employing (+)-ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 2.02 min) afforded (+)-<b>19</b> after RP-HPLC-B purification (31 mg, 32% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97 (s, 1H), 7.93 (t, <i>J</i> = 7.9 Hz, 1H), 7.82–7.78 (m, 1H), 7.68–7.63 (m, 1H), 7.55–7.51 (m, 1H), 7.47 (t, <i>J</i> = 7.5 Hz, 1H), 7.45–7.41 (m, 1H), 6.82–6.75 (m, 2H), 6.69 (d, <i>J</i> = 8.2 Hz, 1H), 6.39–6.34 (m, 1H), 4.64 (d, <i>J</i> = 13.0 Hz, 1H), 4.45 (d, <i>J</i> = 13.6 Hz, 1H), 3.24–3.16 (m, 2H), 3.05–2.95 (m, 1H), 2.78–2.64 (m, 2H), 2.59–2.47 (m, 1H), 2.18–2.08 (m, 1H), 2.05–1.97 (m, 1H), 1.92 (d, <i>J</i> = 13.1 Hz, 1H), 1.84 (d, <i>J</i> = 13.5 Hz, 1H), 1.63 (s, 3H), 1.61–1.44 (m, 2H), 0.93–0.86 (m, 2H), 0.86–0.78 (m, 2H). HRMS calculated for C<sub>35</sub>H<sub>34</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub> (M + H) 631.2532, found 631.2572.</div></div><div id="sec4-10-18" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((−)-<b>19</b>)</h5><div class="NLM_p last">Method C employing (−)-ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 2.19 min) afforded (−)-<b>19</b> after RP-HPLC-B purification (56 mg, 59%). The analytical data were substantially identical to (+)-<b>19</b>.</div></div><div id="sec4-10-19" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (+)- and (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)- and (−)-<b>20</b>)</h5><div class="NLM_p last">Step 1. Following method G, <b>32</b> and <b>42</b>, followed by FCC purification (0–40% EtOAc/heptane), afforded ethyl 1-(6-(3-oxo-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (422 mg, 53% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.19 (d, <i>J</i> = 0.7 Hz, 1H), 8.07 (t, <i>J</i> = 7.9 Hz, 1H), 7.85 (dd, <i>J</i> = 7.8, 0.9 Hz, 1H), 7.77–7.69 (m, 2H), 7.65 (dq, <i>J</i> = 7.7, 1.0 Hz, 1H), 7.56 (dq, <i>J</i> = 7.4, 0.8 Hz, 1H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 3.26–3.18 (m, 2H), 2.77–2.68 (m, 2H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H). Step 2. To a solution of <b>30</b> (60 mg, 0.232 mmol) and ethyl 1-(6-(3-oxo-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate (106 mg, 0.255 mmol) in anhydrous toluene (2.3 mL) was added TsOH (4.42 mg, 0.023 mmol), the reaction flask was fitted with a Dean–Stark trap, and the reaction mixture was stirred at 130 °C for 22 h. The reaction mixture was then concentrated. The residue was dissolved in anhydrous EtOH (2.3 mL) and cooled to 0 °C, and then sodium borohydride (8.79 mg, 0.232 mmol) was added. The mixture was stirred at 0 °C for 1.5 h. The reaction was quenched with H<sub>2</sub>O and saturated aq NaHCO<sub>3</sub>, and then the mixture was extracted with EtOAc. The organic layer was concentrated onto Celite. The residue was purified by FCC (0–50% EtOAc/heptane) to afford <i>rac</i>-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (32 mg, 21% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97–7.92 (m, 2H), 7.90 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 7.63 (dd, <i>J</i> = 5.6, 3.3 Hz, 1H), 7.49 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H), 7.43 (d, <i>J</i> = 5.6 Hz, 2H), 6.80 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.71 (d, <i>J</i> = 2.2 Hz, 1H), 6.54 (d, <i>J</i> = 8.3 Hz, 1H), 5.24 (d, <i>J</i> = 6.5 Hz, 1H), 4.64 (d, <i>J</i> = 13.0 Hz, 1H), 4.45 (d, <i>J</i> = 13.3 Hz, 1H), 4.37 (q, <i>J</i> = 7.1 Hz, 2H), 3.21 (dt, <i>J</i> = 16.3, 8.2 Hz, 2H), 2.94 (ddd, <i>J</i> = 16.1, 8.7, 3.5 Hz, 1H), 2.73 (t, <i>J</i> = 12.7 Hz, 1H), 2.65 (tt, <i>J</i> = 12.0, 3.6 Hz, 1H), 2.37 (dtd, <i>J</i> = 12.8, 8.5, 6.7 Hz, 1H), 2.15–2.06 (m, 1H), 2.04–1.97 (m, 1H), 1.95–1.88 (m, 1H), 1.87–1.79 (m, 1H), 1.69 (s, 3H), 1.66–1.45 (m, 2H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H), 0.94–0.85 (m, 2H), 0.85–0.78 (m, 2H). MS (ESI+) <i>m</i>/<i>z</i> 658.5 (M + H). Step 3. Method A employing <i>rac</i>-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H-</i>pyrazole-4-carboxylate afforded <b>(±)-20</b> after RP-HPLC-B purification. Step 4. Resolution of the racemate was achieved by chiral SFC using Daicel CHIRALCEL OJ-H column with 20% (5 mM NH<sub>4</sub>OH in MeOH) in CO<sub>2</sub> to afford (+)-<b>20</b> (<i>t</i><sub>R</sub> = 3.10 min, > 97% ee) and (−)-<b>20</b> (<i>t</i><sub>R</sub> = 4.40 min, > 97% ee). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.98–7.91 (m, 2H), 7.91–7.87 (m, 1H), 7.67–7.61 (m, 1H), 7.51–7.47 (m, 1H), 7.43 (d, <i>J</i> = 5.9 Hz, 2H), 6.85–6.80 (m, 1H), 6.74–6.71 (m, 1H), 6.55 (d, <i>J</i> = 8.2 Hz, 1H), 5.24 (s, 1H), 4.63 (d, <i>J</i> = 13.0 Hz, 1H), 4.45 (d, <i>J</i> = 13.3 Hz, 1H), 3.26–3.16 (m, 2H), 2.98–2.89 (m, 1H), 2.79–2.61 (m, 2H), 2.42–2.31 (m, 1H), 2.16–2.07 (m, 1H), 2.05–1.97 (m, 1H), 1.93 (d, <i>J</i> = 13.2 Hz, 1H), 1.84 (d, <i>J</i> = 12.9 Hz, 1H), 1.70 (s, 3H), 1.67–1.45 (m, 2H), 0.93–0.78 (m, 4H). HRMS calculated for C<sub>35</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 630.2692, found 630.2451.</div></div><div id="sec4-10-20" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (+)- and (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)- and (−)-<b>21</b>)</h5><div class="NLM_p">Step 1. A mixture of <i>m</i>-tolyl 3-chloropropanoate (3.92 g, 19.7 mmol) and AlCl<sub>3</sub> (10.5 g, 79 mmol) was heated at 100 °C for 1 h, then at 180 °C for 2 h, and subsequently cooled to rt. The excess AlCl<sub>3</sub> was carefully quenched with 1 M aq HCI. The resulting mixture was extracted with DCM. The combined organic layers were washed with water and passed through an ISOLUTE Phase Separator. The filtrate was concentrated to afford 7-hydroxy-5-methyl-2,3-dihydro-1<i>H</i>-inden-1-one, which was used in the next reaction without further purification (946 mg, 30% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.95 (s, 1H), 6.80–6.72 (m, 1H), 6.64–6.52 (m, 1H), 3.08–3.03 (m, 2H), 2.71–2.67 (m, 2H), 2.38 (s, 3H). Step 2. To a solution of 7-hydroxy-5-methyl-2,3-dihydro-1<i>H-</i>inden-1-one (217 mg, 1.34 mmol) and pyridine (325 μL, 4.01 mmol) in DCM (13.4 mL) at 0 °C was added trifluoromethanesulfonic anhydride (316 μL, 1.87 mmol) dropwise. The resulting suspension was stirred at 0 °C for 1 h. The reaction was quenched with H<sub>2</sub>O, and then the mixture was diluted with 1 N aq HCl. The resulting mixture was passed through an ISOLUTE Phase Separator. The organic phase was concentrated to furnish 6-methyl-3-oxo-2,3-dihydro-1<i>H</i>-inden-4-yl trifluoromethanesulfonate, which was used in the next step without any further purification (335 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.25–7.21 (m, 1H), 6.90 (s, 1H), 3.11–3.02 (m, 2H), 2.70–2.63 (m, 2H), 2.41 (s, 3H). MS (ESI+) <i>m</i>/<i>z</i> 295.2 (M + H). Step 3. Following method G, <b>32</b> and 6-methyl-3-oxo-2,3-dihydro-1<i>H</i>-inden-4-yl trifluoromethanesulfonate afforded ethyl 1-(6-(6-methyl-3-oxo-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–50% EtOAc/heptane) (303 mg, 56.2% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.19 (d, <i>J</i> = 0.8 Hz, 1H), 8.06 (t, <i>J</i> = 7.9 Hz, 1H), 7.86 (dd, <i>J</i> = 7.8, 0.9 Hz, 1H), 7.71 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.46 (dq, <i>J</i> = 1.8, 0.9 Hz, 1H), 7.41 (dd, <i>J</i> = 1.7, 0.9 Hz, 1H), 4.37 (q, <i>J</i> = 7.1 Hz, 2H), 3.20–3.15 (m, 2H), 2.73–2.68 (m, 2H), 2.49 (s, 3H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 430.3 (M + H). Step 4. A mixture of <b>30</b> (90 mg, 0.349 mmol), ethyl 1-(6-(6-methyl-3-oxo-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (150 mg, 0.349 mmol), and TsOH (3.32 mg, 0.017 mmol) in anhydrous toluene (3.5 mL) was charged to a flask equipped with a condenser and a Dean–Stark trap. The mixture was stirred at 130 °C for 22 h, and then concentrated. The residue was then dissolved in anhydrous EtOH (3.5 mL). To the solution at 0 °C was added sodium borohydride (13.2 mg, 0.35 mmol). The mixture was stirred at rt for 3 h, with the addition of sodium borohydride (13.2 mg, 0.35 mmol) each hour, for a total of 3 additions. The reaction was quenched with H<sub>2</sub>O and saturated aq. NH<sub>4</sub>Cl. The mixture was then extracted with DCM. The organic layer was passed through an ISOLUTE Phase Separator and concentrated onto Celite. The residue was purified by FCC (0–50% EtOAc/heptane) to afford <i>rac</i>-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (130 mg, 55% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97–7.91 (m, 2H), 7.89 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 7.49–7.45 (m, 2H), 7.25 (s, 1H), 6.81 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.71 (d, <i>J</i> = 2.1 Hz, 1H), 6.54 (d, <i>J</i> = 8.3 Hz, 1H), 5.16 (d, <i>J</i> = 6.4 Hz, 1H), 4.64 (d, <i>J</i> = 13.0 Hz, 1H), 4.45 (d, <i>J</i> = 13.7 Hz, 1H), 4.37 (q, <i>J</i> = 7.1 Hz, 2H), 3.25 (s, 1H), 3.17 (dd, <i>J</i> = 16.4, 8.4 Hz, 1H), 2.88 (ddd, <i>J</i> = 16.1, 8.7, 3.3 Hz, 1H), 2.74 (t, <i>J</i> = 12.3 Hz, 1H), 2.64 (tt, <i>J</i> = 12.1, 3.8 Hz, 1H), 2.44 (s, 3H), 2.40–2.29 (m, 1H), 2.15–2.05 (m, 1H), 2.05–1.97 (m, 1H), 1.92 (d, <i>J</i> = 13.0 Hz, 1H), 1.83 (d, <i>J</i> = 12.9 Hz, 1H), 1.69 (s, 3H), 1.59 (dd, <i>J</i> = 41.5, 16.5 Hz, 2H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H), 0.94–0.86 (m, 2H), 0.85–0.78 (m, 2H). MS (ESI+) <i>m</i>/<i>z</i> 672.4 (M + H). Step 5. Method C employing ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate afforded <i>rac</i><b>-21</b> without any further purification (63% yield).</div><div class="NLM_p last">Resolution of the racemate was achieved by chiral SFC using Daicel CHIRALCEL OJ-H column with isocratic 20% MeOH in CO<sub>2</sub> to afford (+)-<b>21</b> (<i>t</i><sub>R</sub> = 3.23 min, 99% ee) and (−)-<b>21</b> (<i>t</i><sub>R</sub> = 4.73 min, >99% ee). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.94–7.89 (m, 2H), 7.89–7.85 (m, 1H), 7.49–7.45 (m, 2H), 7.25–7.23 (m, 1H), 6.84–6.81 (m, 1H), 6.75–6.71 (m, 1H), 6.55 (d, <i>J</i> = 8.2 Hz, 1H), 5.20–5.16 (m, 1H), 4.63 (d, <i>J</i> = 13.1 Hz, 1H), 4.43 (d, <i>J</i> = 13.1 Hz, 1H), 3.28–3.21 (m, 1H), 3.19–3.12 (m, 1H), 2.93–2.84 (m, 1H), 2.77–2.61 (m, 2H), 2.43 (s, 3H), 2.39–2.28 (m, 1H), 2.15–2.06 (m, 1H), 2.05–1.96 (m, 1H), 1.96–1.89 (m, 1H), 1.87–1.80 (m, 1H), 1.70 (s, 3H), 1.67–1.44 (m, 2H), 0.92–0.79 (m, 4H). HRMS calculated for C<sub>36</sub>H<sub>37</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 644.2848, found 644.2841.</div></div><div id="sec4-10-21" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)-<b>22</b>)</h5><div class="NLM_p last">Step 1. To a suspension of <b>42</b> (10 g, 47.4 mmol) and (<i>R</i>,<i>R</i>)-RuCl(TsDPEN)(p-Cymene) (CAS registry number 192139-92-7, 40 mg, 0.063 mmol) in DMF (40 mL) was added formic acid–triethylamine complex, 5:2 (8 mL). The mixture was then stirred at 60 °C for 22 h and cooled to rt. The mixture was poured into ice/water (ca. 1/1 v/v). The resulting solid was collected by filtration. The solid was then dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and the solution was dried over MgSO<sub>4</sub> and filtered through a plug of silica gel. The silica gel cake was rinsed with a mixture of CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (ca. 9/1). The combined organic layers were concentrated to furnish (−)-<i>R</i>-7-bromo-2,3-dihydro-1<i>H</i>-inden-1-ol without any further purification (7.5 g, 35.2 mmol, 74.3% yield, > 98% ee determined by SFC using Daicel CHIRALPAK OD-H, 10% isocratic IPA in CO<sub>2</sub>; (−)-enantiomer 1 (<i>t</i><sub>R</sub> = 4.87 min) and (+)-enantiomer 2 (<i>t</i><sub>R</sub> = 5.58 min)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41–7.33 (m, 1H), 7.25–7.20 (m, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 5.41–5.34 (m, 1H), 3.30–3.17 (m, 1H), 2.97–2.84 (m, 1H), 2.51–2.35 (m, 1H), 2.20–2.09 (m, 1H). Step 2. Following the procedure described for the synthesis of <b>32</b>, a reaction of 2-bromo-6-hydrazinylpyridine with ethyl 3-(dimethylamino)-2-formyl acrylate afforded ethyl 1-(6-bromopyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylate (1.2 g, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.99 (d, <i>J</i> = 0.7 Hz, 1H), 8.10 (d, <i>J</i> = 0.7 Hz, 1H), 7.95 (dd, <i>J</i> = 8.1, 0.8 Hz, 1H), 7.70 (t, <i>J</i> = 7.9 Hz, 1H), 7.47–7.41 (m, 1H), 4.38–4.30 (m, 2H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 298.0 (M + H). <i>Step 3.</i> Following the procedure as described for the preparation of <i>rac</i>-(4-(4-((7-bromo-2,3-dihydro-1<i>H</i>-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone, a reaction starting with (−)-<i>R</i>-7-bromo-2,3-dihydro-1<i>H</i>-inden-1-ol afforded (+)-(4-(4-((7-bromo-2,3-dihydro-1<i>H</i>-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone (438 mg, 41% yield, 97% ee determined by SFC (stationary phase CHIRALCEL OJ-H; mobile phase, gradient 5–55% IPA in CO<sub>2</sub>; (+)-enantiomer (<i>t</i><sub>R</sub> = 2.38 min) and (−)-enantiomer (<i>t</i><sub>R</sub> = 2.70 min)). MS (ESI+) <i>m</i>/<i>z</i> 456.2 (M + H). Step 4. Following method G, ethyl 1-(6-bromopyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylate and (+)-(4-(4-((7-bromo-2,3-dihydro-1<i>H</i>-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone, followed by FCC purification (0–50% EtOAc/heptane), afforded ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylate (70 mg, 50% yield). MS (ESI+) <i>m</i>/<i>z</i> 591.4 (M + H). Step 5. Method C employing ethyl 1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylate, followed by RP-HPLC-B purification afforded (+)-<b>22</b> (30 mg, 43% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.60 (d, <i>J</i> = 0.7 Hz, 1H), 7.94–7.89 (m, 1H), 7.88 (d, <i>J</i> = 0.7 Hz, 1H), 7.77–7.72 (m, 1H), 7.62–7.56 (m, 2H), 7.47 (t, <i>J</i> = 7.4 Hz, 1H), 7.45–7.41 (m, 1H), 6.92 (d, <i>J</i> = 8.4 Hz, 1H), 6.79–6.75 (m, 1H), 6.62–6.57 (m, 2H), 4.63–4.54 (m, 1H), 4.40 (d, <i>J</i> = 13.4 Hz, 1H), 3.25–3.17 (m, 1H), 3.11–3.03 (m, 0H), 2.90–2.79 (m, 1H), 2.67 (t, <i>J</i> = 12.6 Hz, 1H), 2.58–2.48 (m, 1H), 2.23–2.13 (m, 1H), 2.03–1.95 (m, 1H), 1.82–1.64 (m, 2H), 1.53–1.33 (m, 5H), 0.94–0.77 (m, 4H). HRMS calculated for C<sub>34</sub>H<sub>35</sub>N<sub>4</sub>O<sub>4</sub> (M + H)<sup>+</sup> 563.2658, found 563.2669.</div></div><div id="sec4-10-22" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (+)-(<i>S</i>)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)-<b>23</b>)</h5><div class="NLM_p last">Step 1. A mixture of <b>31</b> (5.04 g, 26.8 mmol) and ethyl 2-acetyl-3-(dimethylamino)acrylate (4.96 g, 26.8 mmol) in EtOH (81 mL) was heated to 70 °C for 1.5 h. The reaction mixture was then allowed to cool to rt and a precipitate formed. H<sub>2</sub>O (80 mL) was then added to the mixture, and the resulting heterogeneous mixture was filtered. The filter cake was washed with H<sub>2</sub>O and dried under reduced pressure to yield ethyl 1-(6-bromopyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (7.1 g, 86 mmol). MS (ESI+) <i>m</i>/<i>z</i> 310.1 (M + H). Step 2. To a mixture of ethyl 1-(6-bromopyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (1.03 g, 3.31 mmol), bis(pinacolato) diboron (0.84 g, 3.31 mmol), and KOAc (0.65 g, 6.61 mmol) in dioxane (11 mL) was added SPhos Pd G1 (0.11 g, 0.165 mmol). The reaction mixture was then stirred at 120 °C under microwave irradiation for 45 min. To the mixture was then added a solution of <b>42</b> (0.66 g, 3.14 mmol) in dioxane (11 mL), followed by sodium carbonate (1 M in H<sub>2</sub>O, 8.3 mL, 8.3 mmol) and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> adduct (0.14 g, 0.165 mmol). The reaction mixture was then stirred under microwave irradiation for 30 min at 110 °C. Celite was added to the reaction mixture, and the mixture was concentrated. The residue was purified by FCC (0–50% EtOAc/heptane) to afford ethyl 5-methyl-1-(6-(3-oxo-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-1<i>H</i>-pyrazole-4-carboxylate (908 mg, 80% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.06–8.00 (m, 2H), 7.80 (dd, <i>J</i> = 8.1, 0.9 Hz, 1H), 7.74 (t, <i>J</i> = 7.6 Hz, 1H), 7.66 (ddd, <i>J</i> = 8.0, 7.1, 0.9 Hz, 2H), 7.54 (dq, <i>J</i> = 7.4, 0.8 Hz, 1H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 3.26–3.20 (m, 2H), 2.83 (s, 3H), 2.75–2.70 (m, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 362.3 (M + H). Step 3. A Dean–Stark trap was fitted to a flask containing a solution of <b>30</b> (162 mg, 0.627 mmol), ethyl 5-methyl-1-(6-(3-oxo-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-1<i>H-</i>pyrazole-4-carboxylate (260 mg, 0.627 mmol), and TsOH (12 mg, 0.063 mmol) in anhydrous toluene (6 mL). The reaction mixture was heated at 130 °C for 22 h, at which point the mixture was concentrated. The resulting residue was dissolved in anhydrous EtOH (6 mL) and cooled to 0 °C. Sodium borohydride (23.74 mg, 0.627 mmol) was added to the cooled solution,and the reaction mixture was allowed to warm to rt. After 3 h, an additional portion of sodium borohydride (23.74 mg, 0.627 mmol) was added at rt. One hour later, the reaction mixture was quenched with H<sub>2</sub>O and saturated aq. NH<sub>4</sub>Cl. The aqueous layer was extracted twice with EtOAc. Celite was added to the combined organic layers, and the mixture was concentrated. The resulting residue was purified by FCC (0–50% EtOAc/heptane gradient) to afford ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (113 mg, 30% yield). MS (ESI+) <i>m</i>/<i>z</i> 657.4 (M + H). Step 4. Resolution of the racemate was achieved by chiral SFC using Daicel CHIRALPAK AD-H column with a gradient 5% to 55% MeOH in CO<sub>2</sub> to afford (+)-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H-</i>pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 2.74 min, >99% ee) and (−)-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H-</i>pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.70 min, >99% ee). Step 5. (+)-Ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H-</i>pyrazole-4-carboxylate ((+)-isomer, <i>t</i><sub>R</sub> = 2.74 min, 168 mg, 0.278 mmol) was dissolved in MeOH (2.8 mL) and THF (2.8 mL) at rt, and the reaction mixture was heated to 50 °C for 2 h. Upon completion, the reaction mixture was cooled to rt and 1 M aq. HCl (2.9 mL) was added. The resulting mixture was extracted with EtOAc, and the combined organic layers were concentrated to provide the title compound after RP-HPLC-B purification (115 mg, 72% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.89 (s, 1H), 7.82 (t, <i>J</i> = 7.9 Hz, 1H), 7.69–7.65 (m, 1H), 7.58–7.54 (m, 1H), 7.53–7.50 (m, 1H), 7.44–7.37 (m, 2H), 6.83–6.79 (m, 1H), 6.74–6.71 (m, 1H), 6.56 (d, <i>J</i> = 8.2 Hz, 1H), 5.38 (s, 1H), 4.61 (d, <i>J</i> = 12.9 Hz, 1H), 4.43 (d, <i>J</i> = 13.2 Hz, 1H), 3.24–3.15 (m, 2H), 3.02–2.93 (m, 1H), 2.75–2.59 (m, 5H), 2.54–2.43 (m, 1H), 2.13–2.04 (m, 1H), 2.03–1.96 (m, 1H), 1.90 (d, <i>J</i> = 13.1 Hz, 1H), 1.80 (d, <i>J</i> = 13.4 Hz, 1H), 1.67 (s, 3H), 1.64–1.41 (m, 2H), 0.92–0.78 (m, 4H). HRMS calculated for C<sub>35</sub>H<sub>38</sub>N<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 576.2975, found 576.3015. The absolute stereochemistry of (+)-<b>23</b> was determined by single crystal X-ray crystallography.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec4-10-23" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H</i>-inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylic Acid ((−)-<b>23</b>)</h5><div class="NLM_p last">Method C employing (−)-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1<i>H-</i>inden-4-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.70 min) afforded (−)-<b>23</b> after RP-HPLC-B purification. The analytical data were substantially identical to (+)-<b>23</b>.</div></div><div id="sec4-10-24" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (+)-1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylic Acid ((+)-<b>24</b>)</h5><div class="NLM_p last">Step 1. Following method D, <i>rac</i>-2-(hydroxymethyl)-3-methylcyclohex-1-en-1-yl trifluoromethanesulfonate and <b>26b</b> afforded <i>rac-tert</i>-butyl 4-(2-ethyl-4-((6-methyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-en-1-yl)methoxy)phenyl)piperidine-1-carboxylate after FCC purification (0–60% EtOAc in heptane) (49% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.10 (d, <i>J</i> = 8.8 Hz, 1H), 6.76–6.70 (m, 2H), 4.79 (d, <i>J</i> = 11.7 Hz, 1H), 4.53–4.47 (m, 1H), 4.25 (d, <i>J</i> = 13.3 Hz, 2H), 2.86–2.76 (m, 3H), 2.74–2.61 (m, 3H), 2.43–2.38 (m, 2H), 1.95–1.77 (m, 2H), 1.74–1.56 (m, 5H), 1.50 (s, 9H), 1.47–1.39 (m, 1H), 1.22 (t, <i>J</i> = 7.5 Hz, 3H), 1.16 (d, <i>J</i> = 7.0 Hz, 3H). <i>Step 2.</i> A mixture of <i>rac</i>-<i>tert</i>-butyl 4-(2-ethyl-4-((6-methyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-en-1-yl)methoxy)phenyl)piperidine-1-carboxylate (450 mg, 0.80 mmol), KOAc (142 mg, 1.44 mmol), bis(pinacolato) diboron (305 mg, 1.2 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (33 mg, 0.04 mmol) in dioxane (4 mL) was stirred at 60 °C under N<sub>2</sub> for 24 h. The reaction mixture was filtered, concentrated, and purified by FCC (0–50% EtOAc in heptane) to afford <i>rac-tert</i>-butyl 4-(2-ethyl-4-((6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-1-en-1-yl)methoxy)phenyl)piperidine-1-carboxylate (345 mg, 80% yield). MS (ESI+) <i>m</i>/<i>z</i> 538.5 (M + H). Step 3. A suspension of S-Phos Pd G1 (22.4 mg, 0.03 mmol), 2 M aq K<sub>3</sub>PO<sub>4</sub> (0.43 mL, 0.87 mmol), <i>rac</i>-<i>tert</i>-butyl 4-(2-ethyl-4-((6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-1-en-1-yl)methoxy)phenyl)piperidine-1-carboxylate (396 mg, 0.73 mmol), and ethyl 1-(6-bromopyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (207 mg, 0.67 mmol) in dioxane (4 mL) was stirred at 100 °C for 20 h. The reaction mixture was concentrated, and the resulting residue was purified by FCC (0–70% EtOAc in heptane) to afford <i>rac-tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-methyl-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)-6-methylcyclohex-1-en-1-yl)methoxy)-2-ethylphenyl)piperidine-1-carboxylate (154 mg, 35% yield). MS (ESI+) <i>m</i>/<i>z</i> 643.7 (M + H). Step 4. Deprotection of the Boc group of <i>rac</i>-<i>tert</i>-butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-methyl-1<i>H</i>-pyrazol-1-yl)pyridin-2-yl)-6-methylcyclohex-1-en-1-yl)methoxy)-2-ethylphenyl)piperidine-1-carboxylate and subsequent acylation was achieved by a similar method as described for the synthesis of <b>27a</b> to furnish <i>rac</i>-ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate after FCC purification (0–70% EtOAc in heptane) (60% yield). MS (ESI+) <i>m</i>/<i>z</i> 611.5 (M + H). Step 5. Resolution of the racemate was performed by chiral SFC using Daicel CHIRALPAK AD-H column, a gradient 5–55% IPA in CO<sub>2</sub>, 5 mL/min to afford (+)-ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.02 min, >98% ee) and (−)-ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.17 min, >98% ee). Step 6. Method C employing (+)-ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.02 min) afforded (+)-<b>24</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.68 (s, 1H), 7.97–7.89 (m, 2H), 7.67 (d, <i>J</i> = 8.1 Hz, 1H), 7.32 (d, <i>J</i> = 7.6 Hz, 1H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 6.63–6.57 (m, 2H), 4.56–4.46 (m, 2H), 4.42–4.31 (m, 2H), 3.21–3.11 (m, 1H), 2.93–2.84 (m, 1H), 2.79 (s, 3H), 2.63–2.58 (m, 4H), 2.41–2.37 (m, 1H), 2.03–1.94 (m, 1H), 1.85–1.74 (m, 2H), 1.72–1.32 (m, 6H), 1.15 (d, <i>J</i> = 7.0 Hz, 1H), 1.07 (t, <i>J</i> = 7.5 Hz, 3H), 0.81–0.64 (m, 4H). HRMS calculated for C<sub>35</sub>H<sub>43</sub>N<sub>4</sub>O<sub>4</sub> (M + H)<sup>+</sup> 583.3284, found 583.3253.</div></div><div id="sec4-10-25" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (−)-1-(6-(2-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylic Acid ((−)-<b>24</b>)</h5><div class="NLM_p last">Method C employing (−)-ethyl 1-(6-(2-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)methyl)-3-methylcyclohex-1-en-1-yl)pyridin-2-yl)-5-methyl-1<i>H</i>-pyrazole-4-carboxylate (<i>t</i><sub>R</sub> = 3.17 min) afforded (−)-<b>24</b>. The analytical data were substantially identical to <b>(</b>+)-<b>24</b>.</div></div><div id="sec4-10-26" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>tert-</i>Butyl 4-(4-Hydroxy-3-methylphenyl)piperidine-1-carboxylate (<b>26a</b>)</h5><div class="NLM_p last">Step 1. To a suspension of 4-bromo-2-methyl phenol (5 g, 26.7 mmol), <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate, <b>25</b> (8.27 g, 26.7 mmol), and K<sub>3</sub>PO<sub>4</sub> (2 M in H<sub>2</sub>O, 26.7 mL, 53.5 mmol) in acetonitrile (54 mL) was added PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (1.09 g, 1.33 mmol). The mixture was stirred at 80 °C for 3 h and then cooled to rt. The reaction mixture was added to Celite and then concentrated. The resulting residue was purified by FCC (0–100% EtOAc/heptane) to afford <i>tert</i>-butyl 4-(4-hydroxy-3-methylphenyl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18–7.12 (m, 1H), 7.12–7.06 (m, 1H), 6.73 (d, <i>J</i> = 8.3 Hz, 1H), 5.98–5.85 (m, 1H), 4.04 (q, <i>J</i> = 2.9 Hz, 2H), 3.62 (t, <i>J</i> = 5.7 Hz, 2H), 2.48 (dtd, <i>J</i> = 6.1, 3.2, 1.8 Hz, 2H), 2.25 (s, 3H), 1.49 (s, 9H). MS (ESI+) <i>m</i>/<i>z</i> 290.1 (M + H). Step 2. A mixture of the above product (4.4 g, 15.21 mmol) and Pd/C (5% w/w, 0.8 g) in MeOH (50 mL) was stirred under H<sub>2</sub> atmosphere at rt for 2 h. The reaction mixture was then filtered through a plug of Celite. The filtrate was then concentrated to furnish <b>26a</b> (4.4 g, 58% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.97 (d, <i>J</i> = 2.2 Hz, 1H), 6.92 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.73 (d, <i>J</i> = 8.2 Hz, 1H), 4.24 (ddt, <i>J</i> = 13.4, 4.0, 1.9 Hz, 2H), 2.86–2.75 (m, 2H), 2.56 (tt, <i>J</i> = 12.2, 3.6 Hz, 1H), 2.26 (s, 3H), 1.85–1.76 (m, 2H), 1.59 (dtd, <i>J</i> = 13.4, 12.3, 4.2 Hz, 2H), 1.50 (s, 9H). MS (ESI−) <i>m</i>/<i>z</i> 290.2 (M – H).</div></div><div id="sec4-10-27" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>tert-</i>Butyl 4-(2-Ethyl-4-hydroxyphenyl)piperidine-1-carboxylate (<b>26b</b>)</h5><div class="NLM_p last">Step 1. To a mixture of 4-chloro-3-ethylphenol (3 g, 19.16 mmol), <b>25</b> (7.70 g, 24.90 mmol), and SPhos Pd G1 methyl-<i>tert</i>-butylether adduct (CAS registry number. 1375325-64-6, 0.644 g, 0.958 mmol) in DMF (96 mL) was added 2 M aq. K<sub>3</sub>PO<sub>4</sub> (28.7 mL, 57.5 mmol). The mixture was stirred at 110 °C for 1 h and then cooled to rt. The reaction mixture was diluted with EtOAc and H<sub>2</sub>O. The organic layer was then separated, and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (heptane/EtOAc = 1/0 to 6/4) to afford <i>tert</i>-butyl 4-(2-ethyl-4-hydroxyphenyl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate. MS (ESI+) <i>m</i>/<i>z</i> 248.2 (M – <i>t</i>Bu + 2H). Step 2. A mixture of the product from step 1 (5.4 g, 17.80 mmol) and 10% Pd/C (1.89 g) in MeOH (250 mL) was stirred under H<sub>2</sub> atmosphere at rt for 1 h. The reaction mixture was filtered through a plug of Celite, which was then washed with MeOH. The filtrate was then concentrated to furnish the title compound without any further purification (4.3 g, 76% yield over 2 steps). MS (ESI+) <i>m</i>/<i>z</i> 250.2 (M – <i>t</i>Bu + 2H).</div></div><div id="sec4-10-28" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Cyclopropyl(4-(4-hydroxy-3-methylphenyl)piperidin-1-yl)methanone (<b>27a</b>)</h5><div class="NLM_p last">Step 1. To a solution of <b>26a</b> (3.98 g, 13.66 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (137 mL) at 0 °C was added TFA (12.63 mL, 164 mmol). The mixture was stirred for 1.5 h and then concentrated to furnish 2-methyl-4-(piperidin-4-yl)phenol as the TFA salt, which was used in the next step without any further purification. MS (ESI+) <i>m</i>/<i>z</i> 192.1 (M + H). Step 2. To a solution of the product obtained in step 1 (2.6 g, 13.59 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (68 mL) at 0 °C was added diisopropylethylamine (9.5 mL, 54.4 mmol), followed by cyclopropanecarbonyl chloride (2.47 mL, 27.2 mmol). The mixture was then stirred at 0 °C for 1 h. The reaction was quenched with H<sub>2</sub>O. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was concentrated. A mixture of the resulting residue and K<sub>2</sub>CO<sub>3</sub> (9.39 g, 68 mmol) in MeOH (68 mL) was stirred for 2 h at rt and then diluted with CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O. The mixture was passed through an ISOLUTE Phase Separator. The resulting organic layer was concentrated to furnish the title compound without any further purification (3.4 g, 96% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.92 (d, <i>J</i> = 2.3 Hz, 1H), 6.85 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.66 (d, <i>J</i> = 8.2 Hz, 1H), 4.62 (d, <i>J</i> = 13.2 Hz, 1H), 4.43 (d, <i>J</i> = 13.4 Hz, 1H), 3.23 (td, <i>J</i> = 12.7, 11.4, 2.9 Hz, 1H), 2.70 (dtt, <i>J</i> = 15.8, 7.6, 4.4 Hz, 2H), 2.15 (s, 3H), 1.99 (tt, <i>J</i> = 8.0, 4.8 Hz, 1H), 1.85 (dd, <i>J</i> = 36.3, 13.3 Hz, 2H), 1.70–1.44 (m, 2H), 0.95–0.75 (m, 4H). MS (ESI+) <i>m</i>/<i>z</i> 260.1 (M + H).</div></div><div id="sec4-10-29" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Cyclopropyl(4-(2-ethyl-4-hydroxyphenyl)piperidin-1-yl)methanone (<b>27b</b>)</h5><div class="NLM_p last">The title compound was synthesized from <b>26b</b> analogously to the preparation of <b>27a</b>. MS (ESI+) <i>m</i>/<i>z</i> 274.3 (M + H).</div></div><div id="sec4-10-30" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>tert-</i>Butyl 4-(3-Methyl-4-nitrophenyl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>28</b>)</h5><div class="NLM_p last">To a suspension of 4-bromo-2-methyl nitrobenzene (10 g, 46.3 mmol), <b>25</b> (14.3 g, 46.3 mmol), and 2 M aq K<sub>3</sub>PO<sub>4</sub> (46.3 mL, 93 mmol) in acetonitrile (154 mL) was added PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (1.89 g, 2.31 mmol). The mixture was then stirred at 80 °C for 3 h and cooled to rt. The reaction mixture was concentrated with Celite. The resulting residue was purified by FCC (0–20% EtOAc in heptane) to afford <b>28</b> (10.6 g, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (d, <i>J</i> = 8.4 Hz, 1H), 7.36–7.32 (m, 2H), 6.20 (s, 1H), 4.14 (q, <i>J</i> = 2.9 Hz, 2H), 3.67 (t, <i>J</i> = 5.7 Hz, 2H), 2.65 (s, 3H), 2.58–2.52 (m, 2H), 1.52 (s, 9H). MS (ESI−) <i>m</i>/<i>z</i> 317.2 (M – H).</div></div><div id="sec4-10-31" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Cyclopropyl(4-(3-methyl-4-nitrophenyl)-5,6-dihydropyridin-1(2<i>H</i>)-yl)methanone (<b>29</b>)</h5><div class="NLM_p last">Step 1. Deprotection of the Boc group on <b>28</b> was achieved by a similar method as described for the synthesis of <b>27a</b>. The product was used in the next step without any further purification (quantitative yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.99 (d, <i>J</i> = 8.5 Hz, 1H), 7.60–7.47 (m, 2H), 6.34 (dt, <i>J</i> = 3.5, 1.8 Hz, 1H), 3.89 (q, <i>J</i> = 2.7 Hz, 2H), 3.49 (t, <i>J</i> = 6.1 Hz, 2H), 2.83 (tq, <i>J</i> = 5.7, 1.9 Hz, 2H), 2.60 (s, 3H). MS (ESI+) <i>m</i>/<i>z</i> 219.2 (M + H). Step 2. Cyclopropanecarbonyl chloride (0.509 mL, 5.61 mmol) was added dropwise to a solution of 4-(3-methyl-4-nitrophenyl)-1,2,3,6-tetrahydropyridine (1.165 g, 5.34 mmol) and diisopropylethylamine (2.80 mL, 16.02 mmol) in DCM (53 mL) at 0 °C. The mixture was stirred at 0 °C for 90 min before being quenched with half saturated aq sodium bicarbonate. The resulting mixture was passed through an ISOLUTE Phase Separator, and the organic layer was concentrated. The resulting residue was purified by FCC (0–50% EtOAc in heptane) to afford <b>29</b> (quantitative yield). MS (ESI+) <i>m</i>/<i>z</i> 287.3 (M + H).</div></div><div id="sec4-10-32" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (4-(4-Amino-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone (<b>30</b>)</h5><div class="NLM_p last">A mixture of <b>29</b> (5.98 g, 20.89 mmol) and Pd/C (1.11 g) in EtOH (104 mL) was stirred under H<sub>2</sub> atmosphere at rt for 16 h. The mixture was filtered through a plug of Celite, which was rinsed with EtOH. The filtrate was concentrated, and the resulting residue was purified by FCC (0–100% [0.2% Et<sub>3</sub>N in EtOAc] in [0.2% Et<sub>3</sub>N in heptane]) to afford the title compound (quantitative yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD<sub>4</sub>) δ 6.87 (d, <i>J</i> = 2.7 Hz, 1H), 6.84 (dd, <i>J</i> = 8.1, 2.2 Hz, 1H), 6.67 (d, <i>J</i> = 8.0 Hz, 1H), 4.62 (d, <i>J</i> = 13.2 Hz, 1H), 4.43 (d, <i>J</i> = 13.5 Hz, 1H), 3.27–3.19 (m, 1H), 2.77–2.62 (m, 2H), 2.14 (s, 3H), 2.03–1.95 (m, 1H), 1.89 (d, <i>J</i> = 13.0 Hz, 1H), 1.80 (d, <i>J</i> = 13.3 Hz, 1H), 1.69–1.44 (m, 2H), 0.92–0.76 (m, 4H).MS (ESI+) <i>m</i>/<i>z</i> 259.3 (M + H).</div></div><div id="sec4-10-33" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Ethyl 1-(6-Bromopyridin-2-yl)-5-(trifliuoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<b>32</b>)</h5><div class="NLM_p last">A solution of 2-bromo-6-hydrazinylpyridine, <b>31</b> (12.63 g, 67 mmol), in THF (350 mL) was cooled in an acetone/dry ice bath, and then ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutyrate (13.72 mL, 71 mmol) was added dropwise. Once the addition was complete, the reaction mixture was gradually allowed to warm to rt over 2 h. The reaction mixture was concentrated, and then the resulting residue was dissolved in EtOAc. The organic layer was washed successively with saturated aq. NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by FCC (10% EtOAc in heptane) to afford <b>32</b> (15.8 g, 65% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.19 (s, 1H), 7.96 (t, <i>J</i> = 7.82 Hz, 1H), 7.74–7.80 (m, 2H), 4.37 (q, <i>J</i> = 7.13 Hz, 2H), 1.38 (t, <i>J</i> = 7.15 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 364.0, 366.0 (M + H).</div></div><div id="sec4-10-34" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Ethyl 1-(6-(3-(Hydroxymethyl)thiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (<b>33</b>)</h5><div class="NLM_p last">Step 1. To a suspension of <b>32</b> (4.44 g, 12.19 mmol), (3-formylthiophen-2-yl)boronic acid (3.75 g, 24.04 mmol), and potassium fluoride (4.19 g, 72.1 mmol) in THF (60 mL) was added Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub> (0.5 g, 0.978 mmol). The mixture was stirred at rt for 18 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and then filtered. The filtrate was concentrated. The resulting residue was purified by FCC (0–100% EtOAc in heptane) to afford ethyl 1-(6-(3-formylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate. MS (ESI+) <i>m</i>/<i>z</i> 396.1 (M + H). Step 2. To a solution of ethyl 1-(6-(3-formylthiophen-2-yl)pyridin-2-yl)-5-(trifluoromethyl)-1<i>H</i>-pyrazole-4-carboxylate (4.42 g, 11.18 mmol) in EtOH (56 mL) at 0 °C was added sodium borohydride (0.423 g, 11.2 mmol) portion-wise. The mixture was stirred at rt for 2 h, and then diluted with H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was passed through an ISOLUTE Phase Separator. The organic layer was then concentrated. The resulting residue was purified by FCC (0–100% EtOAc in heptane) to afford <b>33</b> (4.0 g, 83% yield over 2 steps). MS (ESI+) <i>m</i>/<i>z</i> 398.1 (M + H).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00007" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00007" class="ext-link">10.1021/acs.jmedchem.8b00007</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings for exemplified compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00007/suppl_file/jm8b00007_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00007/suppl_file/jm8b00007_si_001.csv">jm8b00007_si_001.csv (2.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00007" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takeru Ehara</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4889-204X" title="Orcid link">http://orcid.org/0000-0002-4889-204X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d1a5b0bab4a3a4ffb4b9b0a3b091bfbea7b0a3a5b8a2ffb2bebc"><span class="__cf_email__" data-cfemail="bcc8ddd7d9cec992d9d4ddceddfcd2d3caddcec8d5cf92dfd3d1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muneto Mogi</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3459415a51405b1a595b535d745a5b425546405d471a575b59"><span class="__cf_email__" data-cfemail="d6bba3b8b3a2b9f8bbb9b1bf96b8b9a0b7a4a2bfa5f8b5b9bb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher M. Adams</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doug Bevan</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nan Ji</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        N.J.: Kymera Therapeutics, LLC, 400 Technology Square, Cambridge, MA 02139</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik L. Meredith</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David B. Belanger</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        D.B.: Kaleido Biosciences, 18 Crosby Dr., Bedford, MA 01730</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Powers</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitsunori Kato</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Solovay</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglei Liu</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Capparelli</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Bolduc</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan E. Grob</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew H. Daniels</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        M.D.: Goldfinch Bio, 215 First St., Cambridge, MA 02142</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luciana Ferrara</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Research, Novartis Institutes for BioMedical
Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Yang</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Research, Novartis Institutes for BioMedical
Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Byron Li</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Research, Novartis Institutes for BioMedical
Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher S. Towler</span> - <span class="hlFld-Affiliation affiliation">Chemical
and Pharmaceutical Profiling, Novartis Institutes
for BioMedical Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca C. Stacy</span> - <span class="hlFld-Affiliation affiliation">Translational
Medicine, Novartis Institutes for BioMedical
Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ganesh Prasanna</span> - <span class="hlFld-Affiliation affiliation">Ophthalmology
Research, Novartis Institutes for BioMedical
Research, Inc., Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank all of the contributors to the sGC activator project team. The authors also thank Shenouda Yacoub, Rad Daly, Terri Krause, Glen Travis Jernigan, Levi Martin, Daniel Scott, Sarah Webb, and Christopher Long for their help in conducting the <i>in vivo</i> studies. We also acknowledge the contribution of the Novartis Institute for Biomedical Research Analytical Sciences group for aiding in compound characterization. We also thank Philippe Piechon, Ina Dix, and Beatrix Wagner for X-ray crystallography work and S. Skolnik, and L. Yang for determining experimental p<i>K</i><sub>a</sub> values.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">sGC</td><td class="NLM_def"><p class="first last">soluble guanylate cyclase</p></td></tr><tr><td class="NLM_term">IOP</td><td class="NLM_def"><p class="first last">intraocular pressure</p></td></tr><tr><td class="NLM_term">POAG</td><td class="NLM_def"><p class="first last">primary open angle glaucoma</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">trabecular meshwork</p></td></tr><tr><td class="NLM_term">GTM</td><td class="NLM_def"><p class="first last">glaucomatous trabecular meshwork</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">TsDPEN</td><td class="NLM_def"><p class="first last"><i>N</i>-(2-amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">3-isobutyl-1-methylxanthine</p></td></tr><tr><td class="NLM_term">ODQ</td><td class="NLM_def"><p class="first last">1<i>H</i>-[1,2,4]oxadiazolo[4,3-<i>a</i>]quinoxalin-1-one</p></td></tr><tr><td class="NLM_term">FCC</td><td class="NLM_def"><p class="first last">flash silica gel column chromatography.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86478" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86478" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broman, A. T.</span></span> <span> </span><span class="NLM_article-title">The number of people with glaucoma worldwide in 2010 and 2020</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1136/bjo.2005.081224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1136%2Fbjo.2005.081224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=16488940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvFOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2006&pages=262-267&author=H.+A.+Quigleyauthor=A.+T.+Broman&title=The+number+of+people+with+glaucoma+worldwide+in+2010+and+2020&doi=10.1136%2Fbjo.2005.081224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The number of people with glaucoma worldwide in 2010 and 2020</span></div><div class="casAuthors">Quigley H A; Broman A T</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-7</span>
        ISSN:<span class="NLM_cas:issn">0007-1161</span>.
    </div><div class="casAbstract">AIM:  To estimate the number of people with open angle (OAG) and angle closure glaucoma (ACG) in 2010 and 2020.  METHODS:  A review of published data with use of prevalence models.  Data from population based studies of age specific prevalence of OAG and ACG that satisfied standard definitions were used to construct prevalence models for OAG and ACG by age, sex, and ethnicity, weighting data proportional to sample size of each study.  Models were combined with UN world population projections for 2010 and 2020 to derive the estimated number with glaucoma.  RESULTS:  There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG.  Women will comprise 55% of OAG, 70% of ACG, and 59% of all glaucoma in 2010.  Asians will represent 47% of those with glaucoma and 87% of those with ACG.  Bilateral blindness will be present in 4.5 million people with OAG and 3.9 million people with ACG in 2010, rising to 5.9 and 5.3 million people in 2020, respectively.  CONCLUSIONS:  Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPaAfgYdQ5TZp6t8nS6Nc3fW6udTcc2ebh-8pRJG_qL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvFOjsA%253D%253D&md5=6e7eb42ac041183edb63151f67f27c47</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbjo.2005.081224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjo.2005.081224%26sid%3Dliteratum%253Aachs%26aulast%3DQuigley%26aufirst%3DH.%2BA.%26aulast%3DBroman%26aufirst%3DA.%2BT.%26atitle%3DThe%2520number%2520of%2520people%2520with%2520glaucoma%2520worldwide%2520in%25202010%2520and%25202020%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2006%26volume%3D90%26spage%3D262%26epage%3D267%26doi%3D10.1136%2Fbjo.2005.081224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heijl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leske, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial</span>. <i>Arch. Ophthalmol. (Chicago, IL, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1279</span>, <span class="refDoi"> DOI: 10.1001/archopht.120.10.1268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1001%2Farchopht.120.10.1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=12365904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD38nhtVeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2002&pages=1268-1279&author=A.+Heijlauthor=M.+C.+Leskeauthor=B.+Bengtssonauthor=L.+Hymanauthor=B.+Bengtssonauthor=M.+Hussein&title=Reduction+of+intraocular+pressure+and+glaucoma+progression%3A+results+from+the+early+manifest+glaucoma+trial&doi=10.1001%2Farchopht.120.10.1268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial</span></div><div class="casAuthors">Heijl Anders; Leske M Cristina; Bengtsson Bo; Hyman Leslie; Bengtsson Boel; Hussein Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1268-79</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma.  DESIGN:  Randomized clinical trial.  PARTICIPANTS:  Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening.  Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible.  INTERVENTIONS:  Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126).  Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months.  Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter.  MAIN OUTCOME MEASURES:  Glaucoma progression was defined by specific visual field and optic disc outcomes.  Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests.  Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings.  RESULTS:  After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death.  On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up.  Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients.  Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status.  Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P =.002).  CONCLUSIONS:  The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP.  Its intent-to-treat analysis showed considerable beneficial effects of treatment that significantly delayed progression.  Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ-FkfFtp-YYkFb3mqPUYDfW6udTcc2eZlKFBAHZXu1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nhtVeguw%253D%253D&md5=50e90d77a62ab24f3d1204dea66f5e74</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1001%2Farchopht.120.10.1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.120.10.1268%26sid%3Dliteratum%253Aachs%26aulast%3DHeijl%26aufirst%3DA.%26aulast%3DLeske%26aufirst%3DM.%2BC.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHyman%26aufirst%3DL.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHussein%26aufirst%3DM.%26atitle%3DReduction%2520of%2520intraocular%2520pressure%2520and%2520glaucoma%2520progression%253A%2520results%2520from%2520the%2520early%2520manifest%2520glaucoma%2520trial%26jtitle%3DArch.%2520Ophthalmol.%2520%2528Chicago%252C%2520IL%252C%2520U.%2520S.%2529%26date%3D2002%26volume%3D120%26spage%3D1268%26epage%3D1279%26doi%3D10.1001%2Farchopht.120.10.1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leske, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komaroff, E.</span></span> <span> </span><span class="NLM_article-title">Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial</span>. <i>Arch. Ophthalmol. (Chicago, IL, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1001/archopht.121.1.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1001%2Farchopht.121.1.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=12523884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FhslCqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2003&pages=48-56&author=M.+C.+Leskeauthor=A.+Heijlauthor=M.+Husseinauthor=B.+Bengtssonauthor=L.+Hymanauthor=E.+Komaroff&title=Factors+for+glaucoma+progression+and+the+effect+of+treatment%3A+the+early+manifest+glaucoma+trial&doi=10.1001%2Farchopht.121.1.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial</span></div><div class="casAuthors">Leske M Cristina; Heijl Anders; Hussein Mohamed; Bengtsson Bo; Hyman Leslie; Komaroff Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-56</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment.  SETTING/PARTICIPANTS:  Two hundred fifty-five open-angle glaucoma patients randomized to argon laser trabeculoplasty plus topical betaxolol or no immediate treatment (129 treated; 126 controls) and followed up every 3 months.  METHODS:  Progression was determined by perimetric and photographic optic disc criteria.  Patient-based risk of progression was evaluated using Cox proportional hazard regression models and was expressed as hazard ratios (HR) with 95% confidence intervals (95% CI).  RESULTS:  After 6 years, 53% of patients progressed.  In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71).  Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age.  Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94).  The first IOP at that visit (3 months' follow-up) was also related to progression (HR = 1.11 per millimeter of mercury higher; 95% CI, 1.06-1.17), as was the mean IOP at follow-up (HR = 1.13 per millimeter of mercury higher; 95% CI, 1.07-1.19).  The percent of patient follow-up visits with disc hemorrhages was also related to progression (HR = 1.02 per percent higher; 95% CI, 1.01-1.03).  No other factors were identified.  CONCLUSIONS:  Patients treated in the EMGT had half of the progression risk of control patients.  The magnitude of initial IOP reduction was a major factor influencing outcome.  Progression was also increased with higher baseline IOP, exfoliation, bilateral disease, worse mean deviation, and older age, as well as frequent disc hemorrhages during follow-up.  Each higher (or lower) millimeter of mercury of IOP on follow-up was associated with an approximate 10% increased (or decreased) risk of progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEn5-OZe0G3L7NkxioyDXTfW6udTcc2eZlKFBAHZXu1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FhslCqsw%253D%253D&md5=c5e527611f602535b0cb3bbc349ae326</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1001%2Farchopht.121.1.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.121.1.48%26sid%3Dliteratum%253Aachs%26aulast%3DLeske%26aufirst%3DM.%2BC.%26aulast%3DHeijl%26aufirst%3DA.%26aulast%3DHussein%26aufirst%3DM.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHyman%26aufirst%3DL.%26aulast%3DKomaroff%26aufirst%3DE.%26atitle%3DFactors%2520for%2520glaucoma%2520progression%2520and%2520the%2520effect%2520of%2520treatment%253A%2520the%2520early%2520manifest%2520glaucoma%2520trial%26jtitle%3DArch.%2520Ophthalmol.%2520%2528Chicago%252C%2520IL%252C%2520U.%2520S.%2529%26date%3D2003%26volume%3D121%26spage%3D48%26epage%3D56%26doi%3D10.1001%2Farchopht.121.1.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaurin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopczynski, C. C.</span></span> <span> </span><span class="NLM_article-title">Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)</span>. <i>Am. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.ajo.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.ajo.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=29199013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2018&pages=116-127&author=J.+B.+Serleauthor=L.+J.+Katzauthor=E.+McLaurinauthor=T.+Heahauthor=N.+Ramirez-Davisauthor=D.+W.+Usnerauthor=G.+D.+Novackauthor=C.+C.+Kopczynski&title=Two+phase+3+clinical+trials+comparing+the+safety+and+efficacy+of+netarsudil+to+timolol+in+patients+with+elevated+intraocular+pressure%3A+Rho+kinase+elevated+IOP+treatment+trial+1+and+2+%28ROCKET-1+and+ROCKET-2%29&doi=10.1016%2Fj.ajo.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)</span></div><div class="casAuthors">Serle, Janet B.; Katz, L. Jay; McLaurin, Eugene; Heah, Theresa; Ramirez-Davis, Nancy; Usner, Dale W.; Novack, Gary D.; Kopczynski, Casey C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Ophthalmology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-127</span>CODEN:
                <span class="NLM_cas:coden">AJOPAA</span>;
        ISSN:<span class="NLM_cas:issn">0002-9394</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic soln., a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension.  Double-masked, randomized noninferiority clin. trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).  After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive netarsudil 0.02% once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.  Data through 3 mo from both studies are provided in this report.  Enrolled into the 2 studies were 1167 patients.  Treatment with netarsudil q.d. produced clin. and statistically significant redns. from baseline intraocular pressure (P < .001), and was non-inferior to timolol in the per-protocol population with max. baseline IOP < 25 mm Hg in both studies (ROCKET-2, primary outcome measure and population, ROCKET-1, post hoc outcome measure).  Netarsudil b.i.d. was also noninferior to timolol (ROCKET-2).  The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2) for timolol (P < .0001 for netarsudil vs timolol).  In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma.  The novel pharmacol. and aq. humor dynamic effects of this mol. suggest it may be a useful addn. to the armamentarium of ocular hypotensive medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBdq81T17qBrVg90H21EOLACvtfcHk0liPyMNqrA1xHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaktbzJ&md5=d7c92837a386c3b72df473961db11135</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ajo.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajo.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DSerle%26aufirst%3DJ.%2BB.%26aulast%3DKatz%26aufirst%3DL.%2BJ.%26aulast%3DMcLaurin%26aufirst%3DE.%26aulast%3DHeah%26aufirst%3DT.%26aulast%3DRamirez-Davis%26aufirst%3DN.%26aulast%3DUsner%26aufirst%3DD.%2BW.%26aulast%3DNovack%26aufirst%3DG.%2BD.%26aulast%3DKopczynski%26aufirst%3DC.%2BC.%26atitle%3DTwo%2520phase%25203%2520clinical%2520trials%2520comparing%2520the%2520safety%2520and%2520efficacy%2520of%2520netarsudil%2520to%2520timolol%2520in%2520patients%2520with%2520elevated%2520intraocular%2520pressure%253A%2520Rho%2520kinase%2520elevated%2520IOP%2520treatment%2520trial%25201%2520and%25202%2520%2528ROCKET-1%2520and%2520ROCKET-2%2529%26jtitle%3DAm.%2520J.%2520Ophthalmol.%26date%3D2018%26volume%3D186%26spage%3D116%26epage%3D127%26doi%3D10.1016%2Fj.ajo.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scassellati Sforzolini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittitow, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span> <span> </span><span class="NLM_article-title">A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1136/bjophthalmol-2014-305908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1136%2Fbjophthalmol-2014-305908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=25488946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BC2MzmsV2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2015&pages=738-745&author=R.+N.+Weinrebauthor=T.+Ongauthor=B.+Scassellati+Sforzoliniauthor=J.+L.+Vittitowauthor=K.+Singhauthor=P.+L.+Kaufman&title=A+randomised%2C+controlled+comparison+of+latanoprostene+bunod+and+latanoprost+0.005%25+in+the+treatment+of+ocular+hypertension+and+open+angle+glaucoma%3A+the+VOYAGER+study&doi=10.1136%2Fbjophthalmol-2014-305908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study</span></div><div class="casAuthors">Weinreb Robert N; Ong Tuyen; Scassellati Sforzolini Baldo; Vittitow Jason L; Singh Kuldev; Kaufman Paul L</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">738-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension.  METHODS:  Randomised, investigator-masked, parallel-group, dose-ranging study.  Subjects instilled one drop of study medication in the study eye once daily each evening for 28 days and completed five study visits.  The primary efficacy endpoint was the reduction in mean diurnal IOP at Day 28.  RESULTS:  Of the 413 subjects randomised (LBN 0.006%, n=82; LBN 0.012%, n=85; LBN 0.024%, n=83; LBN 0.040%, n=81; latanoprost, n=82), 396 subjects completed the study.  Efficacy for LBN was dose-dependent reaching a plateau at 0.024%-0.040%.  LBN 0.024% led to significantly greater reductions in diurnal IOP compared with latanoprost at the primary endpoint, Day 28 (p=0.005), as well as Days 7 (p=0.033) and 14 (p=0.015).  The incidence of adverse events, mostly mild and transient, was numerically higher in the LBN treatment groups compared with the latanoprost group.  Hyperaemia was similar across treatments.  CONCLUSIONS:  LBN 0.024% dosed once daily was the lower of the two most effective concentrations evaluated, with significantly greater IOP lowering and comparable side effects relative to latanoprost 0.005%.  LBN dosed once daily for 28 days was well tolerated.  CLINICAL TRIAL NUMBER:  NCT01223378.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr03x9-0A1_0HdcurJClFcfW6udTcc2eZcNFPX21ALAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzmsV2hsg%253D%253D&md5=75bccc6699d6af2f059760b57a8a1862</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbjophthalmol-2014-305908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjophthalmol-2014-305908%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DOng%26aufirst%3DT.%26aulast%3DScassellati%2BSforzolini%26aufirst%3DB.%26aulast%3DVittitow%26aufirst%3DJ.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26atitle%3DA%2520randomised%252C%2520controlled%2520comparison%2520of%2520latanoprostene%2520bunod%2520and%2520latanoprost%25200.005%2525%2520in%2520the%2520treatment%2520of%2520ocular%2520hypertension%2520and%2520open%2520angle%2520glaucoma%253A%2520the%2520VOYAGER%2520study%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2015%26volume%3D99%26spage%3D738%26epage%3D745%26doi%3D10.1136%2Fbjophthalmol-2014-305908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasanna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: pitfalls, promises and what lies ahead?</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>787</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.ejphar.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=26948313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=787&publication_year=2016&pages=47-56&author=G.+Prasannaauthor=B.+Liauthor=M.+Mogiauthor=D.+S.+Rice&title=Pharmacology+of+novel+intraocular+pressure-lowering+targets+that+enhance+conventional+outflow+facility%3A+pitfalls%2C+promises+and+what+lies+ahead%3F&doi=10.1016%2Fj.ejphar.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?</span></div><div class="casAuthors">Prasanna, Ganesh; Li, Byron; Mogi, Muneto; Rice, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">787</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Intraocular pressure (IOP) lowering drugs that are approved for the treatment of glaucoma and ocular hypertension have limited activity on increasing aq. humor movement through the trabecular meshwork and Schlemm's canal (TM/SC).  The TM/SC complex is considered the conventional outflow pathway and is a primary site of increased resistance to aq. humor outflow in glaucoma.  Novel mechanisms that enhance conventional outflow have shown promise in IOP redn. via modulation of several pathways including Rho kinase, nitric oxide/sol. guanylate cyclase/cGMP, adenosine A1, prostaglandin EP4/cAMP, and potassium channels.  The clin. translatability of these pharmacol. modulators based on pre-clin. efficacy models is currently being explored.  In addn., identification of pathways from GWAS and other studies involving transgenic rodent models with elevated/reduced IOP phenotypes have begun to yield addnl. insights into IOP regulation and serve as a source for the next generation of IOP lowering targets.  Lastly, improvements in drug delivery technologies to enable sustained IOP redn. are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqworABi0Ds3LVg90H21EOLACvtfcHk0lg1yrFWFcv8eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCjtr8%253D&md5=a6511a3ce63671c7fda56157289f8d73</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DPrasanna%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26aulast%3DRice%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520novel%2520intraocular%2520pressure-lowering%2520targets%2520that%2520enhance%2520conventional%2520outflow%2520facility%253A%2520pitfalls%252C%2520promises%2520and%2520what%2520lies%2520ahead%253F%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D787%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, D. Z.</span></span> <span> </span><span class="NLM_article-title">Guanylate cyclase activators, cell volume changes and IOP reduction</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1159/000335866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1159%2F000335866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=22179003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1emtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1145-1154&author=D.+Z.+Ellis&title=Guanylate+cyclase+activators%2C+cell+volume+changes+and+IOP+reduction&doi=10.1159%2F000335866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylate Cyclase Activators, Cell Volume Changes and IOP Reduction</span></div><div class="casAuthors">Ellis, Dorette Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1145-1154</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Glaucoma afflicts millions of people worldwide and is a major cause of blindness.  The risk to develop glaucoma is enhanced by increases in IOP, which result from deranged flow of aq. humor.  Aq. humor is a fluid located in the front of the eye that gives the eye its buoyancy and supplies nutrients to other eye tissues.  Aq. humor is secreted by a tissue called ciliary processes and exits the eye via two tissues; the trabecular meshwork (TM) and Schlemm's canal.  Because the spaces through which the fluid flows get smaller as the TM joins the area of the Schlemm's canal, there is resistance to aq. humor outflow and this resistance creates IOP.  There is a correlation between changes in TM and Schlemm's canal cell vol. and rates of aq. humor outflow; agents that decrease TM and Schlemm's canal cell vol., increase the rate of aq. humor outflow, thus decreasing IOP.  IOP is regulated by guanylate cyclase activators as shown in humans, rabbits and monkeys.  There are two distinct groups of guanylate cyclases, membrane guanylate cyclase and sol. guanylate cyclase (sGC); activation of both have been shown to decrease IOP.  Members of the membrane guanylate cyclase family of receptors bind to peptide ligands, while the sGC responds to gases (such as NO and CO2) and compds. (such as YC1), [3-(5'-hydroxymethyl-2'furyl)-1-benzyl indazole], a benzyl indazole deriv., and BAY-58-2667; activation of either results in formation of cyclic GMP (cGMP) and activation of protein kinase G (PKG) and subsequent phosphorylation of target proteins, including the high conductance calcium activated potassium channel (BKca channel).  While activators of both membrane guanylate cyclase and sGC have the ability to lower IOP, the IOP lowering effects of sGC are noteworthy because sGC activators can be topically applied to the eye to achieve an effect.  We have demonstrated that activators of sGC increase the rate at which aq. humor exits the eye in a time course that correlates with the time course for sGC-induced decreases in TM and Schlemm's canal cell vol.  Addnl., sGC-induced decrease in cell vol. is accompanied by both K+ and Cl- efflux induced by activation of K+ and Cl- channels, including the BKca channel and/or K+Cl- symport.  This suggests that parallel K+Cl- efflux, and resultant H2O efflux result in decreases in cell vol.  These observations suggest a functional role for sGC activators, and suggest that the sGC/cGMP/PKG systems are potential therapeutic targets in the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67ewK7gyYmrVg90H21EOLACvtfcHk0lg1yrFWFcv8eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1emtLvN&md5=6f87d3f1c6c62fb88b423fb817f07cb6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1159%2F000335866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000335866%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DD.%2BZ.%26atitle%3DGuanylate%2520cyclase%2520activators%252C%2520cell%2520volume%2520changes%2520and%2520IOP%2520reduction%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2011%26volume%3D28%26spage%3D1145%26epage%3D1154%26doi%3D10.1159%2F000335866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/nrd2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1038%2Fnrd2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=16955067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=755-768&author=O.+V.+Evgenovauthor=P.+Pacherauthor=P.+M.+Schmidtauthor=G.+Haskoauthor=H.+H.+W.+Schmidtauthor=J.+P.+Stasch&title=NO-independent+stimulators+and+activators+of+soluble+guanylate+cyclase%3A+discovery+and+therapeutic+potential&doi=10.1038%2Fnrd2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span></div><div class="casAuthors">Evgenov, Oleg V.; Pacher, Pal; Schmidt, Peter M.; Hasko, Gyoergy; Schmidt, Harald H. H. W.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO).  Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases.  Current therapies that involve the use of org. nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomols., lack of response and the development of tolerance following prolonged administration.  Compds. that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.  Here we review the discovery, biochem., pharmacol. and clin. potential of heme-dependent sGC stimulators (including YC-1, BAY 41-2272, BAY 41-8543, CFM-1571 and A-350619) and heme-independent sGC activators (including BAY 58-2667 and HMR-1766).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq-7FoAzI40LVg90H21EOLACvtfcHk0ljB1anqSn2BDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D&md5=6c2a2ad7db529a7fe366bcfa0d61a6af</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2038%26sid%3Dliteratum%253Aachs%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BW.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DNO-independent%2520stimulators%2520and%2520activators%2520of%2520soluble%2520guanylate%2520cyclase%253A%2520discovery%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D755%26epage%3D768%26doi%3D10.1038%2Fnrd2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marletta, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure and regulation of soluble guanylate cyclase</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-050410-100030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1146%2Fannurev-biochem-050410-100030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=22404633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=533-559&author=E.+R.+Derbyshireauthor=M.+A.+Marletta&title=Structure+and+regulation+of+soluble+guanylate+cyclase&doi=10.1146%2Fannurev-biochem-050410-100030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and regulation of soluble guanylate cyclase</span></div><div class="casAuthors">Derbyshire, Emily R.; Marletta, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-559</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is an essential signaling mol. in biol. systems.  In mammals, the diat. gas is crit. to the cyclic guanosine monophosphate (cGMP) pathway as it functions as the primary activator of sol. guanylate cyclase (sGC).  NO is synthesized from L-arginine and oxygen (O2) by the enzyme nitric oxide synthase (NOS).  Once produced, NO rapidly diffuses across cell membranes and binds to the heme cofactor of sGC.  The sGC forms a stable complex with NO and carbon monoxide (CO), but not with O2.  The binding of NO to sGC leads to significant increases in cGMP levels.  The second messenger then directly modulates phosphodiesterases (PDEs), ion-gated channels, or cGMP-dependent protein kinases to regulate physiol. functions, including vasodilation, platelet aggregation, and neurotransmission.  Many studies are focused on elucidating the mol. mechanism of sGC activation and deactivation with a goal of therapeutic intervention in diseases involving the NO/cGMP-signaling pathway.  This review summarizes the current understanding of sGC structure and regulation as well as recent developments in NO signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok39ItXTf-1rVg90H21EOLACvtfcHk0ljB1anqSn2BDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fL&md5=15c5cc20ce17cea7942f01e1828a2a26</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-050410-100030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-050410-100030%26sid%3Dliteratum%253Aachs%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26atitle%3DStructure%2520and%2520regulation%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2012%26volume%3D81%26spage%3D533%26epage%3D559%26doi%3D10.1146%2Fannurev-biochem-050410-100030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e23596</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0023596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1371%2Fjournal.pone.0023596" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=L.+S.+Hoffmannauthor=P.+M.+Schmidtauthor=Y.+Keimauthor=C.+Hoffmannauthor=H.+H.+Schmidtauthor=J.+P.+Stasch&title=Fluorescence+dequenching+makes+haem-free+soluble+guanylate+cyclase+detectable+in+living+Cells&doi=10.1371%2Fjournal.pone.0023596"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0023596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0023596%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DL.%2BS.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DKeim%26aufirst%3DY.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DFluorescence%2520dequenching%2520makes%2520haem-free%2520soluble%2520guanylate%2520cyclase%2520detectable%2520in%2520living%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0023596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtin, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chana, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madge, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meillerais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacey, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1021/jm001034k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001034k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=78-93&author=D.+L.+Selwoodauthor=D.+G.+Brummellauthor=J.+Budworthauthor=G.+E.+Burtinauthor=R.+O.+Campbellauthor=S.+S.+Chanaauthor=I.+G.+Charlesauthor=P.+A.+Fernandezauthor=R.+C.+Glenauthor=M.+C.+Gogginauthor=A.+J.+Hobbsauthor=M.+R.+Klingauthor=Q.+Liuauthor=D.+J.+Madgeauthor=S.+Meilleraisauthor=K.+L.+Powellauthor=K.+Reynoldsauthor=G.+D.+Spaceyauthor=J.+N.+Stablesauthor=M.+A.+Tatlockauthor=K.+A.+Wheelerauthor=G.+Wishartauthor=C.+K.+Woo&title=Synthesis+and+biological+evaluation+of+novel+pyrazoles+and+indazoles+as+activators+of+the+nitric+oxide+receptor%2C+soluble+guanylate+cyclase&doi=10.1021%2Fjm001034k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm001034k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001034k%26sid%3Dliteratum%253Aachs%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DBrummell%26aufirst%3DD.%2BG.%26aulast%3DBudworth%26aufirst%3DJ.%26aulast%3DBurtin%26aufirst%3DG.%2BE.%26aulast%3DCampbell%26aufirst%3DR.%2BO.%26aulast%3DChana%26aufirst%3DS.%2BS.%26aulast%3DCharles%26aufirst%3DI.%2BG.%26aulast%3DFernandez%26aufirst%3DP.%2BA.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DGoggin%26aufirst%3DM.%2BC.%26aulast%3DHobbs%26aufirst%3DA.%2BJ.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMadge%26aufirst%3DD.%2BJ.%26aulast%3DMeillerais%26aufirst%3DS.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26aulast%3DReynolds%26aufirst%3DK.%26aulast%3DSpacey%26aufirst%3DG.%2BD.%26aulast%3DStables%26aufirst%3DJ.%2BN.%26aulast%3DTatlock%26aufirst%3DM.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BA.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520pyrazoles%2520and%2520indazoles%2520as%2520activators%2520of%2520the%2520nitric%2520oxide%2520receptor%252C%2520soluble%2520guanylate%2520cyclase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D78%26epage%3D93%26doi%3D10.1021%2Fjm001034k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">von Wantoch Rekowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marazioti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyroulias, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Akker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, A.</span></span> <span> </span><span class="NLM_article-title">Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8948</span>– <span class="NLM_lpage">8952</span>, <span class="refDoi"> DOI: 10.1021/jm400539d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400539d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8948-8952&author=M.+von+Wantoch+Rekowskiauthor=V.+Kumarauthor=Z.+Zhouauthor=J.+Moschnerauthor=A.+Maraziotiauthor=M.+Bantziauthor=G.+A.+Spyrouliasauthor=F.+van+den+Akkerauthor=A.+Giannisauthor=A.+Papapetropoulos&title=Insights+into+soluble+guanylyl+cyclase+activation+derived+from+improved+heme-mimetics&doi=10.1021%2Fjm400539d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm400539d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400539d%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BWantoch%2BRekowski%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DMoschner%26aufirst%3DJ.%26aulast%3DMarazioti%26aufirst%3DA.%26aulast%3DBantzi%26aufirst%3DM.%26aulast%3DSpyroulias%26aufirst%3DG.%2BA.%26aulast%3Dvan%2Bden%2BAkker%26aufirst%3DF.%26aulast%3DGiannis%26aufirst%3DA.%26aulast%3DPapapetropoulos%26aufirst%3DA.%26atitle%3DInsights%2520into%2520soluble%2520guanylyl%2520cyclase%2520activation%2520derived%2520from%2520improved%2520heme-mimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8948%26epage%3D8952%26doi%3D10.1021%2Fjm400539d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mais, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9462</span>, and references therein <span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.+J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.+P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lhbcLHlmYlZlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.%2BJ.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conole, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Riociguat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1975</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0149-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1007%2Fs40265-013-0149-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1967-1975&author=D.+Conoleauthor=L.+J.+Scott&title=Riociguat%3A+First+global+approval&doi=10.1007%2Fs40265-013-0149-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0149-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0149-5%26sid%3Dliteratum%253Aachs%26aulast%3DConole%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1967%26epage%3D1975%26doi%3D10.1007%2Fs40265-013-0149-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kotikoski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alajuuma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moilanen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmenpera, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksala, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laippala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vapaatalo, H.</span></span> <span> </span><span class="NLM_article-title">Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1089/108076802317233171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2F108076802317233171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11858611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=11-23&author=H.+Kotikoskiauthor=P.+Alajuumaauthor=E.+Moilanenauthor=P.+Salmenperaauthor=O.+Oksalaauthor=P.+Laippalaauthor=H.+Vapaatalo&title=Comparison+of+nitric+oxide+donors+in+lowering+intraocular+pressure+in+rabbits%3A+role+of+cyclic+GMP&doi=10.1089%2F108076802317233171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP</span></div><div class="casAuthors">Kotikoski, Hanna; Alajuuma, Paivi; Moilanen, Eeva; Salmenpera, Pertteli; Oksala, Olli; Laippala, Pekka; Vapaatalo, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">L-arginine-nitric oxide (NO) pathway participates in the physiol. and in many pathol. processes in the eye, such as glaucoma.  The aim of the present study was to compare the ocular hypotensive effect of different NO-donors, and to get more information on the role of cyclic guanosine 3',5'-monophosphate (cGMP) in this process.  The test compds. were administered topically or intravitreally in the eye of a normotensive rabbit.  Intraocular pressure (IOP) was measured with a pneumatonometer after topical anesthesia.  The metabolites of NO (nitrite, nitrate, NOx) and cGMP were assayed from the aq. humor and plasma.  NO-synthase (NOS) protein expression was assayed in the ciliary body by Western blotting.  The maximal lowering of IOP was achieved as follows: atriopeptin III (concn. 78; M, decrease in IOP 50%), atriopeptin II (84; M, 37%), 8-Br-cGMP (90 mM, 37%), zaprinast + 8-Br-cGMP (1 mM + 90 mM, 34%), L-arginine (1 mM, 29%), SNP (40 mM, 28%), nitrosocaptopril (100 mM, 28%), S-nitrosothiol (SNOG) (10 mM, 27%), YC-1 (10; M, 25%), zaprinast + SNP (1 mM + 40 mM, 22%), spermine NONOate (100 mM, 20%).  The decrease in IOP lasted for 2-5 h, except with atriopeptin II and III, when IOP values were first normalized in 6 h and 2 days, resp.  In conclusion, the results of the present study indicate that by increasing the activity of L-arginine/NO/cGMP-pathway it is possible to lower IOP in rabbits equally to the currently used antiglaucoma drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgCQOPqCjB7Vg90H21EOLACvtfcHk0lgwbkBxFDYv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFGgsL8%253D&md5=9b54ba309d7f0e161a7ce42255fd841b</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1089%2F108076802317233171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076802317233171%26sid%3Dliteratum%253Aachs%26aulast%3DKotikoski%26aufirst%3DH.%26aulast%3DAlajuuma%26aufirst%3DP.%26aulast%3DMoilanen%26aufirst%3DE.%26aulast%3DSalmenpera%26aufirst%3DP.%26aulast%3DOksala%26aufirst%3DO.%26aulast%3DLaippala%26aufirst%3DP.%26aulast%3DVapaatalo%26aufirst%3DH.%26atitle%3DComparison%2520of%2520nitric%2520oxide%2520donors%2520in%2520lowering%2520intraocular%2520pressure%2520in%2520rabbits%253A%2520role%2520of%2520cyclic%2520GMP%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D18%26spage%3D11%26epage%3D23%26doi%3D10.1089%2F108076802317233171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Buys, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, B. R.</span></span> <span> </span><span class="NLM_article-title">Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.3389%2Ffnmol.2014.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=24904270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=38&author=E.+S.+Buysauthor=L.+R.+Potterauthor=L.+R.+Pasqualeauthor=B.+R.+Ksander&title=Regulation+of+intraocular+pressure+by+soluble+and+membrane+guanylate+cyclases+and+their+role+in+glaucoma&doi=10.3389%2Ffnmol.2014.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma</span></div><div class="casAuthors">Buys, Emmanuel S.; Potter, Lincoln R.; Pasquale, Louis R.; Ksander, Bruce R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38/1-38/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glaucoma is a progressive optic neuropathy characterized by visual field defects that ultimately lead to irreversible blindness.  By the year 2020, an estd. 80 million people will have glaucoma, 11 million of which will be bilaterally blind.  Primary open-angle glaucoma (POAG) is the most common type of glaucoma.  Elevated intraocular pressure (IOP) is currently the only risk factor amenable to treatment.  How IOP is regulated and can be modulated remains a topic of active investigation.  Available therapies, mostly geared toward lowering IOP, offer incomplete protection, and POAG often goes undetected until irreparable damage has been done, highlighting the need for novel therapeutic approaches, drug targets, and biomarkers.  In this review, the role of sol. (nitric oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate cyclases that generate the secondary signaling mol. cyclic guanosine monophosphate (cGMP) in the regulation of IOP and in the pathophysiol. of POAG will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolqL-7e7fAD7Vg90H21EOLACvtfcHk0lgwbkBxFDYv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqsL%252FF&md5=3fca59de217d718336b2e912c31bbdcb</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00038%26sid%3Dliteratum%253Aachs%26aulast%3DBuys%26aufirst%3DE.%2BS.%26aulast%3DPotter%26aufirst%3DL.%2BR.%26aulast%3DPasquale%26aufirst%3DL.%2BR.%26aulast%3DKsander%26aufirst%3DB.%2BR.%26atitle%3DRegulation%2520of%2520intraocular%2520pressure%2520by%2520soluble%2520and%2520membrane%2520guanylate%2520cyclases%2520and%2520their%2520role%2520in%2520glaucoma%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D38%26doi%3D10.3389%2Ffnmol.2014.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heyne, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiland, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelt, B. T.</span></span> <span> </span><span class="NLM_article-title">Effect of nitric oxide on anterior segment physiology in monkeys</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5103</span>– <span class="NLM_lpage">5110</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-11491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1167%2Fiovs.12-11491" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=5103-5110&author=G.+W.+Heyneauthor=J.+A.+Kilandauthor=P.+L.+Kaufmanauthor=B.+T.+Gabelt&title=Effect+of+nitric+oxide+on+anterior+segment+physiology+in+monkeys&doi=10.1167%2Fiovs.12-11491"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-11491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-11491%26sid%3Dliteratum%253Aachs%26aulast%3DHeyne%26aufirst%3DG.%2BW.%26aulast%3DKiland%26aufirst%3DJ.%2BA.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26aulast%3DGabelt%26aufirst%3DB.%2BT.%26atitle%3DEffect%2520of%2520nitric%2520oxide%2520on%2520anterior%2520segment%2520physiology%2520in%2520monkeys%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D5103%26epage%3D5110%26doi%3D10.1167%2Fiovs.12-11491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="note"><p class="first last">It has previously been shown that in a normotensive rabbit (not glaucomatous) the sGC modulator YC-1, which has an unclear mechanism of stimulation, produces a very modest and transient reduction of IOP, please see ref <a onclick="showRef(event, 'cit11a'); return false;" href="javascript:void(0);" class="ref cit11a">(11a)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toris, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasanna, G.</span></span> <span> </span><span class="NLM_article-title">Effects of Rho kinase inhibitors on intraocular pressure and aqueous humor dynamics in nonhuman primates and rabbits</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1089/jop.2015.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2Fjop.2015.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=27266531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=355-364&author=C.+B.+Torisauthor=M.+A.+McLaughlinauthor=D.+P.+Dworakauthor=S.+Fanauthor=S.+Havensauthor=G.+Zhanauthor=N.+Horanauthor=G.+Prasanna&title=Effects+of+Rho+kinase+inhibitors+on+intraocular+pressure+and+aqueous+humor+dynamics+in+nonhuman+primates+and+rabbits&doi=10.1089%2Fjop.2015.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits</span></div><div class="casAuthors">Toris, Carol B.; McLaughlin, Marsha A.; Dworak, Douglas P.; Fan, Shan; Havens, Shane; Zhan, Gui-Lin; Horan, Nicholas; Prasanna, Ganesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: This study examines the effects of 2 Rho kinase inhibitors on intraocular pressure (IOP) and aq. humor dynamics.  Methods: IOPs of New Zealand albino rabbits with ocular normotension and cynomolgus macaques (nonhuman primate, NHP) with chronic unilateral laser-induced glaucoma were measured at baseline and periodically after a 9 a.m. dose of H-1152, Y-27632, or vehicle.  In a sep. group of NHPs, aq. flow, outflow facility, uveoscleral outflow, and IOP were detd. after treatment with Y-27632 or vehicle control.  Results: Decreases in IOP were found in rabbits (n = 5) at 6 h after one dose of 2% Y-27632 (29%, P = 0.0002) or 1% H-1152 (35%, P = 0.0001), and in hypertensive eyes of NHPs (n = 7-9) at 3 h after one dose of 2% Y-27632 (35%, P = 0.005) or 1% H-1152 (51%, P = 0.0003).  With 2 doses of 1% Y-27632 or vehicle in NHP hypertensive eyes (n = 12), significant drug effects were IOP redn. of 28% (P = 0.05) at 2.5 h after the second dose and increases in aq. flow (36%; P = 0.013), uveoscleral outflow (59%, P = 0.008), and outflow facility (40%; P = 0.01).  In normotensive eyes of the same animals, aq. flow increased by 21% (P = 0.03).  No significant change was found in any of the other parameters.  Conclusions: Y-27632 and H-1152 lower IOP in rabbits and hypertensive eyes of NHPs for at least 6 h after single doses.  The Y-27632 effect on IOP in hypertensive NHP eyes is caused by increases in outflow facility and uveoscleral outflow.  An increase in aq. humor formation attenuates but does not prevent an IOP decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqELhKLgYJMrVg90H21EOLACvtfcHk0lgwbkBxFDYv-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOhtb%252FI&md5=93aa83f8c84d9c4f5047a74d1181021d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1089%2Fjop.2015.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2015.0116%26sid%3Dliteratum%253Aachs%26aulast%3DToris%26aufirst%3DC.%2BB.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DDworak%26aufirst%3DD.%2BP.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DHavens%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DG.%26aulast%3DHoran%26aufirst%3DN.%26aulast%3DPrasanna%26aufirst%3DG.%26atitle%3DEffects%2520of%2520Rho%2520kinase%2520inhibitors%2520on%2520intraocular%2520pressure%2520and%2520aqueous%2520humor%2520dynamics%2520in%2520nonhuman%2520primates%2520and%2520rabbits%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D32%26spage%3D355%26epage%3D364%26doi%3D10.1089%2Fjop.2015.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and the references therein.</p></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">Typically in this model, a single dose of standard care therapies, for example, timolol and travoprost, affords maximum IOP lowering of 20–30%. Please see:</p></div><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliuso, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podos, S. M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</span>. <i>Journal of Glaucoma</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1097/00061198-200012000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1097%2F00061198-200012000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11131752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD3M7hsV2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=458-462&author=R.+F.+Wangauthor=J.+B.+Serleauthor=D.+J.+Gagliusoauthor=S.+M.+Podos&title=Comparison+of+the+ocular+hypotensive+effect+of+brimonidine%2C+dorzolamide%2C+latanoprost%2C+or+artificial+tears+added+to+timolol+in+glaucomatous+monkey+eyes&doi=10.1097%2F00061198-200012000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</span></div><div class="casAuthors">Wang R F; Serle J B; Gagliuso D J; Podos S M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of glaucoma</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458-62</span>
        ISSN:<span class="NLM_cas:issn">1057-0829</span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the additive ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears to timolol in monkey eyes with laser-induced unilateral glaucoma.  METHODS:  Eight monkeys were used and each animal received all four combinations of drugs in a randomized fashion during the study.  The washout period between each combination was at least 2 weeks.  Intraocular pressure (IOP) was measured at 8:30 AM, 11:00 AM, 1:00 PM, and 3:30 PM on day 1 (untreated baseline), day 2 (timolol treatment alone), and days 3 through 5 (combination therapy with two drugs).  One drop of 0.5% timolol was topically applied at 3:45 PM on day 1 and at 8:45 AM and 3:45 PM on days 2 through 5.  One drop of 0.2% brimonidine or 2% dorzolamide or artificial tears was added on day 2 at 4:00 PM and at 9:00 AM and 4:00 PM on days 3 through 5, or latanoprost was added at 9:00 AM on days 3 through 5.  RESULTS:  Compared with timolol alone, the maximal additive reduction in IOP which occurred on day 5 was 4.8 +/- 0.8 mm Hg (mean +/- standard error of the mean) with timolol plus brimonidine, 5.6 +/- 1.0 mm Hg with timolol plus dorzolamide, 4.3 +/- 1.0 mm Hg with timolol plus latanoprost, and 2.0 +/- 0.5 mm Hg with timolol plus artificial tears (P < 0.01).  At all measurements, timolol plus brimonidine, timolol plus dorzolamide, and timolol plus latanoprost caused greater (P < 0.05) IOP reductions than did timolol plus artificial tears.  The additive IOP-lowering effect was similar (P > 0.60) when comparing timolol plus brimonidine and timolol plus dorzolamide, timolol plus brimonidine and timolol plus latanoprost, timolol plus dorzolamide and timolol plus latanoprost at all measurements, but timolol plus dorzolamide caused a greater (P < 0.05) reduction of IOP than did timolol plus latanoprost at 0 hours on day 5.  CONCLUSIONS:  The addition of brimonidine, dorzolamide, or latanoprost to timolol caused similar additional reductions of IOP in glaucomatous monkey eyes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0BHB3Az9wuMNIRw0GKUoEfW6udTcc2eaQwO_Ehm6qV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7hsV2ksQ%253D%253D&md5=489e1606ceed168e19a231b9ac03213a</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1097%2F00061198-200012000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00061198-200012000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%2BF.%26aulast%3DSerle%26aufirst%3DJ.%2BB.%26aulast%3DGagliuso%26aufirst%3DD.%2BJ.%26aulast%3DPodos%26aufirst%3DS.%2BM.%26atitle%3DComparison%2520of%2520the%2520ocular%2520hypotensive%2520effect%2520of%2520brimonidine%252C%2520dorzolamide%252C%2520latanoprost%252C%2520or%2520artificial%2520tears%2520added%2520to%2520timolol%2520in%2520glaucomatous%2520monkey%2520eyes%26jtitle%3DJournal%2520of%2520Glaucoma%26date%3D2000%26volume%3D9%26spage%3D458%26epage%3D462%26doi%3D10.1097%2F00061198-200012000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallee, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinke, P. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1089/108076801753266802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2F108076801753266802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11765147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=421-432&author=M.+R.+Hellbergauthor=V.+L.+Salleeauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=L.+Desantisauthor=T.+R.+Deanauthor=P.+W.+Zinke&title=Preclinical+efficacy+of+travoprost%2C+a+potent+and+selective+FP+prostaglandin+receptor+agonist&doi=10.1089%2F108076801753266802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist</span></div><div class="casAuthors">Hellberg, Mark R.; Sallee, Verney L.; McLaughlin, Marsha A.; Sharif, Naj A.; Desantis, Louis; Dean, Tom R.; Zinke, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Travoprost is the iso-Pr ester prodrug of a high affinity, selective FP prostaglandin full receptor agonist.  In contrast to travoprost acid's high affinity and efficacy at the FP receptor, there is only sub-micromolar affinity for the DP, EP1, EP3, EP4, IP, and TP receptors.  Travoprost produced a lower incidence of ocular irritation than PGF2α iso-Pr ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit.  Topical ocular application of travoprost produced a marked miotic effect in cats following doses of 0.01, 0.03 and 0.1 μg.  In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak redn. in intraocular pressure (IOP) of 22.7% and 28.6%, resp.  Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 μg.  Travoprost is a promising ocular hypotensive prostaglandin FP deriv. that has the ocular hypotensive efficacy of PGF2α iso-Pr ester but with less severe ocular side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CFwMCfgbcLVg90H21EOLACvtfcHk0lhJX6ItBmMQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFehuro%253D&md5=06075165f53c89ce73b9019396621d92</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1089%2F108076801753266802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076801753266802%26sid%3Dliteratum%253Aachs%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DSallee%26aufirst%3DV.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DDesantis%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26atitle%3DPreclinical%2520efficacy%2520of%2520travoprost%252C%2520a%2520potent%2520and%2520selective%2520FP%2520prostaglandin%2520receptor%2520agonist%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D17%26spage%3D421%26epage%3D432%26doi%3D10.1089%2F108076801753266802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shade, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steely, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSantis, L.</span></span> <span> </span><span class="NLM_article-title">Preliminary characterization of a transformed cell strain derived from human trabecular meshwork</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.3109/02713689409042398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.3109%2F02713689409042398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=8156826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADyaK2c3gvVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=51-63&author=I.+H.+Pangauthor=D.+L.+Shadeauthor=A.+F.+Clarkauthor=H.+T.+Steelyauthor=L.+DeSantis&title=Preliminary+characterization+of+a+transformed+cell+strain+derived+from+human+trabecular+meshwork&doi=10.3109%2F02713689409042398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary characterization of a transformed cell strain derived from human trabecular meshwork</span></div><div class="casAuthors">Pang I H; Shade D L; Clark A F; Steely H T; DeSantis L</div><div class="citationInfo"><span class="NLM_cas:title">Current eye research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    </div><div class="casAbstract">Cells isolated from the trabecular meshwork (TM) of a male glaucoma patient were transformed by transfection with an origin defective mutant of SV40 virus.  Transformation dramatically increased the growth rate of these cells (designated HTM-3 cells), allowing biochemical and pharmacological characterization.  The HTM-3 cells had cytoskeletal components that were reported to be present in TM tissue and non-transformed TM cells.  Vimentin, tubulin and smooth muscle specific alpha-actin, but not desmin, were localized in these cells by immunocytochemistry.  The extracellular matrix components collagen types I, III and IV, fibronectin and laminin were found in HTM-3 cells as well as their non-transformed parental cells.  As predicted, the protein profile of the HTM-3 cells revealed by two-dimensional gel electrophoresis was different from that of the non-transformed cells, probably due to the enhanced growth characteristics of these cells.  Furthermore, HTM-3 cells had various intracellular second messenger systems that responded to pharmacological agents.  Forskolin, prostaglandin E2, beta-adrenergic and adenosine A2 agonists stimulated the adenylyl cyclase in these cells, whereas muscarinic, serotonergic, dopaminergic and other agonists were ineffective.  Sodium nitroprusside increased the intracellular concentration of cGMP, demonstrating the presence of a functional guanylyl cyclase.  Phospholipase C activity in these cells was also detected.  Muscarinic agonists, histamine and bradykinin, but not adrenergic, serotonergic agonists or prostaglandins, increased phosphoinositide turnover.  These drug responses of HTM-3 cells agree with published data on primary TM cells and TM tissues, suggesting that the transformed cells may be a valid substitute for certain pharmacological studies of TM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbzRXZAJ5LWsuCWE5mhx1RfW6udTcc2eaQwO_Ehm6qV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3gvVejsQ%253D%253D&md5=1e4e94fb084ea0340571ddab536bccb2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3109%2F02713689409042398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713689409042398%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DI.%2BH.%26aulast%3DShade%26aufirst%3DD.%2BL.%26aulast%3DClark%26aufirst%3DA.%2BF.%26aulast%3DSteely%26aufirst%3DH.%2BT.%26aulast%3DDeSantis%26aufirst%3DL.%26atitle%3DPreliminary%2520characterization%2520of%2520a%2520transformed%2520cell%2520strain%2520derived%2520from%2520human%2520trabecular%2520meshwork%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D1994%26volume%3D13%26spage%3D51%26epage%3D63%26doi%3D10.3109%2F02713689409042398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">Compound <b>3</b> has been described previously; see:</p></div><div class="NLM_citation" id="cit16a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, P. J.</span>; <span class="NLM_string-name">Urbanski, M.</span>; <span class="NLM_string-name">Carson, J. R.</span>; <span class="NLM_string-name">Carmosin, R. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Thiazole Derivatives Useful as Platelet Aggregation Inhibitors</span>. U.S. Patent <span class="NLM_patent">5,342,851</span>, <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=P.+J.+Sanfilippo&author=M.+Urbanski&author=J.+R.+Carson&author=R.+J.+Carmosin&title=Substituted+Thiazole+Derivatives+Useful+as+Platelet+Aggregation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSanfilippo%26aufirst%3DP.%2BJ.%26atitle%3DSubstituted%2520Thiazole%2520Derivatives%2520Useful%2520as%2520Platelet%2520Aggregation%2520Inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Subsequent to our internal HTS campaign where we determined the affinity of <b>3</b> as an sGC activator, there was a more recent patent disclosure highlighting <b>3</b> as an sGC activator; see:</p></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Nakada, Y.</span>; <span class="NLM_string-name">Ohba, Y.</span>; <span class="NLM_string-name">Nakagawa, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazole-containing Heterocyclic Compound Derivatives as Soluble Guanylyl Cyclase (sGC) Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2009123316</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+Matsunaga&author=Y.+Nakada&author=Y.+Ohba&author=H.+Nakagawa&title=Preparation+of+Pyrazole-containing+Heterocyclic+Compound+Derivatives+as+Soluble+Guanylyl+Cyclase+%28sGC%29+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Pyrazole-containing%2520Heterocyclic%2520Compound%2520Derivatives%2520as%2520Soluble%2520Guanylyl%2520Cyclase%2520%2528sGC%2529%2520Activators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span>; <span class="NLM_string-name">Hahn, M. G.</span>; <span class="NLM_string-name">Stasch, J.</span>; <span class="NLM_string-name">Schlemmer, K.</span>; <span class="NLM_string-name">Wunder, F.</span>; <span class="NLM_string-name">El, S. S.</span>; <span class="NLM_string-name">Li, V.
M.</span>; <span class="NLM_string-name">Becker, E.</span>; <span class="NLM_string-name">Stoll, F.</span>; <span class="NLM_string-name">Knorr, A.</span>; <span class="NLM_string-name">Kolkhof, P.</span>; <span class="NLM_string-name">Woltering, E.</span></span> <span> </span><span class="NLM_article-title">Substituted 1-benzylcycloalkylcarboxylic Acids as Soluble Guanylate Cyclase Stimulators and Their Preparation and Use in the Treatment of Cardiovascular Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012076466</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+Lampe&author=M.+G.+Hahn&author=J.+Stasch&author=K.+Schlemmer&author=F.+Wunder&author=S.+S.+El&author=V.%0AM.+Li&author=E.+Becker&author=F.+Stoll&author=A.+Knorr&author=P.+Kolkhof&author=E.+Woltering&title=Substituted+1-benzylcycloalkylcarboxylic+Acids+as+Soluble+Guanylate+Cyclase+Stimulators+and+Their+Preparation+and+Use+in+the+Treatment+of+Cardiovascular+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLampe%26aufirst%3DT.%26atitle%3DSubstituted%25201-benzylcycloalkylcarboxylic%2520Acids%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Stimulators%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cardiovascular%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. Q.</span>; <span class="NLM_string-name">Kim, R. M.</span>; <span class="NLM_string-name">Mirc, J. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Biphenylpyridine Compounds as Soluble Guanylate Cyclase Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012058132</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Q.+Tan&author=R.+M.+Kim&author=J.+W.+Mirc&title=Preparation+of+Biphenylpyridine+Compounds+as+Soluble+Guanylate+Cyclase+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%2BQ.%26atitle%3DPreparation%2520of%2520Biphenylpyridine%2520Compounds%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Activators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. L.</span></span> <span> </span><span class="NLM_article-title">Sequential regioselective C–H functionalization of thiophenes</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3310</span>– <span class="NLM_lpage">3313</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b01205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b01205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWgsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=3310-3313&author=M.+H.+Danielsauthor=J.+R.+Armandauthor=K.+L.+Tan&title=Sequential+regioselective+C%E2%80%93H+functionalization+of+thiophenes&doi=10.1021%2Facs.orglett.6b01205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential Regioselective C-H Functionalization of Thiophenes</span></div><div class="casAuthors">Daniels, Matthew H.; Armand, Jeremy R.; Tan, Kian L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3310-3313</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the sequential functionalization of 5-membered ring heterocycles is disclosed.  By employing a pH sensitive directing group, both directed and nondirected C-H activation pathways are available, providing access to 2,3,4- and 2,4,5-substituted thiophenes.  The C-H arylation was performed in water, and using a surfactant greatly improved the yield and mass recovery.  The use of a directing group with an on/off switch offers a potentially powerful means of generating diversity around medicinally relevant cores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdeQwrpB_LbVg90H21EOLACvtfcHk0lg0bBgQ-WIjUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWgsL%252FE&md5=fe807bb42428067dfb16e1cc6b0be407</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b01205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b01205%26sid%3Dliteratum%253Aachs%26aulast%3DDaniels%26aufirst%3DM.%2BH.%26aulast%3DArmand%26aufirst%3DJ.%2BR.%26aulast%3DTan%26aufirst%3DK.%2BL.%26atitle%3DSequential%2520regioselective%2520C%25E2%2580%2593H%2520functionalization%2520of%2520thiophenes%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D3310%26epage%3D3313%26doi%3D10.1021%2Facs.orglett.6b01205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakamata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikariya, T.</span></span> <span> </span><span class="NLM_article-title">Oxo-tethered ruthenium(II) complex as a bifunctional catalyst for asymmetric transfer hydrogenation and H<sub>2</sub> hydrogenation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">14960</span>– <span class="NLM_lpage">14963</span>, <span class="refDoi"> DOI: 10.1021/ja207283t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja207283t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=14960-14963&author=T.+Tougeauthor=T.+Hakamataauthor=H.+Naraauthor=T.+Kobayashiauthor=N.+Sayoauthor=N.+Saitoauthor=Y.+Kayakiauthor=T.+Ikariya&title=Oxo-tethered+ruthenium%28II%29+complex+as+a+bifunctional+catalyst+for+asymmetric+transfer+hydrogenation+and+H2+hydrogenation&doi=10.1021%2Fja207283t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oxo-Tethered Ruthenium(II) Complex as a Bifunctional Catalyst for Asymmetric Transfer Hydrogenation and H2 Hydrogenation</span></div><div class="casAuthors">Touge, Taichiro; Hakamata, Tomohiko; Nara, Hideki; Kobayashi, Tohru; Sayo, Noboru; Saito, Takao; Kayaki, Yoshihito; Ikariya, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14960-14963</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Newly developed oxo-tethered Ru amido complexes and their HCl adducts exhibited excellent catalytic performance for both asym. transfer hydrogenation and the hydrogenation of ketonic substrates under neutral conditions without any cocatalysts to give chiral secondary alcs. with high levels of enantioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStJMMWyAJYrVg90H21EOLACvtfcHk0lg0bBgQ-WIjUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsrfE&md5=3f738a25a9f24642ca86aaeb3b2b310f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fja207283t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja207283t%26sid%3Dliteratum%253Aachs%26aulast%3DTouge%26aufirst%3DT.%26aulast%3DHakamata%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DSayo%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DKayaki%26aufirst%3DY.%26aulast%3DIkariya%26aufirst%3DT.%26atitle%3DOxo-tethered%2520ruthenium%2528II%2529%2520complex%2520as%2520a%2520bifunctional%2520catalyst%2520for%2520asymmetric%2520transfer%2520hydrogenation%2520and%2520H2%2520hydrogenation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D14960%26epage%3D14963%26doi%3D10.1021%2Fja207283t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rajamannar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, K. K.</span></span> <span> </span><span class="NLM_article-title">Enolate alkylation of bicyclo(2.2.2)oct-5-en-2-one and radical cyclisation - a potential approach for the construction of tricyclic carbocycles</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5789</span>– <span class="NLM_lpage">5792</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)82193-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2FS0040-4039%2800%2982193-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1988&pages=5789-5792&author=T.+Rajamannarauthor=K.+K.+Balasubramanian&title=Enolate+alkylation+of+bicyclo%282.2.2%29oct-5-en-2-one+and+radical+cyclisation+-+a+potential+approach+for+the+construction+of+tricyclic+carbocycles&doi=10.1016%2FS0040-4039%2800%2982193-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2982193-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252982193-0%26sid%3Dliteratum%253Aachs%26aulast%3DRajamannar%26aufirst%3DT.%26aulast%3DBalasubramanian%26aufirst%3DK.%2BK.%26atitle%3DEnolate%2520alkylation%2520of%2520bicyclo%25282.2.2%2529oct-5-en-2-one%2520and%2520radical%2520cyclisation%2520-%2520a%2520potential%2520approach%2520for%2520the%2520construction%2520of%2520tricyclic%2520carbocycles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1988%26volume%3D29%26spage%3D5789%26epage%3D5792%26doi%3D10.1016%2FS0040-4039%2800%2982193-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pitre, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankar, Y. D.</span></span> <span> </span><span class="NLM_article-title">Palladium catalysed conversion of vinyl bromo allylic alcohols into vinylic carbonyl compounds and oxidation of secondary alcohols to ketones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12291</span>– <span class="NLM_lpage">12298</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(96)00715-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2F0040-4020%2896%2900715-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1996&pages=12291-12298&author=S.+V.+Pitreauthor=P.+S.+Vankarauthor=Y.+D.+Vankar&title=Palladium+catalysed+conversion+of+vinyl+bromo+allylic+alcohols+into+vinylic+carbonyl+compounds+and+oxidation+of+secondary+alcohols+to+ketones&doi=10.1016%2F0040-4020%2896%2900715-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2896%2900715-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252896%252900715-6%26sid%3Dliteratum%253Aachs%26aulast%3DPitre%26aufirst%3DS.%2BV.%26aulast%3DVankar%26aufirst%3DP.%2BS.%26aulast%3DVankar%26aufirst%3DY.%2BD.%26atitle%3DPalladium%2520catalysed%2520conversion%2520of%2520vinyl%2520bromo%2520allylic%2520alcohols%2520into%2520vinylic%2520carbonyl%2520compounds%2520and%2520oxidation%2520of%2520secondary%2520alcohols%2520to%2520ketones%26jtitle%3DTetrahedron%26date%3D1996%26volume%3D52%26spage%3D12291%26epage%3D12298%26doi%3D10.1016%2F0040-4020%2896%2900715-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.-L.</span></span> <span> </span><span class="NLM_article-title">Lanthanide triflate-promoted palladium-catalyzed cyclization of alkenyl β-keto Esters and amides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1021/ol0349110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0349110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2869-2871&author=D.+Yangauthor=J.-H.+Liauthor=Q.+Gaoauthor=Y.-L.+Yan&title=Lanthanide+triflate-promoted+palladium-catalyzed+cyclization+of+alkenyl+%CE%B2-keto+Esters+and+amides&doi=10.1021%2Fol0349110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fol0349110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0349110%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DY.-L.%26atitle%3DLanthanide%2520triflate-promoted%2520palladium-catalyzed%2520cyclization%2520of%2520alkenyl%2520%25CE%25B2-keto%2520Esters%2520and%2520amides%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2869%26epage%3D2871%26doi%3D10.1021%2Fol0349110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima-Hirano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of C-labeled retinoic acid, [<sup>11</sup>C]ATRA, via an alkenylboron precursor by Pd(0)-mediated rapid-[<sup>11</sup>C]-methylation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3622</span>– <span class="NLM_lpage">3625</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.bmcl.2014.05.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3622-3625&author=M.+Suzukiauthor=M.+Takashima-Hiranoauthor=H.+Ishiiauthor=C.+Watanabeauthor=K.+Sumiauthor=H.+Koyamaauthor=H.+Doi&title=Synthesis+of+C-labeled+retinoic+acid%2C+%5B11C%5DATRA%2C+via+an+alkenylboron+precursor+by+Pd%280%29-mediated+rapid-%5B11C%5D-methylation&doi=10.1016%2Fj.bmcl.2014.05.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTakashima-Hirano%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DSumi%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DH.%26aulast%3DDoi%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520C-labeled%2520retinoic%2520acid%252C%2520%255B11C%255DATRA%252C%2520via%2520an%2520alkenylboron%2520precursor%2520by%2520Pd%25280%2529-mediated%2520rapid-%255B11C%255D-methylation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3622%26epage%3D3625%26doi%3D10.1016%2Fj.bmcl.2014.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">Off-target activities were discounted as a source of the differences in observed tolerability. Compounds (+)-<b>17</b>, (+)-<b>21</b>, and (+)-<b>24</b> were selective against an internal safety panel of 21 enzymes, receptors, and ion channels, while compound (+)-<b>23</b> was evaluated more comprehensively in a broader panel (Eurofins Panlabs) consisting of 85 targets. Compound (+)-<b>23</b> was >1000× selective against the majority of targets assessed with the exception of the muscarinic receptor-M2 (EC<sub>50</sub> = 3.9 μM), and >50% binding was also noted with prostanoid receptors DP1, EP3, and IP at 10 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><a href="https://clinicaltrials.gov/" class="extLink">ClinicalTrials.gov</a>.
Identifier:
NCT02743780. (accessed Jan 27, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.%0AIdentifier%3A%0ANCT02743780.+%28accessed+Jan+27%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span> <i>MacroModel</i>, v9.9; <span class="NLM_publisher-name">Schrödinger,
LLC</span>, <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MacroModel%2C+v9.9%3B+Schr%C3%B6dinger%2C%0ALLC%2C+New+York%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26pub%3DSchr%25C3%25B6dinger%252C%250ALLC%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Knox, J. E.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Bakken, V.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Jaramillo, J.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Stratmann, R. E.</span>; <span class="NLM_string-name">Yazyev, O.</span>; <span class="NLM_string-name">Austin, A. J.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Pomelli, C.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Ayala, P. Y.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Voth, G. A.</span>; <span class="NLM_string-name">Salvador, P.</span>; <span class="NLM_string-name">Dannenberg, J. J.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Dapprich, S.</span>; <span class="NLM_string-name">Daniels, A. D.</span>; <span class="NLM_string-name">Strain, M. C.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Malick, D. K.</span>; <span class="NLM_string-name">Rabuck, A. D.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Cui, Q.</span>; <span class="NLM_string-name">Baboul, A. G.</span>; <span class="NLM_string-name">Clifford, S.</span>; <span class="NLM_string-name">Cioslowski, J.</span>; <span class="NLM_string-name">Stefanov, B. B.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liashenko, A.</span>; <span class="NLM_string-name">Piskorz, P.</span>; <span class="NLM_string-name">Komaromi, I.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Fox, D. J.</span>; <span class="NLM_string-name">Keith, T.</span>; <span class="NLM_string-name">Al-Laham, M. A.</span>; <span class="NLM_string-name">Peng, C. Y.</span>; <span class="NLM_string-name">Nanayakkara, A.</span>; <span class="NLM_string-name">Challacombe, M.</span>; <span class="NLM_string-name">Gill, P. M. W.</span>; <span class="NLM_string-name">Johnson, B.</span>; <span class="NLM_string-name">Chen, W.</span>; <span class="NLM_string-name">Wong, M. W.</span>; <span class="NLM_string-name">Gonzalez, C.</span>; <span class="NLM_string-name">Pople, J. A.</span></span> <i>Gaussian 03</i>, revision C.02; <span class="NLM_publisher-name">Gaussian, Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=J.+A.+Montgomery&author=T.+Vreven&author=K.+N.+Kudin&author=J.+C.+Burant&author=J.+M.+Millam&author=S.+S.+Iyengar&author=J.+Tomasi&author=V.+Barone&author=B.+Mennucci&author=M.+Cossi&author=G.+Scalmani&author=N.+Rega&author=G.+A.+Petersson&author=H.+Nakatsuji&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=M.+Klene&author=X.+Li&author=J.+E.+Knox&author=H.+P.+Hratchian&author=J.+B.+Cross&author=V.+Bakken&author=C.+Adamo&author=J.+Jaramillo&author=R.+Gomperts&author=R.+E.+Stratmann&author=O.+Yazyev&author=A.+J.+Austin&author=R.+Cammi&author=C.+Pomelli&author=J.+W.+Ochterski&author=P.+Y.+Ayala&author=K.+Morokuma&author=G.+A.+Voth&author=P.+Salvador&author=J.+J.+Dannenberg&author=V.+G.+Zakrzewski&author=S.+Dapprich&author=A.+D.+Daniels&author=M.+C.+Strain&author=O.+Farkas&author=D.+K.+Malick&author=A.+D.+Rabuck&author=K.+Raghavachari&author=J.+B.+Foresman&author=J.+V.+Ortiz&author=Q.+Cui&author=A.+G.+Baboul&author=S.+Clifford&author=J.+Cioslowski&author=B.+B.+Stefanov&author=G.+Liu&author=A.+Liashenko&author=P.+Piskorz&author=I.+Komaromi&author=R.+L.+Martin&author=D.+J.+Fox&author=T.+Keith&author=M.+A.+Al-Laham&author=C.+Y.+Peng&author=A.+Nanayakkara&author=M.+Challacombe&author=P.+M.+W.+Gill&author=B.+Johnson&author=W.+Chen&author=M.+W.+Wong&author=C.+Gonzalez&author=J.+A.+Pople&title=Gaussian+03"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252003%26pub%3DGaussian%252C%2520Inc%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span> <i>Molecular Operating
Environment (MOE)</i>, 2013.08;
Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910,
Montreal, QC, Canada, H3A 2R7, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE%29%2C+2013.08%3B%0AChemical+Computing+Group+ULC%2C+1010+Sherbooke+St.+West%2C+Suite+%23910%2C%0AMontreal%2C+QC%2C+Canada%2C+H3A+2R7%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%2529%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, A. R.</span>; <span class="NLM_string-name">Sinz, C. J.</span>; <span class="NLM_string-name">Chang, J.</span>; <span class="NLM_string-name">Kim, R.
M.</span>; <span class="NLM_string-name">Mirc, J.
W.</span>; <span class="NLM_string-name">Parmee, E.
R.</span>; <span class="NLM_string-name">Tan, Q.</span></span> <span> </span><span class="NLM_article-title">Soluble Guanylate Cyclase Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2009032249</span>, <span class="NLM_year">2009</span> (Example 9).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+R.+Bittner&author=C.+J.+Sinz&author=J.+Chang&author=R.%0AM.+Kim&author=J.%0AW.+Mirc&author=E.%0AR.+Parmee&author=Q.+Tan&title=Soluble+Guanylate+Cyclase+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBittner%26aufirst%3DA.%2BR.%26atitle%3DSoluble%2520Guanylate%2520Cyclase%2520Activators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">Crystallographic data (excluding structure factors) have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1814475. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax (+44) 1223 336033, email: <a href="/cdn-cgi/l/email-protection#1a7e7f6a7569736e5a79797e7934797b77347b79346f71"><span class="__cf_email__" data-cfemail="117574617e62786551727275723f72707c3f70723f647a">[email protected]</span></a>].</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c'],'ref12':[],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d'],'ref21':[],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hexiang Wang, Bo Ren, Ye Liu, Beibei Jiang, Yin Guo, Min Wei, Lusong Luo, Xianzhao Kuang, Ming Qiu, Lei Lv, Hong Xu, Ruipeng Qi, Huibin Yan, Dexu Xu, Zhiwei Wang, Chang-Xin Huo, Yutong Zhu, Yuan Zhao, Yiyuan Wu, Zhen Qin, Dan Su, Tristin Tang, Fan Wang, Xuebing Sun, Yingcai Feng, Hao Peng, Xing Wang, Yajuan Gao, Yong Liu, Wenfeng Gong, Fenglong Yu, Xuesong Liu, Lai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Changyou Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15541-15563. <a href="https://doi.org/10.1021/acs.jmedchem.0c01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPamiparib%252B%252528BGB-290%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BPoly%252B%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%26aulast%3DWang%26aufirst%3DHexiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01082020%26date%3D02122020%26volume%3D63%26issue%3D24%26spage%3D15541%26epage%3D15563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kuei-Ju Cheng, Chien-Ming Hsieh, Kunal Nepali, <span class="NLM_string-name hlFld-ContribAuthor">Jing-Ping Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10533-10593. <a href="https://doi.org/10.1021/acs.jmedchem.9b01033" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01033%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOcular%252BDisease%252BTherapeutics%25253A%252BDesign%252Band%252BDelivery%252Bof%252BDrugs%252Bfor%252BDiseases%252Bof%252Bthe%252BEye%26aulast%3DCheng%26aufirst%3DKuei-Ju%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D28062019%26date%3D02062020%26volume%3D63%26issue%3D19%26spage%3D10533%26epage%3D10593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Glen R.  Rennie</span>, <span class="hlFld-ContribAuthor ">Timothy C.  Barden</span>, <span class="hlFld-ContribAuthor ">Sylvie G.  Bernier</span>, <span class="hlFld-ContribAuthor ">Andrew  Carvalho</span>, <span class="hlFld-ContribAuthor ">Renee  Deming</span>, <span class="hlFld-ContribAuthor ">Peter  Germano</span>, <span class="hlFld-ContribAuthor ">Colleen  Hudson</span>, <span class="hlFld-ContribAuthor ">G-Yoon J.  Im</span>, <span class="hlFld-ContribAuthor ">Rajesh R.  Iyengar</span>, <span class="hlFld-ContribAuthor ">Lei  Jia</span>, <span class="hlFld-ContribAuthor ">Joon  Jung</span>, <span class="hlFld-ContribAuthor ">Elise  Kim</span>, <span class="hlFld-ContribAuthor ">Thomas W.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Ara  Mermerian</span>, <span class="hlFld-ContribAuthor ">Joel  Moore</span>, <span class="hlFld-ContribAuthor ">Takashi  Nakai</span>, <span class="hlFld-ContribAuthor ">Nicholas R.  Perl</span>, <span class="hlFld-ContribAuthor ">Jenny  Tobin</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Zimmer</span>, <span class="hlFld-ContribAuthor ">Paul A.  Renhowe</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127886. <a href="https://doi.org/10.1016/j.bmcl.2021.127886" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127886</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127886%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BCYR715%25253A%252BA%252Bnovel%252Bcarboxylic%252Bacid-containing%252Bsoluble%252Bguanylate%252Bcyclase%252Bstimulator%26aulast%3DRennie%26aufirst%3DGlen%2BR.%26date%3D2021%26volume%3D40%26spage%3D127886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrej Emanuel  Cotman</span>. </span><span class="cited-content_cbyCitation_article-title">Escaping from Flatland: Stereoconvergent Synthesis of Three‐Dimensional Scaffolds via Ruthenium(II)‐Catalyzed Noyori–Ikariya Transfer Hydrogenation. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (1)
                                     , 39-53. <a href="https://doi.org/10.1002/chem.202002779" title="DOI URL">https://doi.org/10.1002/chem.202002779</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202002779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202002779%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DEscaping%252Bfrom%252BFlatland%25253A%252BStereoconvergent%252BSynthesis%252Bof%252BThree%2525E2%252580%252590Dimensional%252BScaffolds%252Bvia%252BRuthenium%252528II%252529%2525E2%252580%252590Catalyzed%252BNoyori%2525E2%252580%252593Ikariya%252BTransfer%252BHydrogenation%26aulast%3DCotman%26aufirst%3DAndrej%2BEmanuel%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D39%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer L.  Dumouchel</span>, <span class="hlFld-ContribAuthor ">Upendra A.  Argikar</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Adams</span>, <span class="hlFld-ContribAuthor ">Ganesh  Prasanna</span>, <span class="hlFld-ContribAuthor ">Takeru  Ehara</span>, <span class="hlFld-ContribAuthor ">Sean  Kim</span>, <span class="hlFld-ContribAuthor ">Chris  Breen</span>, <span class="hlFld-ContribAuthor ">Muneto  Mogi</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding metabolism related differences in ocular efficacy of MGV354. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2021,</strong> <em>51 </em>
                                    (1)
                                     , 5-14. <a href="https://doi.org/10.1080/00498254.2020.1794658" title="DOI URL">https://doi.org/10.1080/00498254.2020.1794658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2020.1794658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2020.1794658%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DUnderstanding%252Bmetabolism%252Brelated%252Bdifferences%252Bin%252Bocular%252Befficacy%252Bof%252BMGV354%26aulast%3DDumouchel%26aufirst%3DJennifer%2BL.%26date%3D2021%26date%3D2020%26volume%3D51%26issue%3D1%26spage%3D5%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Adams</span>, <span class="hlFld-ContribAuthor ">Julien P. N.  Papillon</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments for the Treatment of Glaucoma. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 189-256. <a href="https://doi.org/10.1007/7355_2019_92" title="DOI URL">https://doi.org/10.1007/7355_2019_92</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2019_92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2019_92%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BDevelopments%252Bfor%252Bthe%252BTreatment%252Bof%252BGlaucoma%26aulast%3DAdams%26aufirst%3DChristopher%2BM.%26date%3D2020%26date%3D2020%26spage%3D189%26epage%3D256%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DDrug%252BDelivery%252BChallenges%252Band%252BNovel%252BTherapeutic%252BApproaches%252Bfor%252BRetinal%252BDiseases%26aulast%3DCioffi%26aufirst%3DChristopher%2BL.%26date%3D2020%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sijia  Xiao</span>, <span class="hlFld-ContribAuthor ">Qianbin  Li</span>, <span class="hlFld-ContribAuthor ">Liqing  Hu</span>, <span class="hlFld-ContribAuthor ">Zutao  Yu</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Qi  Chang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Gaoyun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (18)
                                     , 1544-1557. <a href="https://doi.org/10.2174/1389557519666190730110600" title="DOI URL">https://doi.org/10.2174/1389557519666190730110600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557519666190730110600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557519666190730110600%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DSoluble%252BGuanylate%252BCyclase%252BStimulators%252Band%252BActivators%25253A%252BWhere%252Bare%252BWe%252Band%252BWhere%252Bto%252BGo%25253F%26aulast%3DXiao%26aufirst%3DSijia%26date%3D2019%26volume%3D19%26issue%3D18%26spage%3D1544%26epage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christin  Elgert</span>, <span class="hlFld-ContribAuthor ">Anne  Rühle</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Sönke  Behrends</span>. </span><span class="cited-content_cbyCitation_article-title">A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>163 </em>, 142-153. <a href="https://doi.org/10.1016/j.bcp.2019.02.007" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DA%252Bnovel%252Bsoluble%252Bguanylyl%252Bcyclase%252Bactivator%25252C%252BBR%252B11257%25252C%252Bacts%252Bas%252Ba%252Bnon-stabilising%252Bpartial%252Bagonist%252Bof%252BsGC%26aulast%3DElgert%26aufirst%3DChristin%26date%3D2019%26volume%3D163%26spage%3D142%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca  Stacy</span>, <span class="hlFld-ContribAuthor ">Kenneth  Huttner</span>, <span class="hlFld-ContribAuthor ">Jen  Watts</span>, <span class="hlFld-ContribAuthor ">James  Peace</span>, <span class="hlFld-ContribAuthor ">David  Wirta</span>, <span class="hlFld-ContribAuthor ">Tom  Walters</span>, <span class="hlFld-ContribAuthor ">Kenneth  Sall</span>, <span class="hlFld-ContribAuthor ">John  Seaman</span>, <span class="hlFld-ContribAuthor ">Xiao  Ni</span>, <span class="hlFld-ContribAuthor ">Ganesh  Prasanna</span>, <span class="hlFld-ContribAuthor ">Muneto  Mogi</span>, <span class="hlFld-ContribAuthor ">Christopher  Adams</span>, <span class="hlFld-ContribAuthor ">Jing-He  Yan</span>, <span class="hlFld-ContribAuthor ">Michael  Wald</span>, <span class="hlFld-ContribAuthor ">Yunsheng  He</span>, <span class="hlFld-ContribAuthor ">Ronald  Newton</span>, <span class="hlFld-ContribAuthor ">Randall  Kolega</span>, <span class="hlFld-ContribAuthor ">Cynthia  Grosskreutz</span>. </span><span class="cited-content_cbyCitation_article-title">A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Ophthalmology</span><span> <strong>2018,</strong> <em>192 </em>, 113-123. <a href="https://doi.org/10.1016/j.ajo.2018.05.015" title="DOI URL">https://doi.org/10.1016/j.ajo.2018.05.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ajo.2018.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ajo.2018.05.015%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Ophthalmology%26atitle%3DA%252BRandomized%25252C%252BControlled%252BPhase%252BI%25252FII%252BStudy%252Bto%252BEvaluate%252Bthe%252BSafety%252Band%252BEfficacy%252Bof%252BMGV354%252Bfor%252BOcular%252BHypertension%252Bor%252BGlaucoma%26aulast%3DStacy%26aufirst%3DRebecca%26date%3D2018%26volume%3D192%26spage%3D113%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported sGC activators tested in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. HTS hit (<b>3</b>), lead molecule (<b>4</b>), and pharmacophore model on <b>4</b>. Common feature points are carboxylic acid (red), hydrophobic groups (yellow and green), and a hydrogen bond acceptor (cyan), whereas occupancy of a tail group (purple dotted circle) varies depending on a molecule.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Activator Tails<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromo-2-methyl phenol (for <b>26a</b>) or 4-chloro-3-ethylphenol (for <b>26b</b>), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct, aq. K<sub>3</sub>PO<sub>4</sub>, CH<sub>3</sub>CN, 80 °C; or SPhos-Pd (first generation), aq. K<sub>3</sub>PO<sub>4</sub>, DMF, 110 °C; (b) H<sub>2</sub>, Pd/C 5%, MeOH, rt; (c) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (2) cyclopropanecarbonyl chloride, <i>i-</i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (3) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) 4-bromo-2-methyl-1-nitrobenzene, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct, aq. K<sub>3</sub>PO<sub>4</sub>, CH<sub>3</sub>CN, 80 °C; (e) (1) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (2) cyclopropanecarbonyl chloride, <i>i-</i>Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Activators <b>4</b>–<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate, EtOH, rt; (b) (3-formylthiophen-2-yl)boronic acid, KF, Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub>, THF, rt; (c) NaBH<sub>4</sub>, EtOH, 0 °C; (d) NBS, DMF, rt; or NCS, DMF; (e) corresponding dialkylzinc, Pd(<i>t</i>-Bu<sub>3</sub>P)<sub>2</sub>, THF, rt; (f) <b>26</b>, DIAD, PPh<sub>3</sub>, THF; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (h) propionyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; or cyclopropylmethyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C; or 2-cyclopropylacetic acid, HATU, <i>i-</i>Pr<sub>2</sub>NEt, DMF, rt; (i) LiOH, THF, MeOH, H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Indane Amine Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) bis(pinacolato)diboron, KOAc, SPhos–Pd (first generation), dioxane, 120 °C (microwave); (2) <b>42</b>, aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos–Pd (first generation), dioxane, 110 °C conventional heating (one pot); (b) (1) <b>30</b>, cat. TsOH, 130 °C with Dean–Stark apparatus; (2) NaBH<sub>4</sub>, EtOH, 0 °C to rt; (c) LiOH, MeOH/THF/H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Indane Ether Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 0 °C to rt; or RuCl[(<i>R</i>,<i>R</i>)-Tsdpen](p-cymene), TEA·HC(O)OH, DMF, 60 °C; (b) <b>27</b>, azodicarboxylic dimorpholide, <i>n-</i>Bu<sub>3</sub>P, THF, rt; (c) bis(pinacolato)diboron, KOAc, SPhos-Pd (first generation), dioxane, 120 °C (microwave); (2) aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos-Pd (first generation), dioxane, 110 °C conventional heating (one pot); (d) LiOH, MeOH/THF/H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Cycloalkenyl Activators<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) bis(pinacolato)diboron, potassium acetate, SPhos–Pd (first generation), dioxane, 110 °C; (2) corresponding cycloalkene intermediate, aq. Na<sub>2</sub>CO<sub>3</sub>, SPhos–Pd (first generation) (one pot); (b) TBAF, THF, rt; (c) <b>27</b>, DIAD, PPh<sub>3</sub>, THF; (d) LiOH, THF, MeOH, H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/medium/jm-2018-00007g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. IOP reduction (%) in the cynomolgus monkey laser-induced hypertensive model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.8b00007/20180315/images/large/jm-2018-00007g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00007&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broman, A. T.</span></span> <span> </span><span class="NLM_article-title">The number of people with glaucoma worldwide in 2010 and 2020</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1136/bjo.2005.081224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1136%2Fbjo.2005.081224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=16488940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FpvFOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2006&pages=262-267&author=H.+A.+Quigleyauthor=A.+T.+Broman&title=The+number+of+people+with+glaucoma+worldwide+in+2010+and+2020&doi=10.1136%2Fbjo.2005.081224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The number of people with glaucoma worldwide in 2010 and 2020</span></div><div class="casAuthors">Quigley H A; Broman A T</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-7</span>
        ISSN:<span class="NLM_cas:issn">0007-1161</span>.
    </div><div class="casAbstract">AIM:  To estimate the number of people with open angle (OAG) and angle closure glaucoma (ACG) in 2010 and 2020.  METHODS:  A review of published data with use of prevalence models.  Data from population based studies of age specific prevalence of OAG and ACG that satisfied standard definitions were used to construct prevalence models for OAG and ACG by age, sex, and ethnicity, weighting data proportional to sample size of each study.  Models were combined with UN world population projections for 2010 and 2020 to derive the estimated number with glaucoma.  RESULTS:  There will be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020, and of these, 74% will have OAG.  Women will comprise 55% of OAG, 70% of ACG, and 59% of all glaucoma in 2010.  Asians will represent 47% of those with glaucoma and 87% of those with ACG.  Bilateral blindness will be present in 4.5 million people with OAG and 3.9 million people with ACG in 2010, rising to 5.9 and 5.3 million people in 2020, respectively.  CONCLUSIONS:  Glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPaAfgYdQ5TZp6t8nS6Nc3fW6udTcc2ebkm8bLVBCTG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FpvFOjsA%253D%253D&md5=6e7eb42ac041183edb63151f67f27c47</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1136%2Fbjo.2005.081224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjo.2005.081224%26sid%3Dliteratum%253Aachs%26aulast%3DQuigley%26aufirst%3DH.%2BA.%26aulast%3DBroman%26aufirst%3DA.%2BT.%26atitle%3DThe%2520number%2520of%2520people%2520with%2520glaucoma%2520worldwide%2520in%25202010%2520and%25202020%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2006%26volume%3D90%26spage%3D262%26epage%3D267%26doi%3D10.1136%2Fbjo.2005.081224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heijl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leske, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M.</span></span> <span> </span><span class="NLM_article-title">Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial</span>. <i>Arch. Ophthalmol. (Chicago, IL, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1279</span>, <span class="refDoi"> DOI: 10.1001/archopht.120.10.1268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1001%2Farchopht.120.10.1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=12365904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD38nhtVeguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2002&pages=1268-1279&author=A.+Heijlauthor=M.+C.+Leskeauthor=B.+Bengtssonauthor=L.+Hymanauthor=B.+Bengtssonauthor=M.+Hussein&title=Reduction+of+intraocular+pressure+and+glaucoma+progression%3A+results+from+the+early+manifest+glaucoma+trial&doi=10.1001%2Farchopht.120.10.1268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial</span></div><div class="casAuthors">Heijl Anders; Leske M Cristina; Bengtsson Bo; Hyman Leslie; Bengtsson Boel; Hussein Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1268-79</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma.  DESIGN:  Randomized clinical trial.  PARTICIPANTS:  Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening.  Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible.  INTERVENTIONS:  Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126).  Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months.  Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter.  MAIN OUTCOME MEASURES:  Glaucoma progression was defined by specific visual field and optic disc outcomes.  Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests.  Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings.  RESULTS:  After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death.  On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up.  Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients.  Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status.  Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P =.002).  CONCLUSIONS:  The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP.  Its intent-to-treat analysis showed considerable beneficial effects of treatment that significantly delayed progression.  Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ-FkfFtp-YYkFb3mqPUYDfW6udTcc2ebkm8bLVBCTG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nhtVeguw%253D%253D&md5=50e90d77a62ab24f3d1204dea66f5e74</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1001%2Farchopht.120.10.1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.120.10.1268%26sid%3Dliteratum%253Aachs%26aulast%3DHeijl%26aufirst%3DA.%26aulast%3DLeske%26aufirst%3DM.%2BC.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHyman%26aufirst%3DL.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHussein%26aufirst%3DM.%26atitle%3DReduction%2520of%2520intraocular%2520pressure%2520and%2520glaucoma%2520progression%253A%2520results%2520from%2520the%2520early%2520manifest%2520glaucoma%2520trial%26jtitle%3DArch.%2520Ophthalmol.%2520%2528Chicago%252C%2520IL%252C%2520U.%2520S.%2529%26date%3D2002%26volume%3D120%26spage%3D1268%26epage%3D1279%26doi%3D10.1001%2Farchopht.120.10.1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leske, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengtsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komaroff, E.</span></span> <span> </span><span class="NLM_article-title">Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial</span>. <i>Arch. Ophthalmol. (Chicago, IL, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1001/archopht.121.1.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1001%2Farchopht.121.1.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=12523884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FhslCqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2003&pages=48-56&author=M.+C.+Leskeauthor=A.+Heijlauthor=M.+Husseinauthor=B.+Bengtssonauthor=L.+Hymanauthor=E.+Komaroff&title=Factors+for+glaucoma+progression+and+the+effect+of+treatment%3A+the+early+manifest+glaucoma+trial&doi=10.1001%2Farchopht.121.1.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial</span></div><div class="casAuthors">Leske M Cristina; Heijl Anders; Hussein Mohamed; Bengtsson Bo; Hyman Leslie; Komaroff Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-56</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">OBJECTIVE:  To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment.  SETTING/PARTICIPANTS:  Two hundred fifty-five open-angle glaucoma patients randomized to argon laser trabeculoplasty plus topical betaxolol or no immediate treatment (129 treated; 126 controls) and followed up every 3 months.  METHODS:  Progression was determined by perimetric and photographic optic disc criteria.  Patient-based risk of progression was evaluated using Cox proportional hazard regression models and was expressed as hazard ratios (HR) with 95% confidence intervals (95% CI).  RESULTS:  After 6 years, 53% of patients progressed.  In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71).  Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age.  Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94).  The first IOP at that visit (3 months' follow-up) was also related to progression (HR = 1.11 per millimeter of mercury higher; 95% CI, 1.06-1.17), as was the mean IOP at follow-up (HR = 1.13 per millimeter of mercury higher; 95% CI, 1.07-1.19).  The percent of patient follow-up visits with disc hemorrhages was also related to progression (HR = 1.02 per percent higher; 95% CI, 1.01-1.03).  No other factors were identified.  CONCLUSIONS:  Patients treated in the EMGT had half of the progression risk of control patients.  The magnitude of initial IOP reduction was a major factor influencing outcome.  Progression was also increased with higher baseline IOP, exfoliation, bilateral disease, worse mean deviation, and older age, as well as frequent disc hemorrhages during follow-up.  Each higher (or lower) millimeter of mercury of IOP on follow-up was associated with an approximate 10% increased (or decreased) risk of progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEn5-OZe0G3L7NkxioyDXTfW6udTcc2ebS36tWEBH277ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FhslCqsw%253D%253D&md5=c5e527611f602535b0cb3bbc349ae326</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1001%2Farchopht.121.1.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.121.1.48%26sid%3Dliteratum%253Aachs%26aulast%3DLeske%26aufirst%3DM.%2BC.%26aulast%3DHeijl%26aufirst%3DA.%26aulast%3DHussein%26aufirst%3DM.%26aulast%3DBengtsson%26aufirst%3DB.%26aulast%3DHyman%26aufirst%3DL.%26aulast%3DKomaroff%26aufirst%3DE.%26atitle%3DFactors%2520for%2520glaucoma%2520progression%2520and%2520the%2520effect%2520of%2520treatment%253A%2520the%2520early%2520manifest%2520glaucoma%2520trial%26jtitle%3DArch.%2520Ophthalmol.%2520%2528Chicago%252C%2520IL%252C%2520U.%2520S.%2529%26date%3D2003%26volume%3D121%26spage%3D48%26epage%3D56%26doi%3D10.1001%2Farchopht.121.1.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaurin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novack, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopczynski, C. C.</span></span> <span> </span><span class="NLM_article-title">Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)</span>. <i>Am. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.ajo.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.ajo.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=29199013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVaktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2018&pages=116-127&author=J.+B.+Serleauthor=L.+J.+Katzauthor=E.+McLaurinauthor=T.+Heahauthor=N.+Ramirez-Davisauthor=D.+W.+Usnerauthor=G.+D.+Novackauthor=C.+C.+Kopczynski&title=Two+phase+3+clinical+trials+comparing+the+safety+and+efficacy+of+netarsudil+to+timolol+in+patients+with+elevated+intraocular+pressure%3A+Rho+kinase+elevated+IOP+treatment+trial+1+and+2+%28ROCKET-1+and+ROCKET-2%29&doi=10.1016%2Fj.ajo.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)</span></div><div class="casAuthors">Serle, Janet B.; Katz, L. Jay; McLaurin, Eugene; Heah, Theresa; Ramirez-Davis, Nancy; Usner, Dale W.; Novack, Gary D.; Kopczynski, Casey C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Ophthalmology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-127</span>CODEN:
                <span class="NLM_cas:coden">AJOPAA</span>;
        ISSN:<span class="NLM_cas:issn">0002-9394</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic soln., a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension.  Double-masked, randomized noninferiority clin. trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).  After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive netarsudil 0.02% once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d.  Data through 3 mo from both studies are provided in this report.  Enrolled into the 2 studies were 1167 patients.  Treatment with netarsudil q.d. produced clin. and statistically significant redns. from baseline intraocular pressure (P < .001), and was non-inferior to timolol in the per-protocol population with max. baseline IOP < 25 mm Hg in both studies (ROCKET-2, primary outcome measure and population, ROCKET-1, post hoc outcome measure).  Netarsudil b.i.d. was also noninferior to timolol (ROCKET-2).  The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2) for timolol (P < .0001 for netarsudil vs timolol).  In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma.  The novel pharmacol. and aq. humor dynamic effects of this mol. suggest it may be a useful addn. to the armamentarium of ocular hypotensive medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBdq81T17qBrVg90H21EOLACvtfcHk0lhICrU3lHAkgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVaktbzJ&md5=d7c92837a386c3b72df473961db11135</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ajo.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajo.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DSerle%26aufirst%3DJ.%2BB.%26aulast%3DKatz%26aufirst%3DL.%2BJ.%26aulast%3DMcLaurin%26aufirst%3DE.%26aulast%3DHeah%26aufirst%3DT.%26aulast%3DRamirez-Davis%26aufirst%3DN.%26aulast%3DUsner%26aufirst%3DD.%2BW.%26aulast%3DNovack%26aufirst%3DG.%2BD.%26aulast%3DKopczynski%26aufirst%3DC.%2BC.%26atitle%3DTwo%2520phase%25203%2520clinical%2520trials%2520comparing%2520the%2520safety%2520and%2520efficacy%2520of%2520netarsudil%2520to%2520timolol%2520in%2520patients%2520with%2520elevated%2520intraocular%2520pressure%253A%2520Rho%2520kinase%2520elevated%2520IOP%2520treatment%2520trial%25201%2520and%25202%2520%2528ROCKET-1%2520and%2520ROCKET-2%2529%26jtitle%3DAm.%2520J.%2520Ophthalmol.%26date%3D2018%26volume%3D186%26spage%3D116%26epage%3D127%26doi%3D10.1016%2Fj.ajo.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scassellati Sforzolini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittitow, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span> <span> </span><span class="NLM_article-title">A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1136/bjophthalmol-2014-305908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1136%2Fbjophthalmol-2014-305908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=25488946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BC2MzmsV2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2015&pages=738-745&author=R.+N.+Weinrebauthor=T.+Ongauthor=B.+Scassellati+Sforzoliniauthor=J.+L.+Vittitowauthor=K.+Singhauthor=P.+L.+Kaufman&title=A+randomised%2C+controlled+comparison+of+latanoprostene+bunod+and+latanoprost+0.005%25+in+the+treatment+of+ocular+hypertension+and+open+angle+glaucoma%3A+the+VOYAGER+study&doi=10.1136%2Fbjophthalmol-2014-305908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study</span></div><div class="casAuthors">Weinreb Robert N; Ong Tuyen; Scassellati Sforzolini Baldo; Vittitow Jason L; Singh Kuldev; Kaufman Paul L</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">738-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  To assess the efficacy and safety of latanoprostene bunod (LBN) compared with latanoprost 0.005%, and to determine the optimum drug concentration(s) of LBN in reducing intraocular pressure (IOP) in subjects with open angle glaucoma or ocular hypertension.  METHODS:  Randomised, investigator-masked, parallel-group, dose-ranging study.  Subjects instilled one drop of study medication in the study eye once daily each evening for 28 days and completed five study visits.  The primary efficacy endpoint was the reduction in mean diurnal IOP at Day 28.  RESULTS:  Of the 413 subjects randomised (LBN 0.006%, n=82; LBN 0.012%, n=85; LBN 0.024%, n=83; LBN 0.040%, n=81; latanoprost, n=82), 396 subjects completed the study.  Efficacy for LBN was dose-dependent reaching a plateau at 0.024%-0.040%.  LBN 0.024% led to significantly greater reductions in diurnal IOP compared with latanoprost at the primary endpoint, Day 28 (p=0.005), as well as Days 7 (p=0.033) and 14 (p=0.015).  The incidence of adverse events, mostly mild and transient, was numerically higher in the LBN treatment groups compared with the latanoprost group.  Hyperaemia was similar across treatments.  CONCLUSIONS:  LBN 0.024% dosed once daily was the lower of the two most effective concentrations evaluated, with significantly greater IOP lowering and comparable side effects relative to latanoprost 0.005%.  LBN dosed once daily for 28 days was well tolerated.  CLINICAL TRIAL NUMBER:  NCT01223378.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr03x9-0A1_0HdcurJClFcfW6udTcc2ebS36tWEBH277ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzmsV2hsg%253D%253D&md5=75bccc6699d6af2f059760b57a8a1862</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbjophthalmol-2014-305908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjophthalmol-2014-305908%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DR.%2BN.%26aulast%3DOng%26aufirst%3DT.%26aulast%3DScassellati%2BSforzolini%26aufirst%3DB.%26aulast%3DVittitow%26aufirst%3DJ.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26atitle%3DA%2520randomised%252C%2520controlled%2520comparison%2520of%2520latanoprostene%2520bunod%2520and%2520latanoprost%25200.005%2525%2520in%2520the%2520treatment%2520of%2520ocular%2520hypertension%2520and%2520open%2520angle%2520glaucoma%253A%2520the%2520VOYAGER%2520study%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2015%26volume%3D99%26spage%3D738%26epage%3D745%26doi%3D10.1136%2Fbjophthalmol-2014-305908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasanna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, D. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: pitfalls, promises and what lies ahead?</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>787</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2016.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.ejphar.2016.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=26948313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=787&publication_year=2016&pages=47-56&author=G.+Prasannaauthor=B.+Liauthor=M.+Mogiauthor=D.+S.+Rice&title=Pharmacology+of+novel+intraocular+pressure-lowering+targets+that+enhance+conventional+outflow+facility%3A+pitfalls%2C+promises+and+what+lies+ahead%3F&doi=10.1016%2Fj.ejphar.2016.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?</span></div><div class="casAuthors">Prasanna, Ganesh; Li, Byron; Mogi, Muneto; Rice, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">787</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Intraocular pressure (IOP) lowering drugs that are approved for the treatment of glaucoma and ocular hypertension have limited activity on increasing aq. humor movement through the trabecular meshwork and Schlemm's canal (TM/SC).  The TM/SC complex is considered the conventional outflow pathway and is a primary site of increased resistance to aq. humor outflow in glaucoma.  Novel mechanisms that enhance conventional outflow have shown promise in IOP redn. via modulation of several pathways including Rho kinase, nitric oxide/sol. guanylate cyclase/cGMP, adenosine A1, prostaglandin EP4/cAMP, and potassium channels.  The clin. translatability of these pharmacol. modulators based on pre-clin. efficacy models is currently being explored.  In addn., identification of pathways from GWAS and other studies involving transgenic rodent models with elevated/reduced IOP phenotypes have begun to yield addnl. insights into IOP regulation and serve as a source for the next generation of IOP lowering targets.  Lastly, improvements in drug delivery technologies to enable sustained IOP redn. are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqworABi0Ds3LVg90H21EOLACvtfcHk0lg_aDTP66jSYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCjtr8%253D&md5=a6511a3ce63671c7fda56157289f8d73</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2016.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2016.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DPrasanna%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26aulast%3DRice%26aufirst%3DD.%2BS.%26atitle%3DPharmacology%2520of%2520novel%2520intraocular%2520pressure-lowering%2520targets%2520that%2520enhance%2520conventional%2520outflow%2520facility%253A%2520pitfalls%252C%2520promises%2520and%2520what%2520lies%2520ahead%253F%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D787%26spage%3D47%26epage%3D56%26doi%3D10.1016%2Fj.ejphar.2016.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, D. Z.</span></span> <span> </span><span class="NLM_article-title">Guanylate cyclase activators, cell volume changes and IOP reduction</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1159/000335866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1159%2F000335866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=22179003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1emtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1145-1154&author=D.+Z.+Ellis&title=Guanylate+cyclase+activators%2C+cell+volume+changes+and+IOP+reduction&doi=10.1159%2F000335866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylate Cyclase Activators, Cell Volume Changes and IOP Reduction</span></div><div class="casAuthors">Ellis, Dorette Z.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1145-1154</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Glaucoma afflicts millions of people worldwide and is a major cause of blindness.  The risk to develop glaucoma is enhanced by increases in IOP, which result from deranged flow of aq. humor.  Aq. humor is a fluid located in the front of the eye that gives the eye its buoyancy and supplies nutrients to other eye tissues.  Aq. humor is secreted by a tissue called ciliary processes and exits the eye via two tissues; the trabecular meshwork (TM) and Schlemm's canal.  Because the spaces through which the fluid flows get smaller as the TM joins the area of the Schlemm's canal, there is resistance to aq. humor outflow and this resistance creates IOP.  There is a correlation between changes in TM and Schlemm's canal cell vol. and rates of aq. humor outflow; agents that decrease TM and Schlemm's canal cell vol., increase the rate of aq. humor outflow, thus decreasing IOP.  IOP is regulated by guanylate cyclase activators as shown in humans, rabbits and monkeys.  There are two distinct groups of guanylate cyclases, membrane guanylate cyclase and sol. guanylate cyclase (sGC); activation of both have been shown to decrease IOP.  Members of the membrane guanylate cyclase family of receptors bind to peptide ligands, while the sGC responds to gases (such as NO and CO2) and compds. (such as YC1), [3-(5'-hydroxymethyl-2'furyl)-1-benzyl indazole], a benzyl indazole deriv., and BAY-58-2667; activation of either results in formation of cyclic GMP (cGMP) and activation of protein kinase G (PKG) and subsequent phosphorylation of target proteins, including the high conductance calcium activated potassium channel (BKca channel).  While activators of both membrane guanylate cyclase and sGC have the ability to lower IOP, the IOP lowering effects of sGC are noteworthy because sGC activators can be topically applied to the eye to achieve an effect.  We have demonstrated that activators of sGC increase the rate at which aq. humor exits the eye in a time course that correlates with the time course for sGC-induced decreases in TM and Schlemm's canal cell vol.  Addnl., sGC-induced decrease in cell vol. is accompanied by both K+ and Cl- efflux induced by activation of K+ and Cl- channels, including the BKca channel and/or K+Cl- symport.  This suggests that parallel K+Cl- efflux, and resultant H2O efflux result in decreases in cell vol.  These observations suggest a functional role for sGC activators, and suggest that the sGC/cGMP/PKG systems are potential therapeutic targets in the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp67ewK7gyYmrVg90H21EOLACvtfcHk0lg_aDTP66jSYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1emtLvN&md5=6f87d3f1c6c62fb88b423fb817f07cb6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1159%2F000335866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000335866%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DD.%2BZ.%26atitle%3DGuanylate%2520cyclase%2520activators%252C%2520cell%2520volume%2520changes%2520and%2520IOP%2520reduction%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2011%26volume%3D28%26spage%3D1145%26epage%3D1154%26doi%3D10.1159%2F000335866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Evgenov, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1038/nrd2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1038%2Fnrd2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=16955067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=755-768&author=O.+V.+Evgenovauthor=P.+Pacherauthor=P.+M.+Schmidtauthor=G.+Haskoauthor=H.+H.+W.+Schmidtauthor=J.+P.+Stasch&title=NO-independent+stimulators+and+activators+of+soluble+guanylate+cyclase%3A+discovery+and+therapeutic+potential&doi=10.1038%2Fnrd2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span></div><div class="casAuthors">Evgenov, Oleg V.; Pacher, Pal; Schmidt, Peter M.; Hasko, Gyoergy; Schmidt, Harald H. H. W.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO).  Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases.  Current therapies that involve the use of org. nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomols., lack of response and the development of tolerance following prolonged administration.  Compds. that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.  Here we review the discovery, biochem., pharmacol. and clin. potential of heme-dependent sGC stimulators (including YC-1, BAY 41-2272, BAY 41-8543, CFM-1571 and A-350619) and heme-independent sGC activators (including BAY 58-2667 and HMR-1766).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq-7FoAzI40LVg90H21EOLACvtfcHk0lg_aDTP66jSYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D&md5=6c2a2ad7db529a7fe366bcfa0d61a6af</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2038%26sid%3Dliteratum%253Aachs%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BW.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DNO-independent%2520stimulators%2520and%2520activators%2520of%2520soluble%2520guanylate%2520cyclase%253A%2520discovery%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D755%26epage%3D768%26doi%3D10.1038%2Fnrd2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Derbyshire, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marletta, M. A.</span></span> <span> </span><span class="NLM_article-title">Structure and regulation of soluble guanylate cyclase</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-050410-100030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1146%2Fannurev-biochem-050410-100030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=22404633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=533-559&author=E.+R.+Derbyshireauthor=M.+A.+Marletta&title=Structure+and+regulation+of+soluble+guanylate+cyclase&doi=10.1146%2Fannurev-biochem-050410-100030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and regulation of soluble guanylate cyclase</span></div><div class="casAuthors">Derbyshire, Emily R.; Marletta, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-559</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is an essential signaling mol. in biol. systems.  In mammals, the diat. gas is crit. to the cyclic guanosine monophosphate (cGMP) pathway as it functions as the primary activator of sol. guanylate cyclase (sGC).  NO is synthesized from L-arginine and oxygen (O2) by the enzyme nitric oxide synthase (NOS).  Once produced, NO rapidly diffuses across cell membranes and binds to the heme cofactor of sGC.  The sGC forms a stable complex with NO and carbon monoxide (CO), but not with O2.  The binding of NO to sGC leads to significant increases in cGMP levels.  The second messenger then directly modulates phosphodiesterases (PDEs), ion-gated channels, or cGMP-dependent protein kinases to regulate physiol. functions, including vasodilation, platelet aggregation, and neurotransmission.  Many studies are focused on elucidating the mol. mechanism of sGC activation and deactivation with a goal of therapeutic intervention in diseases involving the NO/cGMP-signaling pathway.  This review summarizes the current understanding of sGC structure and regulation as well as recent developments in NO signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok39ItXTf-1rVg90H21EOLACvtfcHk0lg_aDTP66jSYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fL&md5=15c5cc20ce17cea7942f01e1828a2a26</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-050410-100030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-050410-100030%26sid%3Dliteratum%253Aachs%26aulast%3DDerbyshire%26aufirst%3DE.%2BR.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26atitle%3DStructure%2520and%2520regulation%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2012%26volume%3D81%26spage%3D533%26epage%3D559%26doi%3D10.1146%2Fannurev-biochem-050410-100030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e23596</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0023596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1371%2Fjournal.pone.0023596" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=L.+S.+Hoffmannauthor=P.+M.+Schmidtauthor=Y.+Keimauthor=C.+Hoffmannauthor=H.+H.+Schmidtauthor=J.+P.+Stasch&title=Fluorescence+dequenching+makes+haem-free+soluble+guanylate+cyclase+detectable+in+living+Cells&doi=10.1371%2Fjournal.pone.0023596"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0023596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0023596%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DL.%2BS.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DKeim%26aufirst%3DY.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DFluorescence%2520dequenching%2520makes%2520haem-free%2520soluble%2520guanylate%2520cyclase%2520detectable%2520in%2520living%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0023596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtin, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chana, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goggin, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madge, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meillerais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacey, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">78</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1021/jm001034k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001034k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=78-93&author=D.+L.+Selwoodauthor=D.+G.+Brummellauthor=J.+Budworthauthor=G.+E.+Burtinauthor=R.+O.+Campbellauthor=S.+S.+Chanaauthor=I.+G.+Charlesauthor=P.+A.+Fernandezauthor=R.+C.+Glenauthor=M.+C.+Gogginauthor=A.+J.+Hobbsauthor=M.+R.+Klingauthor=Q.+Liuauthor=D.+J.+Madgeauthor=S.+Meilleraisauthor=K.+L.+Powellauthor=K.+Reynoldsauthor=G.+D.+Spaceyauthor=J.+N.+Stablesauthor=M.+A.+Tatlockauthor=K.+A.+Wheelerauthor=G.+Wishartauthor=C.+K.+Woo&title=Synthesis+and+biological+evaluation+of+novel+pyrazoles+and+indazoles+as+activators+of+the+nitric+oxide+receptor%2C+soluble+guanylate+cyclase&doi=10.1021%2Fjm001034k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm001034k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001034k%26sid%3Dliteratum%253Aachs%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DBrummell%26aufirst%3DD.%2BG.%26aulast%3DBudworth%26aufirst%3DJ.%26aulast%3DBurtin%26aufirst%3DG.%2BE.%26aulast%3DCampbell%26aufirst%3DR.%2BO.%26aulast%3DChana%26aufirst%3DS.%2BS.%26aulast%3DCharles%26aufirst%3DI.%2BG.%26aulast%3DFernandez%26aufirst%3DP.%2BA.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DGoggin%26aufirst%3DM.%2BC.%26aulast%3DHobbs%26aufirst%3DA.%2BJ.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMadge%26aufirst%3DD.%2BJ.%26aulast%3DMeillerais%26aufirst%3DS.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26aulast%3DReynolds%26aufirst%3DK.%26aulast%3DSpacey%26aufirst%3DG.%2BD.%26aulast%3DStables%26aufirst%3DJ.%2BN.%26aulast%3DTatlock%26aufirst%3DM.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BA.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520pyrazoles%2520and%2520indazoles%2520as%2520activators%2520of%2520the%2520nitric%2520oxide%2520receptor%252C%2520soluble%2520guanylate%2520cyclase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D78%26epage%3D93%26doi%3D10.1021%2Fjm001034k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">von Wantoch Rekowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marazioti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyroulias, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Akker, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, A.</span></span> <span> </span><span class="NLM_article-title">Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8948</span>– <span class="NLM_lpage">8952</span>, <span class="refDoi"> DOI: 10.1021/jm400539d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400539d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8948-8952&author=M.+von+Wantoch+Rekowskiauthor=V.+Kumarauthor=Z.+Zhouauthor=J.+Moschnerauthor=A.+Maraziotiauthor=M.+Bantziauthor=G.+A.+Spyrouliasauthor=F.+van+den+Akkerauthor=A.+Giannisauthor=A.+Papapetropoulos&title=Insights+into+soluble+guanylyl+cyclase+activation+derived+from+improved+heme-mimetics&doi=10.1021%2Fjm400539d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm400539d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400539d%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BWantoch%2BRekowski%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DMoschner%26aufirst%3DJ.%26aulast%3DMarazioti%26aufirst%3DA.%26aulast%3DBantzi%26aufirst%3DM.%26aulast%3DSpyroulias%26aufirst%3DG.%2BA.%26aulast%3Dvan%2Bden%2BAkker%26aufirst%3DF.%26aulast%3DGiannis%26aufirst%3DA.%26aulast%3DPapapetropoulos%26aufirst%3DA.%26atitle%3DInsights%2520into%2520soluble%2520guanylyl%2520cyclase%2520activation%2520derived%2520from%2520improved%2520heme-mimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8948%26epage%3D8952%26doi%3D10.1021%2Fjm400539d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mais, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9462</span>, and references therein <span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.+J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.+P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lgEL0jmPgGvVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.%2BJ.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conole, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Riociguat: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1975</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0149-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1007%2Fs40265-013-0149-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1967-1975&author=D.+Conoleauthor=L.+J.+Scott&title=Riociguat%3A+First+global+approval&doi=10.1007%2Fs40265-013-0149-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0149-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0149-5%26sid%3Dliteratum%253Aachs%26aulast%3DConole%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1967%26epage%3D1975%26doi%3D10.1007%2Fs40265-013-0149-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kotikoski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alajuuma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moilanen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmenpera, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksala, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laippala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vapaatalo, H.</span></span> <span> </span><span class="NLM_article-title">Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1089/108076802317233171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2F108076802317233171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11858611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFGgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2002&pages=11-23&author=H.+Kotikoskiauthor=P.+Alajuumaauthor=E.+Moilanenauthor=P.+Salmenperaauthor=O.+Oksalaauthor=P.+Laippalaauthor=H.+Vapaatalo&title=Comparison+of+nitric+oxide+donors+in+lowering+intraocular+pressure+in+rabbits%3A+role+of+cyclic+GMP&doi=10.1089%2F108076802317233171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP</span></div><div class="casAuthors">Kotikoski, Hanna; Alajuuma, Paivi; Moilanen, Eeva; Salmenpera, Pertteli; Oksala, Olli; Laippala, Pekka; Vapaatalo, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">L-arginine-nitric oxide (NO) pathway participates in the physiol. and in many pathol. processes in the eye, such as glaucoma.  The aim of the present study was to compare the ocular hypotensive effect of different NO-donors, and to get more information on the role of cyclic guanosine 3',5'-monophosphate (cGMP) in this process.  The test compds. were administered topically or intravitreally in the eye of a normotensive rabbit.  Intraocular pressure (IOP) was measured with a pneumatonometer after topical anesthesia.  The metabolites of NO (nitrite, nitrate, NOx) and cGMP were assayed from the aq. humor and plasma.  NO-synthase (NOS) protein expression was assayed in the ciliary body by Western blotting.  The maximal lowering of IOP was achieved as follows: atriopeptin III (concn. 78; M, decrease in IOP 50%), atriopeptin II (84; M, 37%), 8-Br-cGMP (90 mM, 37%), zaprinast + 8-Br-cGMP (1 mM + 90 mM, 34%), L-arginine (1 mM, 29%), SNP (40 mM, 28%), nitrosocaptopril (100 mM, 28%), S-nitrosothiol (SNOG) (10 mM, 27%), YC-1 (10; M, 25%), zaprinast + SNP (1 mM + 40 mM, 22%), spermine NONOate (100 mM, 20%).  The decrease in IOP lasted for 2-5 h, except with atriopeptin II and III, when IOP values were first normalized in 6 h and 2 days, resp.  In conclusion, the results of the present study indicate that by increasing the activity of L-arginine/NO/cGMP-pathway it is possible to lower IOP in rabbits equally to the currently used antiglaucoma drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgCQOPqCjB7Vg90H21EOLACvtfcHk0lhqCImbcyq32g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFGgsL8%253D&md5=9b54ba309d7f0e161a7ce42255fd841b</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1089%2F108076802317233171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076802317233171%26sid%3Dliteratum%253Aachs%26aulast%3DKotikoski%26aufirst%3DH.%26aulast%3DAlajuuma%26aufirst%3DP.%26aulast%3DMoilanen%26aufirst%3DE.%26aulast%3DSalmenpera%26aufirst%3DP.%26aulast%3DOksala%26aufirst%3DO.%26aulast%3DLaippala%26aufirst%3DP.%26aulast%3DVapaatalo%26aufirst%3DH.%26atitle%3DComparison%2520of%2520nitric%2520oxide%2520donors%2520in%2520lowering%2520intraocular%2520pressure%2520in%2520rabbits%253A%2520role%2520of%2520cyclic%2520GMP%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D18%26spage%3D11%26epage%3D23%26doi%3D10.1089%2F108076802317233171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Buys, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ksander, B. R.</span></span> <span> </span><span class="NLM_article-title">Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2014.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.3389%2Ffnmol.2014.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=24904270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=38&author=E.+S.+Buysauthor=L.+R.+Potterauthor=L.+R.+Pasqualeauthor=B.+R.+Ksander&title=Regulation+of+intraocular+pressure+by+soluble+and+membrane+guanylate+cyclases+and+their+role+in+glaucoma&doi=10.3389%2Ffnmol.2014.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma</span></div><div class="casAuthors">Buys, Emmanuel S.; Potter, Lincoln R.; Pasquale, Louis R.; Ksander, Bruce R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38/1-38/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Glaucoma is a progressive optic neuropathy characterized by visual field defects that ultimately lead to irreversible blindness.  By the year 2020, an estd. 80 million people will have glaucoma, 11 million of which will be bilaterally blind.  Primary open-angle glaucoma (POAG) is the most common type of glaucoma.  Elevated intraocular pressure (IOP) is currently the only risk factor amenable to treatment.  How IOP is regulated and can be modulated remains a topic of active investigation.  Available therapies, mostly geared toward lowering IOP, offer incomplete protection, and POAG often goes undetected until irreparable damage has been done, highlighting the need for novel therapeutic approaches, drug targets, and biomarkers.  In this review, the role of sol. (nitric oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate cyclases that generate the secondary signaling mol. cyclic guanosine monophosphate (cGMP) in the regulation of IOP and in the pathophysiol. of POAG will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolqL-7e7fAD7Vg90H21EOLACvtfcHk0lhqCImbcyq32g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqsL%252FF&md5=3fca59de217d718336b2e912c31bbdcb</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00038%26sid%3Dliteratum%253Aachs%26aulast%3DBuys%26aufirst%3DE.%2BS.%26aulast%3DPotter%26aufirst%3DL.%2BR.%26aulast%3DPasquale%26aufirst%3DL.%2BR.%26aulast%3DKsander%26aufirst%3DB.%2BR.%26atitle%3DRegulation%2520of%2520intraocular%2520pressure%2520by%2520soluble%2520and%2520membrane%2520guanylate%2520cyclases%2520and%2520their%2520role%2520in%2520glaucoma%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D38%26doi%3D10.3389%2Ffnmol.2014.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heyne, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiland, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelt, B. T.</span></span> <span> </span><span class="NLM_article-title">Effect of nitric oxide on anterior segment physiology in monkeys</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5103</span>– <span class="NLM_lpage">5110</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-11491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1167%2Fiovs.12-11491" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=5103-5110&author=G.+W.+Heyneauthor=J.+A.+Kilandauthor=P.+L.+Kaufmanauthor=B.+T.+Gabelt&title=Effect+of+nitric+oxide+on+anterior+segment+physiology+in+monkeys&doi=10.1167%2Fiovs.12-11491"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-11491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-11491%26sid%3Dliteratum%253Aachs%26aulast%3DHeyne%26aufirst%3DG.%2BW.%26aulast%3DKiland%26aufirst%3DJ.%2BA.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26aulast%3DGabelt%26aufirst%3DB.%2BT.%26atitle%3DEffect%2520of%2520nitric%2520oxide%2520on%2520anterior%2520segment%2520physiology%2520in%2520monkeys%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D5103%26epage%3D5110%26doi%3D10.1167%2Fiovs.12-11491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="note"><p class="first last">It has previously been shown that in a normotensive rabbit (not glaucomatous) the sGC modulator YC-1, which has an unclear mechanism of stimulation, produces a very modest and transient reduction of IOP, please see ref <a onclick="showRef(event, 'cit11a'); return false;" href="javascript:void(0);" class="ref cit11a">(11a)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toris, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworak, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasanna, G.</span></span> <span> </span><span class="NLM_article-title">Effects of Rho kinase inhibitors on intraocular pressure and aqueous humor dynamics in nonhuman primates and rabbits</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1089/jop.2015.0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2Fjop.2015.0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=27266531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=355-364&author=C.+B.+Torisauthor=M.+A.+McLaughlinauthor=D.+P.+Dworakauthor=S.+Fanauthor=S.+Havensauthor=G.+Zhanauthor=N.+Horanauthor=G.+Prasanna&title=Effects+of+Rho+kinase+inhibitors+on+intraocular+pressure+and+aqueous+humor+dynamics+in+nonhuman+primates+and+rabbits&doi=10.1089%2Fjop.2015.0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits</span></div><div class="casAuthors">Toris, Carol B.; McLaughlin, Marsha A.; Dworak, Douglas P.; Fan, Shan; Havens, Shane; Zhan, Gui-Lin; Horan, Nicholas; Prasanna, Ganesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: This study examines the effects of 2 Rho kinase inhibitors on intraocular pressure (IOP) and aq. humor dynamics.  Methods: IOPs of New Zealand albino rabbits with ocular normotension and cynomolgus macaques (nonhuman primate, NHP) with chronic unilateral laser-induced glaucoma were measured at baseline and periodically after a 9 a.m. dose of H-1152, Y-27632, or vehicle.  In a sep. group of NHPs, aq. flow, outflow facility, uveoscleral outflow, and IOP were detd. after treatment with Y-27632 or vehicle control.  Results: Decreases in IOP were found in rabbits (n = 5) at 6 h after one dose of 2% Y-27632 (29%, P = 0.0002) or 1% H-1152 (35%, P = 0.0001), and in hypertensive eyes of NHPs (n = 7-9) at 3 h after one dose of 2% Y-27632 (35%, P = 0.005) or 1% H-1152 (51%, P = 0.0003).  With 2 doses of 1% Y-27632 or vehicle in NHP hypertensive eyes (n = 12), significant drug effects were IOP redn. of 28% (P = 0.05) at 2.5 h after the second dose and increases in aq. flow (36%; P = 0.013), uveoscleral outflow (59%, P = 0.008), and outflow facility (40%; P = 0.01).  In normotensive eyes of the same animals, aq. flow increased by 21% (P = 0.03).  No significant change was found in any of the other parameters.  Conclusions: Y-27632 and H-1152 lower IOP in rabbits and hypertensive eyes of NHPs for at least 6 h after single doses.  The Y-27632 effect on IOP in hypertensive NHP eyes is caused by increases in outflow facility and uveoscleral outflow.  An increase in aq. humor formation attenuates but does not prevent an IOP decrease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqELhKLgYJMrVg90H21EOLACvtfcHk0lgsApr_FyCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOhtb%252FI&md5=93aa83f8c84d9c4f5047a74d1181021d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1089%2Fjop.2015.0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2015.0116%26sid%3Dliteratum%253Aachs%26aulast%3DToris%26aufirst%3DC.%2BB.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DDworak%26aufirst%3DD.%2BP.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DHavens%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DG.%26aulast%3DHoran%26aufirst%3DN.%26aulast%3DPrasanna%26aufirst%3DG.%26atitle%3DEffects%2520of%2520Rho%2520kinase%2520inhibitors%2520on%2520intraocular%2520pressure%2520and%2520aqueous%2520humor%2520dynamics%2520in%2520nonhuman%2520primates%2520and%2520rabbits%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D32%26spage%3D355%26epage%3D364%26doi%3D10.1089%2Fjop.2015.0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and the references therein.</p></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">Typically in this model, a single dose of standard care therapies, for example, timolol and travoprost, affords maximum IOP lowering of 20–30%. Please see:</p></div><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagliuso, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podos, S. M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</span>. <i>Journal of Glaucoma</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1097/00061198-200012000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1097%2F00061198-200012000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11131752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADC%252BD3M7hsV2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=458-462&author=R.+F.+Wangauthor=J.+B.+Serleauthor=D.+J.+Gagliusoauthor=S.+M.+Podos&title=Comparison+of+the+ocular+hypotensive+effect+of+brimonidine%2C+dorzolamide%2C+latanoprost%2C+or+artificial+tears+added+to+timolol+in+glaucomatous+monkey+eyes&doi=10.1097%2F00061198-200012000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes</span></div><div class="casAuthors">Wang R F; Serle J B; Gagliuso D J; Podos S M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of glaucoma</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458-62</span>
        ISSN:<span class="NLM_cas:issn">1057-0829</span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the additive ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears to timolol in monkey eyes with laser-induced unilateral glaucoma.  METHODS:  Eight monkeys were used and each animal received all four combinations of drugs in a randomized fashion during the study.  The washout period between each combination was at least 2 weeks.  Intraocular pressure (IOP) was measured at 8:30 AM, 11:00 AM, 1:00 PM, and 3:30 PM on day 1 (untreated baseline), day 2 (timolol treatment alone), and days 3 through 5 (combination therapy with two drugs).  One drop of 0.5% timolol was topically applied at 3:45 PM on day 1 and at 8:45 AM and 3:45 PM on days 2 through 5.  One drop of 0.2% brimonidine or 2% dorzolamide or artificial tears was added on day 2 at 4:00 PM and at 9:00 AM and 4:00 PM on days 3 through 5, or latanoprost was added at 9:00 AM on days 3 through 5.  RESULTS:  Compared with timolol alone, the maximal additive reduction in IOP which occurred on day 5 was 4.8 +/- 0.8 mm Hg (mean +/- standard error of the mean) with timolol plus brimonidine, 5.6 +/- 1.0 mm Hg with timolol plus dorzolamide, 4.3 +/- 1.0 mm Hg with timolol plus latanoprost, and 2.0 +/- 0.5 mm Hg with timolol plus artificial tears (P < 0.01).  At all measurements, timolol plus brimonidine, timolol plus dorzolamide, and timolol plus latanoprost caused greater (P < 0.05) IOP reductions than did timolol plus artificial tears.  The additive IOP-lowering effect was similar (P > 0.60) when comparing timolol plus brimonidine and timolol plus dorzolamide, timolol plus brimonidine and timolol plus latanoprost, timolol plus dorzolamide and timolol plus latanoprost at all measurements, but timolol plus dorzolamide caused a greater (P < 0.05) reduction of IOP than did timolol plus latanoprost at 0 hours on day 5.  CONCLUSIONS:  The addition of brimonidine, dorzolamide, or latanoprost to timolol caused similar additional reductions of IOP in glaucomatous monkey eyes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0BHB3Az9wuMNIRw0GKUoEfW6udTcc2eYbnkcWbUDL_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7hsV2ksQ%253D%253D&md5=489e1606ceed168e19a231b9ac03213a</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1097%2F00061198-200012000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00061198-200012000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%2BF.%26aulast%3DSerle%26aufirst%3DJ.%2BB.%26aulast%3DGagliuso%26aufirst%3DD.%2BJ.%26aulast%3DPodos%26aufirst%3DS.%2BM.%26atitle%3DComparison%2520of%2520the%2520ocular%2520hypotensive%2520effect%2520of%2520brimonidine%252C%2520dorzolamide%252C%2520latanoprost%252C%2520or%2520artificial%2520tears%2520added%2520to%2520timolol%2520in%2520glaucomatous%2520monkey%2520eyes%26jtitle%3DJournal%2520of%2520Glaucoma%26date%3D2000%26volume%3D9%26spage%3D458%26epage%3D462%26doi%3D10.1097%2F00061198-200012000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallee, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desantis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinke, P. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1089/108076801753266802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1089%2F108076801753266802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=11765147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=421-432&author=M.+R.+Hellbergauthor=V.+L.+Salleeauthor=M.+A.+McLaughlinauthor=N.+A.+Sharifauthor=L.+Desantisauthor=T.+R.+Deanauthor=P.+W.+Zinke&title=Preclinical+efficacy+of+travoprost%2C+a+potent+and+selective+FP+prostaglandin+receptor+agonist&doi=10.1089%2F108076801753266802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist</span></div><div class="casAuthors">Hellberg, Mark R.; Sallee, Verney L.; McLaughlin, Marsha A.; Sharif, Naj A.; Desantis, Louis; Dean, Tom R.; Zinke, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-432</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Travoprost is the iso-Pr ester prodrug of a high affinity, selective FP prostaglandin full receptor agonist.  In contrast to travoprost acid's high affinity and efficacy at the FP receptor, there is only sub-micromolar affinity for the DP, EP1, EP3, EP4, IP, and TP receptors.  Travoprost produced a lower incidence of ocular irritation than PGF2α iso-Pr ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit.  Topical ocular application of travoprost produced a marked miotic effect in cats following doses of 0.01, 0.03 and 0.1 μg.  In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak redn. in intraocular pressure (IOP) of 22.7% and 28.6%, resp.  Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 μg.  Travoprost is a promising ocular hypotensive prostaglandin FP deriv. that has the ocular hypotensive efficacy of PGF2α iso-Pr ester but with less severe ocular side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CFwMCfgbcLVg90H21EOLACvtfcHk0lgsApr_FyCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFehuro%253D&md5=06075165f53c89ce73b9019396621d92</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1089%2F108076801753266802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108076801753266802%26sid%3Dliteratum%253Aachs%26aulast%3DHellberg%26aufirst%3DM.%2BR.%26aulast%3DSallee%26aufirst%3DV.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BA.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26aulast%3DDesantis%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DT.%2BR.%26aulast%3DZinke%26aufirst%3DP.%2BW.%26atitle%3DPreclinical%2520efficacy%2520of%2520travoprost%252C%2520a%2520potent%2520and%2520selective%2520FP%2520prostaglandin%2520receptor%2520agonist%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D17%26spage%3D421%26epage%3D432%26doi%3D10.1089%2F108076801753266802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shade, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steely, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSantis, L.</span></span> <span> </span><span class="NLM_article-title">Preliminary characterization of a transformed cell strain derived from human trabecular meshwork</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.3109/02713689409042398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.3109%2F02713689409042398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=8156826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A280%3ADyaK2c3gvVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1994&pages=51-63&author=I.+H.+Pangauthor=D.+L.+Shadeauthor=A.+F.+Clarkauthor=H.+T.+Steelyauthor=L.+DeSantis&title=Preliminary+characterization+of+a+transformed+cell+strain+derived+from+human+trabecular+meshwork&doi=10.3109%2F02713689409042398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary characterization of a transformed cell strain derived from human trabecular meshwork</span></div><div class="casAuthors">Pang I H; Shade D L; Clark A F; Steely H T; DeSantis L</div><div class="citationInfo"><span class="NLM_cas:title">Current eye research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-63</span>
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    </div><div class="casAbstract">Cells isolated from the trabecular meshwork (TM) of a male glaucoma patient were transformed by transfection with an origin defective mutant of SV40 virus.  Transformation dramatically increased the growth rate of these cells (designated HTM-3 cells), allowing biochemical and pharmacological characterization.  The HTM-3 cells had cytoskeletal components that were reported to be present in TM tissue and non-transformed TM cells.  Vimentin, tubulin and smooth muscle specific alpha-actin, but not desmin, were localized in these cells by immunocytochemistry.  The extracellular matrix components collagen types I, III and IV, fibronectin and laminin were found in HTM-3 cells as well as their non-transformed parental cells.  As predicted, the protein profile of the HTM-3 cells revealed by two-dimensional gel electrophoresis was different from that of the non-transformed cells, probably due to the enhanced growth characteristics of these cells.  Furthermore, HTM-3 cells had various intracellular second messenger systems that responded to pharmacological agents.  Forskolin, prostaglandin E2, beta-adrenergic and adenosine A2 agonists stimulated the adenylyl cyclase in these cells, whereas muscarinic, serotonergic, dopaminergic and other agonists were ineffective.  Sodium nitroprusside increased the intracellular concentration of cGMP, demonstrating the presence of a functional guanylyl cyclase.  Phospholipase C activity in these cells was also detected.  Muscarinic agonists, histamine and bradykinin, but not adrenergic, serotonergic agonists or prostaglandins, increased phosphoinositide turnover.  These drug responses of HTM-3 cells agree with published data on primary TM cells and TM tissues, suggesting that the transformed cells may be a valid substitute for certain pharmacological studies of TM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbzRXZAJ5LWsuCWE5mhx1RfW6udTcc2eYbnkcWbUDL_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c3gvVejsQ%253D%253D&md5=1e4e94fb084ea0340571ddab536bccb2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3109%2F02713689409042398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713689409042398%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DI.%2BH.%26aulast%3DShade%26aufirst%3DD.%2BL.%26aulast%3DClark%26aufirst%3DA.%2BF.%26aulast%3DSteely%26aufirst%3DH.%2BT.%26aulast%3DDeSantis%26aufirst%3DL.%26atitle%3DPreliminary%2520characterization%2520of%2520a%2520transformed%2520cell%2520strain%2520derived%2520from%2520human%2520trabecular%2520meshwork%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D1994%26volume%3D13%26spage%3D51%26epage%3D63%26doi%3D10.3109%2F02713689409042398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">Compound <b>3</b> has been described previously; see:</p></div><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanfilippo, P. J.</span>; <span class="NLM_string-name">Urbanski, M.</span>; <span class="NLM_string-name">Carson, J. R.</span>; <span class="NLM_string-name">Carmosin, R. J.</span></span> <span> </span><span class="NLM_article-title">Substituted Thiazole Derivatives Useful as Platelet Aggregation Inhibitors</span>. U.S. Patent <span class="NLM_patent">5,342,851</span>, <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=P.+J.+Sanfilippo&author=M.+Urbanski&author=J.+R.+Carson&author=R.+J.+Carmosin&title=Substituted+Thiazole+Derivatives+Useful+as+Platelet+Aggregation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSanfilippo%26aufirst%3DP.%2BJ.%26atitle%3DSubstituted%2520Thiazole%2520Derivatives%2520Useful%2520as%2520Platelet%2520Aggregation%2520Inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Subsequent to our internal HTS campaign where we determined the affinity of <b>3</b> as an sGC activator, there was a more recent patent disclosure highlighting <b>3</b> as an sGC activator; see:</p></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span>; <span class="NLM_string-name">Nakada, Y.</span>; <span class="NLM_string-name">Ohba, Y.</span>; <span class="NLM_string-name">Nakagawa, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazole-containing Heterocyclic Compound Derivatives as Soluble Guanylyl Cyclase (sGC) Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2009123316</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+Matsunaga&author=Y.+Nakada&author=Y.+Ohba&author=H.+Nakagawa&title=Preparation+of+Pyrazole-containing+Heterocyclic+Compound+Derivatives+as+Soluble+Guanylyl+Cyclase+%28sGC%29+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Pyrazole-containing%2520Heterocyclic%2520Compound%2520Derivatives%2520as%2520Soluble%2520Guanylyl%2520Cyclase%2520%2528sGC%2529%2520Activators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span>; <span class="NLM_string-name">Hahn, M. G.</span>; <span class="NLM_string-name">Stasch, J.</span>; <span class="NLM_string-name">Schlemmer, K.</span>; <span class="NLM_string-name">Wunder, F.</span>; <span class="NLM_string-name">El, S. S.</span>; <span class="NLM_string-name">Li, V.
M.</span>; <span class="NLM_string-name">Becker, E.</span>; <span class="NLM_string-name">Stoll, F.</span>; <span class="NLM_string-name">Knorr, A.</span>; <span class="NLM_string-name">Kolkhof, P.</span>; <span class="NLM_string-name">Woltering, E.</span></span> <span> </span><span class="NLM_article-title">Substituted 1-benzylcycloalkylcarboxylic Acids as Soluble Guanylate Cyclase Stimulators and Their Preparation and Use in the Treatment of Cardiovascular Diseases</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012076466</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=T.+Lampe&author=M.+G.+Hahn&author=J.+Stasch&author=K.+Schlemmer&author=F.+Wunder&author=S.+S.+El&author=V.%0AM.+Li&author=E.+Becker&author=F.+Stoll&author=A.+Knorr&author=P.+Kolkhof&author=E.+Woltering&title=Substituted+1-benzylcycloalkylcarboxylic+Acids+as+Soluble+Guanylate+Cyclase+Stimulators+and+Their+Preparation+and+Use+in+the+Treatment+of+Cardiovascular+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLampe%26aufirst%3DT.%26atitle%3DSubstituted%25201-benzylcycloalkylcarboxylic%2520Acids%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Stimulators%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cardiovascular%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. Q.</span>; <span class="NLM_string-name">Kim, R. M.</span>; <span class="NLM_string-name">Mirc, J. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of Biphenylpyridine Compounds as Soluble Guanylate Cyclase Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012058132</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+Q.+Tan&author=R.+M.+Kim&author=J.+W.+Mirc&title=Preparation+of+Biphenylpyridine+Compounds+as+Soluble+Guanylate+Cyclase+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%2BQ.%26atitle%3DPreparation%2520of%2520Biphenylpyridine%2520Compounds%2520as%2520Soluble%2520Guanylate%2520Cyclase%2520Activators%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. L.</span></span> <span> </span><span class="NLM_article-title">Sequential regioselective C–H functionalization of thiophenes</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3310</span>– <span class="NLM_lpage">3313</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b01205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b01205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWgsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=3310-3313&author=M.+H.+Danielsauthor=J.+R.+Armandauthor=K.+L.+Tan&title=Sequential+regioselective+C%E2%80%93H+functionalization+of+thiophenes&doi=10.1021%2Facs.orglett.6b01205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential Regioselective C-H Functionalization of Thiophenes</span></div><div class="casAuthors">Daniels, Matthew H.; Armand, Jeremy R.; Tan, Kian L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3310-3313</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, the sequential functionalization of 5-membered ring heterocycles is disclosed.  By employing a pH sensitive directing group, both directed and nondirected C-H activation pathways are available, providing access to 2,3,4- and 2,4,5-substituted thiophenes.  The C-H arylation was performed in water, and using a surfactant greatly improved the yield and mass recovery.  The use of a directing group with an on/off switch offers a potentially powerful means of generating diversity around medicinally relevant cores.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdeQwrpB_LbVg90H21EOLACvtfcHk0lhxTBC--MZFIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWgsL%252FE&md5=fe807bb42428067dfb16e1cc6b0be407</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b01205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b01205%26sid%3Dliteratum%253Aachs%26aulast%3DDaniels%26aufirst%3DM.%2BH.%26aulast%3DArmand%26aufirst%3DJ.%2BR.%26aulast%3DTan%26aufirst%3DK.%2BL.%26atitle%3DSequential%2520regioselective%2520C%25E2%2580%2593H%2520functionalization%2520of%2520thiophenes%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D3310%26epage%3D3313%26doi%3D10.1021%2Facs.orglett.6b01205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakamata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikariya, T.</span></span> <span> </span><span class="NLM_article-title">Oxo-tethered ruthenium(II) complex as a bifunctional catalyst for asymmetric transfer hydrogenation and H<sub>2</sub> hydrogenation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">14960</span>– <span class="NLM_lpage">14963</span>, <span class="refDoi"> DOI: 10.1021/ja207283t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja207283t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=14960-14963&author=T.+Tougeauthor=T.+Hakamataauthor=H.+Naraauthor=T.+Kobayashiauthor=N.+Sayoauthor=N.+Saitoauthor=Y.+Kayakiauthor=T.+Ikariya&title=Oxo-tethered+ruthenium%28II%29+complex+as+a+bifunctional+catalyst+for+asymmetric+transfer+hydrogenation+and+H2+hydrogenation&doi=10.1021%2Fja207283t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oxo-Tethered Ruthenium(II) Complex as a Bifunctional Catalyst for Asymmetric Transfer Hydrogenation and H2 Hydrogenation</span></div><div class="casAuthors">Touge, Taichiro; Hakamata, Tomohiko; Nara, Hideki; Kobayashi, Tohru; Sayo, Noboru; Saito, Takao; Kayaki, Yoshihito; Ikariya, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14960-14963</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Newly developed oxo-tethered Ru amido complexes and their HCl adducts exhibited excellent catalytic performance for both asym. transfer hydrogenation and the hydrogenation of ketonic substrates under neutral conditions without any cocatalysts to give chiral secondary alcs. with high levels of enantioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrStJMMWyAJYrVg90H21EOLACvtfcHk0lgVvKMiuIEWfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsrfE&md5=3f738a25a9f24642ca86aaeb3b2b310f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fja207283t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja207283t%26sid%3Dliteratum%253Aachs%26aulast%3DTouge%26aufirst%3DT.%26aulast%3DHakamata%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DSayo%26aufirst%3DN.%26aulast%3DSaito%26aufirst%3DN.%26aulast%3DKayaki%26aufirst%3DY.%26aulast%3DIkariya%26aufirst%3DT.%26atitle%3DOxo-tethered%2520ruthenium%2528II%2529%2520complex%2520as%2520a%2520bifunctional%2520catalyst%2520for%2520asymmetric%2520transfer%2520hydrogenation%2520and%2520H2%2520hydrogenation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D14960%26epage%3D14963%26doi%3D10.1021%2Fja207283t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rajamannar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, K. K.</span></span> <span> </span><span class="NLM_article-title">Enolate alkylation of bicyclo(2.2.2)oct-5-en-2-one and radical cyclisation - a potential approach for the construction of tricyclic carbocycles</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">5789</span>– <span class="NLM_lpage">5792</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)82193-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2FS0040-4039%2800%2982193-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1988&pages=5789-5792&author=T.+Rajamannarauthor=K.+K.+Balasubramanian&title=Enolate+alkylation+of+bicyclo%282.2.2%29oct-5-en-2-one+and+radical+cyclisation+-+a+potential+approach+for+the+construction+of+tricyclic+carbocycles&doi=10.1016%2FS0040-4039%2800%2982193-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2982193-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252982193-0%26sid%3Dliteratum%253Aachs%26aulast%3DRajamannar%26aufirst%3DT.%26aulast%3DBalasubramanian%26aufirst%3DK.%2BK.%26atitle%3DEnolate%2520alkylation%2520of%2520bicyclo%25282.2.2%2529oct-5-en-2-one%2520and%2520radical%2520cyclisation%2520-%2520a%2520potential%2520approach%2520for%2520the%2520construction%2520of%2520tricyclic%2520carbocycles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1988%26volume%3D29%26spage%3D5789%26epage%3D5792%26doi%3D10.1016%2FS0040-4039%2800%2982193-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pitre, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankar, Y. D.</span></span> <span> </span><span class="NLM_article-title">Palladium catalysed conversion of vinyl bromo allylic alcohols into vinylic carbonyl compounds and oxidation of secondary alcohols to ketones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12291</span>– <span class="NLM_lpage">12298</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(96)00715-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2F0040-4020%2896%2900715-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1996&pages=12291-12298&author=S.+V.+Pitreauthor=P.+S.+Vankarauthor=Y.+D.+Vankar&title=Palladium+catalysed+conversion+of+vinyl+bromo+allylic+alcohols+into+vinylic+carbonyl+compounds+and+oxidation+of+secondary+alcohols+to+ketones&doi=10.1016%2F0040-4020%2896%2900715-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2896%2900715-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252896%252900715-6%26sid%3Dliteratum%253Aachs%26aulast%3DPitre%26aufirst%3DS.%2BV.%26aulast%3DVankar%26aufirst%3DP.%2BS.%26aulast%3DVankar%26aufirst%3DY.%2BD.%26atitle%3DPalladium%2520catalysed%2520conversion%2520of%2520vinyl%2520bromo%2520allylic%2520alcohols%2520into%2520vinylic%2520carbonyl%2520compounds%2520and%2520oxidation%2520of%2520secondary%2520alcohols%2520to%2520ketones%26jtitle%3DTetrahedron%26date%3D1996%26volume%3D52%26spage%3D12291%26epage%3D12298%26doi%3D10.1016%2F0040-4020%2896%2900715-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.-L.</span></span> <span> </span><span class="NLM_article-title">Lanthanide triflate-promoted palladium-catalyzed cyclization of alkenyl β-keto Esters and amides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2871</span>, <span class="refDoi"> DOI: 10.1021/ol0349110</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0349110" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2869-2871&author=D.+Yangauthor=J.-H.+Liauthor=Q.+Gaoauthor=Y.-L.+Yan&title=Lanthanide+triflate-promoted+palladium-catalyzed+cyclization+of+alkenyl+%CE%B2-keto+Esters+and+amides&doi=10.1021%2Fol0349110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fol0349110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0349110%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DY.-L.%26atitle%3DLanthanide%2520triflate-promoted%2520palladium-catalyzed%2520cyclization%2520of%2520alkenyl%2520%25CE%25B2-keto%2520Esters%2520and%2520amides%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2869%26epage%3D2871%26doi%3D10.1021%2Fol0349110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima-Hirano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of C-labeled retinoic acid, [<sup>11</sup>C]ATRA, via an alkenylboron precursor by Pd(0)-mediated rapid-[<sup>11</sup>C]-methylation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3622</span>– <span class="NLM_lpage">3625</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;key=10.1016%2Fj.bmcl.2014.05.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3622-3625&author=M.+Suzukiauthor=M.+Takashima-Hiranoauthor=H.+Ishiiauthor=C.+Watanabeauthor=K.+Sumiauthor=H.+Koyamaauthor=H.+Doi&title=Synthesis+of+C-labeled+retinoic+acid%2C+%5B11C%5DATRA%2C+via+an+alkenylboron+precursor+by+Pd%280%29-mediated+rapid-%5B11C%5D-methylation&doi=10.1016%2Fj.bmcl.2014.05.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTakashima-Hirano%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DSumi%26aufirst%3DK.%26aulast%3DKoyama%26aufirst%3DH.%26aulast%3DDoi%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520C-labeled%2520retinoic%2520acid%252C%2520%255B11C%255DATRA%252C%2520via%2520an%2520alkenylboron%2520precursor%2520by%2520Pd%25280%2529-mediated%2520rapid-%255B11C%255D-methylation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3622%26epage%3D3625%26doi%3D10.1016%2Fj.bmcl.2014.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">Off-target activities were discounted as a source of the differences in observed tolerability. Compounds (+)-<b>17</b>, (+)-<b>21</b>, and (+)-<b>24</b> were selective against an internal safety panel of 21 enzymes, receptors, and ion channels, while compound (+)-<b>23</b> was evaluated more comprehensively in a broader panel (Eurofins Panlabs) consisting of 85 targets. Compound (+)-<b>23</b> was >1000× selective against the majority of targets assessed with the exception of the muscarinic receptor-M2 (EC<sub>50</sub> = 3.9 μM), and >50% binding was also noted with prostanoid receptors DP1, EP3, and IP at 10 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><a href="https://clinicaltrials.gov/" class="extLink">ClinicalTrials.gov</a>.
Identifier:
NCT02743780. (accessed Jan 27, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.%0AIdentifier%3A%0ANCT02743780.+%28accessed+Jan+27%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span> <i>MacroModel</i>, v9.9; <span class="NLM_publisher-name">Schrödinger,
LLC</span>, <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MacroModel%2C+v9.9%3B+Schr%C3%B6dinger%2C%0ALLC%2C+New+York%2C+2012."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMacroModel%26pub%3DSchr%25C3%25B6dinger%252C%250ALLC%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Montgomery, J. A.,  Jr.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Knox, J. E.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Cross, J. B.</span>; <span class="NLM_string-name">Bakken, V.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Jaramillo, J.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Stratmann, R. E.</span>; <span class="NLM_string-name">Yazyev, O.</span>; <span class="NLM_string-name">Austin, A. J.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Pomelli, C.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Ayala, P. Y.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Voth, G. A.</span>; <span class="NLM_string-name">Salvador, P.</span>; <span class="NLM_string-name">Dannenberg, J. J.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Dapprich, S.</span>; <span class="NLM_string-name">Daniels, A. D.</span>; <span class="NLM_string-name">Strain, M. C.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Malick, D. K.</span>; <span class="NLM_string-name">Rabuck, A. D.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Cui, Q.</span>; <span class="NLM_string-name">Baboul, A. G.</span>; <span class="NLM_string-name">Clifford, S.</span>; <span class="NLM_string-name">Cioslowski, J.</span>; <span class="NLM_string-name">Stefanov, B. B.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Liashenko, A.</span>; <span class="NLM_string-name">Piskorz, P.</span>; <span class="NLM_string-name">Komaromi, I.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Fox, D. J.</span>; <span class="NLM_string-name">Keith, T.</span>; <span class="NLM_string-name">Al-Laham, M. A.</span>; <span class="NLM_string-name">Peng, C. Y.</span>; <span class="NLM_string-name">Nanayakkara, A.</span>; <span class="NLM_string-name">Challacombe, M.</span>; <span class="NLM_string-name">Gill, P. M. W.</span>; <span class="NLM_string-name">Johnson, B.</span>; <span class="NLM_string-name">Chen, W.</span>; <span class="NLM_string-name">Wong, M. W.</span>; <span class="NLM_string-name">Gonzalez, C.</span>; <span class="NLM_string-name">Pople, J. A.</span></span> <i>Gaussian 03</i>, revision C.02; <span class="NLM_publisher-name">Gaussian, Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=J.+A.+Montgomery&author=T.+Vreven&author=K.+N.+Kudin&author=J.+C.+Burant&author=J.+M.+Millam&author=S.+S.+Iyengar&author=J.+Tomasi&author=V.+Barone&author=B.+Mennucci&author=M.+Cossi&author=G.+Scalmani&author=N.+Rega&author=G.+A.+Petersson&author=H.+Nakatsuji&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=M.+Klene&author=X.+Li&author=J.+E.+Knox&author=H.+P.+Hratchian&author=J.+B.+Cross&author=V.+Bakken&author=C.+Adamo&author=J.+Jaramillo&author=R.+Gomperts&author=R.+E.+Stratmann&author=O.+Yazyev&author=A.+J.+Austin&author=R.+Cammi&author=C.+Pomelli&author=J.+W.+Ochterski&author=P.+Y.+Ayala&author=K.+Morokuma&author=G.+A.+Voth&author=P.+Salvador&author=J.+J.+Dannenberg&author=V.+G.+Zakrzewski&author=S.+Dapprich&author=A.+D.+Daniels&author=M.+C.+Strain&author=O.+Farkas&author=D.+K.+Malick&author=A.+D.+Rabuck&author=K.+Raghavachari&author=J.+B.+Foresman&author=J.+V.+Ortiz&author=Q.+Cui&author=A.+G.+Baboul&author=S.+Clifford&author=J.+Cioslowski&author=B.+B.+Stefanov&author=G.+Liu&author=A.+Liashenko&author=P.+Piskorz&author=I.+Komaromi&author=R.+L.+Martin&author=D.+J.+Fox&author=T.+Keith&author=M.+A.+Al-Laham&author=C.+Y.+Peng&author=A.+Nanayakkara&author=M.+Challacombe&author=P.+M.+W.+Gill&author=B.+Johnson&author=W.+Chen&author=M.+W.+Wong&author=C.+Gonzalez&author=J.+A.+Pople&title=Gaussian+03"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252003%26pub%3DGaussian%252C%2520Inc%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span> <i>Molecular Operating
Environment (MOE)</i>, 2013.08;
Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910,
Montreal, QC, Canada, H3A 2R7, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE%29%2C+2013.08%3B%0AChemical+Computing+Group+ULC%2C+1010+Sherbooke+St.+West%2C+Suite+%23910%2C%0AMontreal%2C+QC%2C+Canada%2C+H3A+2R7%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%2529%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, A. R.</span>; <span class="NLM_string-name">Sinz, C. J.</span>; <span class="NLM_string-name">Chang, J.</span>; <span class="NLM_string-name">Kim, R.
M.</span>; <span class="NLM_string-name">Mirc, J.
W.</span>; <span class="NLM_string-name">Parmee, E.
R.</span>; <span class="NLM_string-name">Tan, Q.</span></span> <span> </span><span class="NLM_article-title">Soluble Guanylate Cyclase Activators</span>. PCT Int. Appl. <span class="NLM_patent">WO 2009032249</span>, <span class="NLM_year">2009</span> (Example 9).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+R.+Bittner&author=C.+J.+Sinz&author=J.+Chang&author=R.%0AM.+Kim&author=J.%0AW.+Mirc&author=E.%0AR.+Parmee&author=Q.+Tan&title=Soluble+Guanylate+Cyclase+Activators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBittner%26aufirst%3DA.%2BR.%26atitle%3DSoluble%2520Guanylate%2520Cyclase%2520Activators%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">Crystallographic data (excluding structure factors) have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1814475. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax (+44) 1223 336033, email: <a href="/cdn-cgi/l/email-protection#6c08091c031f05182c0f0f080f420f0d01420d0f421907"><span class="__cf_email__" data-cfemail="6e0a0b1e011d071a2e0d0d0a0d400d0f03400f0d401b05">[email protected]</span></a>].</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00007">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_05234"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00007">10.1021/acs.jmedchem.8b00007</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings for exemplified compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00007/suppl_file/jm8b00007_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00007/suppl_file/jm8b00007_si_001.csv">jm8b00007_si_001.csv (2.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00007&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00007%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00007" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799da83ab723da6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
